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The genus Mycobacterium comprises a variety of organisms, of which only a few are 
pathogenic, causing diseases of varying nature and severity. Despite this diversity, it is well 
established that CD4+ T helper type 1 (Th1) cells are instrumental in generating effective anti-
mycobacterial immune responses. In addition, Th17 cells are required for mucosal vaccine recall 
responses. In this work, we studied T cell plasticity and how cytokine defects or co-infections 
that skew the immune response to a predominantly Th2 or Th17 type, can affect the outcome of 
primary and recall responses to mycobacterial infections. We explored the plasticity of 
Mycobacterium tuberculosis (Mtb)-specific Th responses, showing that Mtb-specific Th1 and 
Th17 cells can acquire the cytokine secretion patterns of other Th subsets. In a vaccination 
setting, where Mtb-specific Th17 cells are required for protection, we studied the requirements 
for Mtb control following Th17 transfer. Firstly, we found that upon re-exposure to Mtb antigen, 
Th17 cells were plastic and required external signaling via IL-23 and CXCR5 expression for 
protection. Surprisingly, IFN-γ−deficient Th17 cells conferred enhanced protection against Mtb. 
Together, our data suggest that optimizing vaccine strategies to boost CXCR5 and IL-23 
expression, while limiting IFN-γ production, may enhance vaccine efficacy. In countries with 
poorly developed infrastructure, Mtb is often co-endemic with helminth infections. Thus, using a 
model helminth organism (Schistosoma mansoni), we assessed whether helminth co-infection or 
antigens impact T cell plasticity during Mtb infection. Our data show that helminth infection 
enhances arginase expression in macrophages within the lung, reduces Th1 responses and 
diminishes Mtb control. Importantly, antihelminthic treatment of co-infected mice was sufficient 
for restoring T cell responses and reducing inflammation, suggesting that T cell modulation is 
reversible. In addition, we determined the effect of Aspergillus fumigatus co-infection on 
Mycobacterium abscessus (Mabs), which is an emerging pathogen in cystic fibrosis. 
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Interestingly, we found that A.fumigatus alleviated Mabs-induced lung pathology in a mouse 
model. Future studies will establish if modulation of Th1 and Th17 commitment toward a 
regulatory phenotype underlies the decreased inflammation. Together, our results provide novel 
information on the dynamic interplay between host genetics, competing host responses to 
parasitic and fungal antigens and Mtb co-infection.  
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1.0  INTRODUCTION-THE IMPACT OF MYCOBACTERIAL DISEASE 
The genus Mycobacterium comprises a variety of mostly saprophytic organisms, of which only a 
few members are pathogenic, causing diseases of varying nature and severity. Several 
mycobacterial pathogens can establish infections that pose a serious challenge to global health. 
Infection by Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), 
constitutes the second leading cause of death from an infectious disease in the world, with 9 
million new TB cases and 1.5 million TB-related deaths per annum [1]. Furthermore, about one 
third of the world’s population is latently infected with Mtb, and at risk of progressing to active 
disease. In fact, of the two billion infected individuals, 10%, that is, 200 million people, will 
likely progress to active disease throughout their lifetime [1]. Current efforts to control this 
disease are aimed at the development of novel, effective vaccines, the generation of new drug 
regimens and an improvement in diagnostic and prognostic markers [2-4].  
In turn, non-tuberculous mycobacterial (NTM) infections are currently emerging as a 
serious health concern in patients with previous lung conditions and transplant patients, 
including cystic fibrosis (CF) patients [5]. Of particular relevance is M. abscessus infection, 
which constitutes the most drug-resistant NTM and is associated with poor treatment outcome. 
Indeed, sputum conversion occurs in 50-60% of treated patients, highlighting the low efficacy of 
treatment. Further, transition of M. abscessus from an environmentally-adapted form to the 
human-adapted morphotype has been associated with development of a highly invasive and 
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pathogenic disease [6]. Defining the mechanisms that potentiate bacterial persistence in patients 
at high risk of NTM infections will enable the development of novel therapeutic avenues for 
treatment of NTM disease.  
In natural populations, mycobacterial infections rarely occur in isolation, and can be 
affected by a range of physiological and environmental factors, including socio-economical 
factors, nutritional status, and the presence of other co-colonizing or co-infecting organisms. 
While the full impact of co-infections on the severity of mycobacterial diseases and the 
development of immunity to mycobacteria remains an open question, there is a wealth of 
persuasive published evidence, supported by our data, to warrant investigation of co-infections as 
a relevant and important factor for the control of mycobacterial disease. An important secondary 
consideration is that it will be important to understand whether treatments for mycobacteria 
affect disease manifestations associated with co-infections. In this work, we have studied T cell 
plasticity during mycobacterial infections, specifically the effect of changes to the host 
microenvironment elicited by co-infections or alterations in the balance of cytokines on the 
outcome of mycobacterial infections and vaccine-induced protection against TB. 
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2.0  TUBERCULOSIS 
2.1.1 Disease manifestations 
Mtb can establish infection upon reaching the lower airways of the lung via inhalation of droplets 
containing the bacterium, generated during coughing or sneezing. Successful transmission can be 
detected in 20-50% of individuals exposed to Mtb by the presence of antigen-specific T cell 
responses [7], which are usually apparent within 42 days after exposure [8, 9]. In infected 
individuals, TB can manifest as a spectrum of disease, ranging from absence of clinical signs 
(latent TB-LTB) in the majority of infected individuals to primary active clinical TB disease in 
5-10% of individuals, with symptoms typically including cough, sputum production, appetite 
loss, weight loss, fever, chest pain, fatigue and hemoptysis [10]. However, latently infected 
individuals constitute a reservoir for the bacterium, as 10% of them will progress to develop 
active TB (ATB) during their lifetime and become contagious, a process called reactivation [10]. 
Although the lung is the primary organ affected by the disease, extrapulmonary tuberculosis can 
occur in 10 to 42% of patients and affect different organs in the body, including the spleen, 
lymph node, kidneys, joints and central nervous system [11]. 
 The hallmark feature of TB is the granuloma, an organized collection of immune and 
stromal cells with a macrophage-rich center and a leukocytic periphery, which can be detected 
by chest X-rays in individuals with LTB, primary ATB and TB reactivation [12]. Given their 
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structure, granulomas were classically thought to constitute a physical barrier to contain an 
infectious organism that could not be eradicated, forming a wall that prevents Mtb dissemination. 
However, over the past two decades, our understanding of the granuloma has shifted toward a 
more dynamic, complex structure, that may limit or favor bacterial persistence depending on 
host, pathogen and environmental factors [13]. 
2.1.2 Disease burden and challenges to its control 
The World Health Organization (WHO) declared TB a global emergency in 1993. Since then, the 
2015 Millenium Development Goal of halting and reversing TB incidence has been achieved 
globally, with TB incidence falling at a rate of 1.5% per year between 2000 and 2013 [1].  
However, despite over half a century of anti-TB chemotherapy, one third of the world’s 
population remains latently infected with Mtb, 10% of which is at risk for development of active 
TB [1]. This is further aggravated by the burden of the HIV epidemic, which constitutes the most 
important risk factor for progression to active TB, increasing the risk of latent TB reactivation 26 
to 31-fold [14]. Of the 9 million people who developed active TB in 2013, 1.1 million (13%) 
were HIV-positive [1]. Despite the favorable drop in the number of TB HIV-related deaths over 
the past decade, TB remains the largest single cause of death in patients with AIDS, accounting 
for 26% of AIDS-related deaths [14].  
The current recommended antibiotic regimen for drug-susceptible TB has a high efficacy, 
with cure rates of about 90% in HIV-negative patients [15]. It consists of an initial 2-month 
phase of isoniazid, a rifamycin, pyrazinamide and ethambutol, followed by a 4-month 
continuation phase of isoniazid and a rifamycin [15]. However, these treatments are lengthy and 
require patient compliance with the treatment regimen for the entire treatment period.  
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In recent years, emergence of drug-resistant Mtb strains is presenting new challenges in 
the management and control of this disease. It has been estimated that 3.5% of new and 20.5% of 
previously treated TB cases were caused by multidrug resistant TB (MDR-TB) in 2013, while 
9% of patients with MDR-TB had extensively drug resistant TB (XDR-TB) [16]. Treatment of 
MDR-TB, which is resistant to isoniazid and rifampicin, takes at least 20 months of treatment, 
with lower cure rates and increased side effects [15]. XDR-TB, in turn, is resistant to isoniazid 
and rifampicin, fluoroquinolones and any second-line injectable drugs (amikacin, kanamycin or 
capreomycin) and is associated with very high mortality rates [15]. In addition, in HIV and Mtb 
co-infected patients, interactions between some of the anti-TB and antiretroviral drugs limit 
treatment options. Given that the last licensed TB antibiotic with a defined mechanism of action 
was rifampicin, which was discovered in 1963, and taking the aforementioned factors into 
consideration, drug development is therefore an area of strong investigation and 10 new or 
repurposed drugs are currently under Phase II or Phase III trials [15].   
An alternative strategy to control the emergence of MDR-TB and XDR-TB is the 
development of an effective vaccine against TB. The current available vaccine, Mycobacterium 
bovis BCG (Bacille Calmette-Guérin), is effective at preventing disseminated cases of TB in 
children, particularly meningitis. However, it confers variable protection to adult pulmonary TB, 
ranging from 0 to 80%. A great deal of effort has been invested in the development of new 
vaccines, and currently, 15 vaccine candidates are in different stages in clinical trials, ranging 
from Phase I to Phase III. However, the failure of the MVA85A booster, an attenuated vaccinia 
virus vector expressing Mtb antigen Ag85A, to enhance protection against pulmonary TB despite 
its strong immunogenicity in animal models [17-20], highlights our incomplete understanding of 
the immunological pathways that should be harnessed to elicit improved, long-lasting protection 
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to TB. If we want to reach the deadline of elimination of TB as a public health problem by 2050, 
the development of safe and more effective vaccines against TB is urgent and an area of top 
priority. 
2.1.3 Animal models 
One of our current limitations to study and understand human TB is the inherent variability of 
human populations. In fact, environmental factors, genetic diversity, age, sex, differences in 
bacterial strains and infectious load, as well as the duration of infection, can confound 
conclusions drawn from Mtb-infected human subjects. In addition, human tissues for study 
normally derive from either deceased patients or lung resections, two scenarios representing 
terminal or serious disease [13]. When available, samples from latently infected individuals are 
normally peripheral cells, which may not represent events occurring at the primary site of 
infection. Furthermore, since patients diagnosed with TB are readily put on an antibiotic 
treatment regimen, samples from untreated individuals are extremely scarce [21]. TB is a disease 
that takes years to progress, and as such, obtaining a clear understanding of the mechanisms 
required for Mtb containment and the factors leading to reactivation throughout every step of the 
disease is paramount. Over the past decades, a number of animal models have been developed to 
address these issues.    
Guinea pigs have been instrumental in TB studies, as the initial experiments performed 
by Koch that established Mtb as the etiological agent of TB were done in that model [22]. 
Importantly, guinea pigs can be infected with very low doses of Mtb, and possess granuloma 
features similar to those present in humans, including multinucleated giant cells and lung 
necrosis [23]. However, unlike humans, they are highly susceptible to TB disease, the majority 
 6 
of infected animals developing features of active disease that eventually leads to their death [22]. 
Rabbits have also proven a useful model for TB, as they display a spectrum of disease that is 
similar to that seen in human TB [24]. Unlike guinea pigs, and similar to humans, rabbits are 
mostly resistant to TB, and lung pathological features seen in humans can be reproduced by 
infecting the animals with M. bovis [25]. However, tools to study immune responses in the 
guinea pig and the rabbit models are limited, which is an obstacle to the use of these models to 
establish the mechanistic basis of disease progression.   
Mice have several advantages for modeling disease, including their relatively low cost, 
low generation time, the availability of numerous tools to study their immune system, and 
relative simplicity to alter their genotype. Numerous mouse models have been used to study TB, 
but arguably the low-dose aerosol model of TB is the one that best reproduces the natural route 
of infection in humans [26]. In this model, mice are exposed to droplet nuclei containing Mtb in 
a chamber where mice can move naturally [27]. Following a growth lag during the first 3 days 
after infection, Mtb grows exponentially in the lungs for about two weeks, a time where adaptive 
immune cells begin to infiltrate the lung [28]. Following this phase, the bacterial burden in the 
lung plateaus at a level dependent on the mouse genotype, typically 5-6 logs for C57BL/6 mice 
[29]. This is a chronic disseminated model of disease, where bacteria can be detected throughout 
the life of the animal at both pulmonary and extrapulmonary sites, such as the lymph nodes, 
spleen and liver. Much has been debated about the utility of the mouse model of TB, mainly due 
to the different granulomatous structures formed in this model and to the chronic nature of the 
disease [29]. Namely, mouse granulomas are more lymphocytic in nature, less structured than 
human granulomas and generally do not caseate. However, they serve as an extremely useful tool 
to study mechanistic immunological processes that are conserved between mice and humans 
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[22]. Although the infection in mice is chronic, several models of latency have been developed, 
including the modified Cornell mouse model, where mice are put on an antibiotic regimen 
consisting of isoniazid and rifampicin in the drinking water, until bacteria are no longer 
cultivable. Following that phase, antibiotics are suspended and mice will spontaneously 
“reactivate”, which is detected as new bacterial growth arising from persisting bacteria [30].  
Although the mouse model has greatly contributed to our understanding of TB, non-
human primates (NHP) are arguably the model that best reproduces the pathological features of 
human TB [31]. Not only do they develop the spectrum of granuloma formation and disease 
observed in humans [32], but they can also be infected with the simian immunodeficiency virus 
(SIV, the NHP variant of HIV) to model TB and HIV co-infection [29]. However, the elevated 
cost and infrastructure requirements of this model, the limited tools to study the immune 
response in NHPs and ethical considerations are some of the constraints to the widespread use of 
this model [31]. 
More recently, infection of zebrafish embryos [33, 34] or adult organisms with 
Mycobacterium marinum, a mycobacterial species related to Mtb [35], has provided a novel tool 
for the study of TB. Infection can be performed by intraperitoneal injection of the 
microorganism, and is associated with the formation of caseous granulomas [36], as is the case in 
humans. Despite the fact that these organisms form granulomas containing a larger proportion of 
innate cells [36], the variety of genetic tools to study zebrafish, the transparency of the embryos 
facilitating imaging experiments and the possibility of performing large scale drug screens 
together make this an interesting organism for TB research. 
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2.1.4 Immune mechanisms involved in control of mycobacteria 
Although Mtb infects a substantial proportion of the human population worldwide, only a small 
percentage of individuals progress to active disease [1]. HIV infection [37], malnutrition [38] 
and anti-TNF-α therapy [39] all have been shown to increase the risk of TB reactivation, 
illustrating that specific immune mechanisms can restrict bacterial growth. Upon entry into the 
lung, mycobacteria are taken up by alveolar macrophages, where Mtb replicates while inhibiting 
macrophage killing mechanisms [40]. Despite this, ligation of pattern recognition receptors 
(PRRs) in infected cells initiates a response characterized by the secretion of proinflammatory 
cytokines, such as IL-12 and TNF-α, chemokines and the upregulation of adhesion receptors 
[41]. This activation of innate cells results in the recruitment and activation of several immune 
cell populations to the lung [40]. Indeed, in the mouse model of low dose aerosol infection, 
around day 12 post-infection there is an early influx of innate cells into the lungs, including γδ T 
cells, NK cells, monocyte-derived macrophages, dendritic cells and neutrophils [42]. Despite the 
accumulation of these innate immune cells, Mtb continues to grow exponentially over the first 2-
3 weeks following infection [42]. Thus, activation of adaptive immunity and recruitment of 
effector T cells into the lung is required for bacterial burden control [43]. The priming of T cells 
is initiated by dendritic cells (DCs), primary antigen presenting cells (APCs) that serve as a 
direct link between the innate branch of the immune response and the adaptive response [44].  
Lung resident DCs can take up live Mtb within the lungs and transport them to the lung-
draining mediastinal lymph nodes [45]. Migration of DCs from the lungs to the mediastinal 
lymph nodes is governed by chemokine-receptor interactions, and occurs around day 14 post-
infection in the mouse model of TB [45]. Uptake of Mtb by DCs leads to the upregulation of 
CCR7 expression [46], which guides the cells to the mediastinal lymph node following a 
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gradient of the homeostatic chemokines CCL-19 and CCL-21 [45]. Recently, it has come to light 
that the myeloid cell populations that become infected and carry antigen to the lymph node, and 
those that directly prime the T cells, are distinct. Indeed, infected CCR2+ inflammatory 
monocytes are important for antigen delivery into the lung, where they release soluble antigen 
that can be taken up and presented by resident lymph node DCs [47, 48]. Subsequent recognition 
of Mtb antigens by naïve T cells bearing specific T cell receptors, in the presence of 
costimulatory signals and adequate cytokines in the microenvironment leads to the activation, 
proliferation and differentiation of naïve T cells into effector cells [49].  
While Mtb actively replicates in the lung, induction of inflammatory chemokines 
ultimately results in the recruitment of newly activated effector T cells from the periphery. This 
onset of adaptive immunity correlates with arrest of bacterial growth in the mouse model of TB 
[50]. As the increased incidence of mycobacterial TB reactivation in HIV patients demonstrates, 
CD4+ T helper cells (Th) cells are key to infection containment [37, 51]. Th cell responses can be 
classified into different subsets according to their functional characteristics. These subsets 
include Th1 cells, which have classically been viewed as orchestrators of immune responses 
against intracellular bacteria and viruses, Th2 cells, which have been associated with anti-
helminth responses, and, more recently, the Th17, Treg and T follicular helper (Tfh) subsets 
[52]. Multiple studies have shown that Th1 cells, which are generated in the presence of IL-12 
and secrete IFN-γ, play a major role in the adaptive branch of the response against mycobacteria 
[53, 54]. Th1 cell activity, through IFN-γ secretion, is instrumental for macrophage activation, a 
process that leads to the potentiation of macrophage killing mechanisms, such as the production 
of reactive oxygen and nitrogen species [55]. Additional T cell subsets, namely, Tfh-like cells 
have also been shown to participate in primary containment of Mtb infection [56] and Th17 cells 
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have been involved in vaccine recall responses to Mtb challenge [57]. However, T cell plasticity 
in the context of mycobacterial infections is an understudied area of research.  
T cells that exit the lymph node are able to enter the lung via the circulation through 
ligation of surface endothelial receptors that are upregulated in response to inflammation. Upon 
commitment to the Th1 subset, the main CD4+ T cell subset implicated in Mtb control, effector T 
cells upregulate the chemokine receptors CXCR3 and CCR5 [58, 59]. It is thought that this is 
directly related to their recruitment into the infected lung, as the ligands for these receptors, 
CXCL-9, CXCL-10 and CXCL-11 for CXCR3 and CCL-3, CCL-4, CCL-5 and CCL-8 for 
CCR5, are upregulated in Mtb-infected mouse [42] and NHP lungs [60].  
Upon entry into the lung parenchyma, however, proper Mtb containment is dependent on 
the correct localization of effector T cells in apposition to Mtb-infected macrophages. In recent 
years, several reports have demonstrated the expression of homeostatic chemokines, which are 
commonly expressed in secondary lymphoid organs (SLOs), in Mtb-infected lungs [42, 61]. 
Such chemokines, including CCL-19, CCL-21, CXCL-12 and CXCL-13, drive the organization 
of lymphoid follicles in SLOs and in the periphery [61]. These organized lymphoid and stromal 
aggregates, known as ectopic lymphoid follicles, have been reported in conditions of chronic 
infection and inflammation [62]. Interestingly, during Mtb infection in mice, non-human 
primates and humans, CXCR5-expressing CD4+ T cells also accumulate in the lungs, within 
ectopic lymphoid follicles [56]. Importantly, these CXCR5+ CD4+ T cells produce high levels of 
proinflammatory cytokines and upon accumulation in the lung, respond to CXCL-13 likely 
produced by stromal cells early during infection, and localize near Mtb-infected macrophages to 
mediate Mtb control [56]. Accordingly, both CXCR5 and CXCL13-deficient mice lacked the 
formation of ectopic lymphoid follicles and exhibited decreased control of Mtb, thus projecting a 
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non-redundant role for the CXCR5-CXCL-13 axis in TB. CXCR5 deficiency resulted in 
localization of CD4+ T cells around blood vessels in the Mtb-infected lungs, forming 
perivascular cuffs indicative of their inability to localize in apposition to infected macrophages 
[56]. Therefore, not only is the timely induction of chemokine-mediated recruitment of T cells to 
the lung critical for Mtb control, but emerging evidence suggests that chemokines also play a 
critical role in the precise positioning of Mtb-specific T cells within the lung parenchyma for 
maximal Mtb control. Indeed, early vaccine-induced production of CXCL-9, CXCL-10 and 
associated recruitment of CXCR3-expressing T cells is beneficial in vaccine-induced protection 
against Mtb challenge [63]. In addition, vaccine strategies that induce early CXCL-13 production 
to enhance and improve early T cell localization near Mtb-infected macrophages can be 
harnessed for vaccine design against TB [64].  
Together, there is accumulating evidence that the cytokines and chemokines induced in 
response to Mtb infection effectively mediate DC activation and trafficking to the LNs, priming 
and recruitment of activated T cells to the lung and correct localization of T cells within the lung 
parenchyma to mediate optimal Mtb control (Fig 1). However, although these processes mediate 
control of Mtb growth, they often do not completely eliminate the bacteria. Further 
understanding of the mechanisms that lead to Mtb containment will not only allow the better 
development of novel therapies against TB, but will be of particular relevance for vaccine and 
adjuvant design.  
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 Figure 1. Mechanisms that mediate lung Mtb containment.  
Upon Mtb entry into the lungs, alveolar macrophages become infected, leading to secretion of cytokines and 
chemokines, which drive additional innate cell recruitment (1). Infected DCs migrate into the lung draining lymph 
nodes (dLN) (2), carrying antigen that can be subsequently taken up by other APCs to activate naïve T cells (3). 
After activation, T cells (along with B cells) regulate their chemokine receptor expression, which guide their exit 
from the lymph node (4), homing to the infected lung (5), and subsequent migration. These responses are mediated 
by differential expression of chemokines, a process that enables ectopic lymphoid follicle formation (6). Additional 
innate cells, such as monocytes and neutrophils are also recruited into the lung (7). Together, interactions between 
innate and adaptive cells lead to granuloma formation and Mtb containment (8). Dashed blue lines represent 
chemokine-driven mechanisms. 
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2.1.5 Vaccination strategies against TB 
The Bacille Calmette-Guérin (BCG) vaccine, remains the sole licensed vaccine against TB and 
constitutes the most widely used vaccine worldwide, with more than three billion doses 
administered [65]. It was developed by Albert Calmette and Camille Guérin in the early 1900s 
through attenuation of a virulent M. bovis isolate by 230 serial passages on bile potato medium 
[66]. BCG is effective in preventing disseminated forms of TB in children. However, the 
variable efficacy of the current TB vaccine Mycobacterium bovis BCG against adult pulmonary 
TB, along with the recent emergence of drug-resistant Mtb strains has prompted the search for 
novel vaccines for TB [67].  
IFN-γ has been shown to promote macrophage activation, enhancing of antimicrobial 
mechanisms, and is required primary protection against TB. Hence, the paradigm for TB vaccine 
development in the past decade has been focused on targeting enhancement of IFN-γ secretion in 
T cells to mediate early macrophage activation and bacterial killing [68]. However, a number of 
studies have shown that IFN-γ is not a good correlate of vaccine-mediated protection [69, 70]. 
More recently, this has been highlighted by the failure of the recombinant TB vaccine MVA85A 
to enhance protection against Mtb infection in human clinical trials [71], despite induction of 
high levels of IFN-γ in humans [72] and animal models [17]. There are currently 11 TB vaccine 
candidates at different stages in clinical trials, including genetically modified strains of BCG, 
attenuated Mtb, subunit vaccines and viruses expressing Mtb proteins [73]. Exploring new and 
more effective pathways associated with vaccine protection will enable us to better assess current 
candidates whilst allowing rational design of novel vaccines against TB. 
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Th17 cells, which produce the cytokines IL-17A, IL-17F, IL-21, TNF-α and IL-22, 
differentiate in a multistep process that is initiated by antigen presentation in the presence of the 
cytokines IL-6 and TGF-β [74-76]. This induces strong IL-21 production by these differentiating 
cells, which is then thought to amplify differentiation through autocrine signaling [77]. Finally, 
signaling from IL-23 seems to be required for full differentiation and commitment to the Th17 
subset [78, 79]. In recent years, Th17 cells have emerged as one of the primary effector cells that 
mediate inflammation in autoimmune diseases [80, 81]. On the other hand, Th17 cells are critical 
for mediating immunity against extracellular bacterial and fungal pathogens [82], and in vaccine-
induced protection against several mucosal pathogens [83], including Mtb [84]. Indeed, our 
studies were amongst the earliest to show that parenteral vaccine-induced Th17 cells populate 
the lung and respond rapidly to Mtb infection, thus enabling Mtb containment [84]. More 
recently, we have shown that mucosal vaccine-driven protection is dependent on the induction of 
Th17-derived IL-17, production of chemokines, and formation of organized ectopic B cell 
follicles facilitating activation of Mtb-infected macrophages [64]. In addition, several vaccination 
strategies have been shown to promote potent, lasting Th17 responses. For example, 
immunization with antigen Mtb32 in adjuvant CAF01 [85], and vaccination with the 
recombinant BCG strain rBCG∆ureC:Hly in mice [86], both induce strong Th17 responses, 
which are associated with superior protection to Mtb challenge. However, despite the emerging 
consensus that Th17 cells are critical for vaccine-induced immunity against TB, the exact 
cytokine and immune requirements that enable Th17-induced recall protection upon Mtb 
challenge remain unclear. Delineating the immune characteristics of Th17 cells that mediate 
recall protection against TB is critical for targeting Th17 responses for future development of 
vaccines against TB.  
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2.1.6 T cell plasticity 
Adequate differentiation of T helper cells is required for promotion of either primary protection 
or vaccine-mediated protection to TB, a process that relies on signals present in the 
microenvironment at the time of differentiation. The classical paradigm of T helper subsets was 
that Th1, Th17, Th2 or Tregs are lineages, being terminally differentiated or irreversibly 
committed to their phenotype. Such a classification of T cell populations facilitated the 
elucidation of basic immune processes. However, the distinction between subsets is not always 
obvious and recently, several reports have shown that T cell subsets are not rigid populations, but 
rather, are plastic and can adapt to changing microenvironments in the host [87]. Given the 
relevance of Th1 and Th17 responses for anti-mycobacterial immune responses, we will address 
studies related to plasticity of those particular subsets. 
 Th17 cells have been found to be a relatively plastic subset, with a number of cytokines, 
including IL-4 [88], IFN-γ [89, 90], high-dose TGF-β [76], and IL-2 [91], being able of 
suppressing Th17 differentiation or cytokine secretion. Both in vitro and ex vivo, polyfunctional 
Th cells co-producing IL-17A and IFN-γ have been described, and have been associated with 
pathology development in autoimmune conditions [92]. Using a reporter fate mapping mouse 
system, it was shown that the origin of these polyfunctional Th1/Th17 cells was from Th17 cells 
acquiring IFN-γ secreting capacity in a mouse model of multiple sclerosis [93]. Similarly, Th17 
cells have been shown to acquire IL-4 secreting capacity both in vitro and in vivo during 
helminth infection [94]. Furthermore, IL-13+IL-17+ Th cells have been described in mice 
stimulated with repeated doses of ovalbumin-pulsed dendritic cells [95]. Culture of these 
dendritic cells in vitro with mouse Th17 cells led to the upregulation of IL-13 production, 
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indicating that these cells can acquire Th2-like cytokine secretion [95]. Polyfunctional IL-17+IL-
4+ T cells have been described in patients with chronic asthma [96], but the origin of these cells 
is still under debate. In vitro, human Th17 cells cultured in the presence of IL-4 were able to 
upregulate IL-4 production, indicating that this cell subset may be plastic both in mice and 
humans [87]. 
 Th1 cells, however, seem to be a more rigid population, with very limited evidence 
suggesting that Th1 to Th17 conversion can occur [87]. In vitro culture of Th1 cells under Th17-
skewing conditions failed to upregulated RORγt or IL-17A, and overall does not seem to happen 
in C57BL/6 mice [97]. A possible explanation for this is the early downregulation of IL-6 
receptor expression on activated T cells [98], which is required for Th17 differentiation. Th1 to 
Th2 conversion, however, has been described. Th2 polarized LCMV-specific cells transferred to 
LCMV-infected mice were able to co-express IL-4 and IFN-γ [99]. This ability of Th1 cells to 
acquire a Th2 cytokine secretion pattern may be affected by the degree of commitment to the 
Th1 subset, as Th1 cells seem to be less plastic the more rounds of division they undergo [100]. 
In the context of TB, a chronic disease where patients frequently present with additional co-
morbidities, the yet unexplored question of T cell plasticity is of particular importance and is 
being explored in this study. 
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3.0  REQUIREMENTS FOR TH17-INDUCED RECALL PROTECTION IN 
TUBERCULOSIS 
3.1 SUMMARY 
Tuberculosis (TB) vaccine development has focused largely on targeting T helper type 1 (Th1) 
cells. However, despite inducing Th1 cells, the recombinant TB vaccine MVA85A failed to 
enhance protection against Mtb infection in humans. In recent years, Th17 cells have emerged as 
key players in vaccine-induced protection against TB. However, the exact cytokine and immune 
requirements that enable Th17-induced recall protection remain unclear. In this study, we have 
investigated the requirements for Th17 cell-induced recall protection against Mtb challenge by 
utilizing a tractable adoptive transfer model in mice. Firstly, we show that Mtb-specific T1 and 
Th17 cells are plastic, and can acquire the cytokine secretion properties of other T cell subsets. 
We demonstrate that adoptive transfer of Mtb-specific Th17 cells into naïve hosts, and upon Mtb 
challenge, results in Th17 recall responses that confer protection at levels similar to vaccination 
strategies. Importantly, while IL-23 is critical, IL-12 and IL-21 are dispensable for protective 
Th17 recall responses. Unexpectedly, we demonstrate that IFN-γ produced by adoptively 
transferred Th17 cells impairs long-term protective recall immunity against Mtb challenge. This 
suggests that Th17 plasticity may have a negative effect on vaccine-induced protection to TB. In 
contrast, CXCR5 expression is crucial for localization of Th17 cells near macrophages within 
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well-formed B cell follicles to mediate Mtb control. Thus, our data identify new immune 
characteristics that can be harnessed to improve Th17 recall responses for enhancing vaccine 
design against TB.  
3.2 METHODS 
Animals 
C57BL/6 (B6) animals were purchased from Taconic. Ifng-/- mice on the B6 background 
were purchased from The Jackson Laboratory (Bar Harbor, ME). Early Secretory Antigenic 
Target-6 (ESAT-6) αβ TCR Tg mice recognize IAb/ESAT-61–20 and were provided by G. 
Winslow (Wadsworth Center, Albany, New York, USA) and D. Woodland (Trudeau Institute, 
Saranac Lake, New York, USA) [101]. The ESAT-6 TCR Tg mice were crossed and maintained 
on the Rag1–/– background or crossed to Thy1.1 mice for in vivo tracking experiments. ESAT-
6.Rag-/- mice were further crossed to Ifng-/- and CXCR5-/- mice to generate ESAT-6 TCR Tg 
mice deficient in these specific genes. Il12p35-/-, Il21-/- [102] and Il23p19-/- [103] mice were 
maintained in the animal facility either at the University of Pittsburgh or at Washington 
University in St. Louis. Experimental mice were age- and sex-matched and used between the 
ages of 6-8 weeks. All mice were maintained and used in accordance with the approved 
University of Pittsburgh and Washington University in St. Louis IACUC guidelines. 
T cell differentiation and adoptive T cell transfer  
Naïve T cells were isolated from ESAT-6 Tg mice using CD4+ (L3T4) magnetic bead 
sorting (Miltenyi Biotec, San Diego, CA). To generate Th17 cells, CD4+ T cells were cultured at 
a 1:1 ratio with BMDCs in the presence of ESAT-61-20 peptide (10 µg/mL), recombinant (r)-
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mouse IL-2 (10 U/mL), r-mouse IL-6 (30 ng/ml R&D Systems), r-mouse IL-23 (50 ng/ml R&D 
Systems), r-human TGF-β (5 ng/mL R&D Systems), anti-IL-4 antibody (10 µg/mL), and anti-
IFN-γ antibody (10 µg/mL) in Iscove’s Modified Dulbecco’s Medium (Life Technologies, Grand 
Island, NY). For Th1 cells, CD4+ T cells were cultured at a 1:1 ratio with BMDCs in the 
presence of ESAT-61-20 peptide (10 µg/mL), r-mouse IL-2 (10 U/mL), r-mouse IL-12 (10 ng/ml 
R&D Systems) and anti-IL-4 antibody (10 µg/mL) in Iscove’s Modified Dulbecco’s Medium 
(Life Technologies, Grand Island, NY). In some experiments, cultured T cells were re-stimulated 
for 48 hours in the presence of a 1:1 ratio of irradiated splenocytes and ESAT-61-20 peptide (10 
µg/mL) for analysis of cytokine production in the supernatant or by intracellular staining and 
flow cytometry. 
T cell subsets were generated in vitro as described above, purified from infected mice 
using CD4+ magnetic bead sorting or FACS, or IFN-γ-producing CD4+ cells were purified from 
Mtb-infected mice using a bead-based strategy (Miltenyi Biotec, San Diego, CA). T cells were 
laid over irradiated splenocytes (1:1) in the presence of 5 µg/mL ESAT-6 peptide and 10 U/mL 
IL-2, in combination with Th1, Th2 or Th17 differentiating cytokines. T cells were incubated for 
six days at 37°C and 5% CO2 and supplemented with an equivalent volume of media containing 
IL-2 (10U/mL) on day 3. After 6 days, supernatants were removed and T cells were restimulated 
with irradiated splenocytes and 5 µg/mL ESAT-6 peptide for 48 h. Tissue culture supernatants 
were then harvested and cells were processed for RNA extraction.  
For adoptive transfer, mice received 2x106 T cells by intravenous transfer, following 
which mice were rested for an average of 7 days before exposure to Mtb. 
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Experimental infections 
The H37Rv strain of Mtb was grown in Proskauer Beck medium containing 0.05% 
Tween-80 to mid-log phase and frozen in 1mL aliquots at -80°C. For Mtb aerosol infections, 
animals were infected with 100 Colony Forming Units (CFU) of bacteria using a Glas-Col 
airborne infection system as described previously [104]. Infection with 1x106 cfu of BCG 
Pasteur was performed using the tongue-pull method. Briefly, mice were anesthetized with 3% 
isoflurane, suspended by their front incisors, and the tongue was extended using forceps. The 
bacterial suspension was pipetted into the trachea, and the tongue was held until normal 
breathing resumed. Lung bacterial burden was established by plating out organ homogenates on 
7H11 agar plates [104]. For vaccination, 400 µg of the immunodominant I-Ab-restricted ESAT-
61-20 peptide (New England Peptide) were administered subcutaneously in the adjuvant mixture 
of MPL (monophosphoryl lipid A, Sigma-Aldrich), TDM (trehalose dicorynomycolate, Sigma-
Aldrich) and DDA (dimethyl dioctadecylammonium bromide, Eastman Kodak) in a final volume 
of 200 µL and mice were challenged after a 30-day period of rest [84].  
Lung single-cell preparation and detection of cytokine-producing cells by ELISpot 
assay 
Lung suspensions from Mtb-infected mice were prepared as described previously[84] and 
were used in ELISpot assays as described below. Antigen-specific IFN-γ-producing and IL-17-
producing cells were analyzed by ELISpot assay. Multi-screen HA filter plates (Millipore, 
Billerica, MA) were coated with anti-IFN-γ (BD Biosciences) or anti-IL-17 (R&D Systems) 
antibodies. Single cell suspensions were added to the plate at a starting concentration of 1x105 
cells/well and doubling dilutions made. Cells were cultured overnight in the presence of 1x106 
irradiated splenocytes and 10 µg/mL ESAT-61-20 peptide and 10 U/mL recombinant mouse IL-2. 
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The following day, biotinylated anti-IFN-γ or anti-IL-17 antibody (both from eBioscience, San 
Diego, CA) was added and incubated overnight. Plates were developed by incubation with 
streptavidin-alkaline phosphatase (Vector Labs, Burlingame, CA) for two hours, followed by 
incubation with NBT/BCIP (Sigma Aldrich). Spots were enumerated using a CTL-ImmunoSpot 
analyzer (CTL, Shaker Heights, OH) and the frequency and total number of responding cells 
calculated as described before [84]. 
Detection of cytokine-producing cells by flow cytometry 
The presence of Thy1.1+ congenically labeled ESAT-6 TCR Tg T cells, as well as the 
presence of cells producing IFN-γ and IL-17 was determined by flow cytometry. Single cell 
suspensions were stimulated for six hours in the presence of 50 ng/mL phorbol-myristate acetate 
and 750 ng/mL ionomycin, as well as 5 µL/mL GolgiStop (BD Biosciences). Cells were treated 
with Fc Block (anti-CD16/CD32, BD Biosciences) before surface staining for CD3 (clone 
500A2, AlexaFluor 700-conjugated, BD Biosciences), CD4 (clone RM4-5, Pacific Blue-
conjugated, BD Biosciences) and CD44 (clone IM7, PE-Cy7-conjugated, eBiosciene). Cells 
were then fixed and permeabilized using the Cytofix/Cytoperm fixation permeabilization kit (BD 
Biosciences) before staining for IL-17 (clone TC11-18H10, PE-conjugated, BD Biosciences) and 
IFN-γ (clone XMG1.2, APC-conjugated, BD Biosciences). Cell staining was analyzed on an 
LSR Fortessa (BD Biosciences), and results were processed using FlowJo (Treestar, Ashland, 
OR). 
Determination of protein concentration 
ELISA antibody pairs were used to detect cytokine levels (DuoSet; R&D Biosystems) in 
cell culture supernatants.  
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Immunohistochemistry 
Lung lobes were perfused with 10% neutral-buffered formalin and embedded in paraffin. 
For immunofluorescent staining, formalin-fixed lung sections were cut, immersed in xylene to 
remove paraffin, and then hydrated in 96% alcohol, and phosphate-buffered saline. Antigens 
were unmasked with a DakoCytomation Target Retrieval Solution (Dako, Carpinteria, CA) and 
non-specific binding was blocked with 5% (v/v) normal donkey serum and Fc block (BD 
Pharmingen). Endogenous biotin (Sigma-Aldrich) was neutralized by adding avidin followed by 
incubation with biotin. Sections were probed with anti-B220 to detect B cells (Clone RA3-6B2, 
BD Pharmingen), anti-CXCL13 (AF470, R&D systems) and anti-CD3 to detect T cells (Clone 
M-20, Santa Cruz Biotechnology, Santa Cruz, CA). B-cell follicles were outlined with the 
automated tool of the Zeiss Axioplan 2 microscope (Carl Zeiss, Thornwood, NY) and average 
size in squared microns was calculated as described before [64].  
Statistical analysis 
Statistical analysis to determine differences between experimental groups was performed 
in GraphPad Prism 5 (Graph Pad, La Jolla, CA) using two-tailed Student’s t-test. Differences 
between the means of multiple experimental groups were analyzed using one-way ANOVA with 
Tukey’s post-hoc test. Differences were considered significant when p≤0.05. All analyses were 
performed using GraphPad Prism Software.  
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3.3 RESULTS 
Th17 recall responses mediate Mtb control in an IL-12 and IL-21-independent, but IL-23-
dependent manner 
Th17 recall responses are associated with vaccine-induced protection against TB [64, 84, 105, 
106], but the cytokines and factors that are required for effective Th17 recall responses in vivo 
upon Mtb challenge are not well described. In order to study the requirements for Th17 recall 
responses in vivo upon Mtb challenge, we isolated naïve CD4+ T cells from ESAT-6 T cell 
receptor (TCR) transgenic (Tg) mice and differentiated them in vitro under Th1 or Th17-skewing 
conditions. As expected, Th17 cells produced high levels of IL-17A (IL-17) and IL-21, but not 
IFN-γ upon restimulation in vitro, when compared to Th1 cells which produced IFN-γ (Fig 2). 
In vitro differentiated Th17 cells were then adoptively transferred into C57BL/6 (B6) 
hosts and following a period of rest, mice were challenged with low doses of aerosolized Mtb 
H37Rv. We found that adoptive transfer of Th17 cells into B6 hosts resulted in lower lung 
bacterial burden, when compared with control B6 mice that did not receive cells (published data, 
[107]). Importantly, the level of protection conferred by adoptive transfer of Th17 cells was 
comparable to parenteral or mucosal immunization with ESAT-61-20 (published data, [107]), an 
immunodominant Mtb antigen, known to confer vaccine-induced protection upon Mtb challenge 
[84, 105]. Importantly, upon Mtb challenge, early IL-17 antigen-specific recall responses were 
observed in mice that received Th17 cells and mice that were previously vaccinated when 
compared with unvaccinated mice that did not exhibit early IL-17 responses (published data, 
[107]). In addition, mucosally vaccinated mice had increased recall protection when compared 
with parenterally vaccinated mice and this coincided with increased accumulation of early IL-17 
responses in the lung upon Mtb challenge (published data, [107]). These data suggest that the 
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Th17 recall response mediated by adoptive transfer of in vitro generated Th17 cells was by itself 
sufficient to control Mtb to levels comparable to prior vaccination. Thus, our model of adoptive 
transfer of antigen-experienced Th17 cells is a useful tool to study the factors that are required 
for effective Th17 recall responses in vivo upon Mtb challenge.  
 
 
Figure 2. In vitro-differentiated Th17 cells produce high levels of Th17 cognate cytokines, but not IFN-γ.  
Th1 or Th17 cells were differentiated in vitro from ESAT-6 TCR Tg mice. Levels of IL-17A, IL-21 and IFN-γ were 
determined in tissue culture supernatants following a 48-hour restimulation with ESAT-6 peptide. The data points 
represent the mean (±SD) of values from 3 independent samples. ***p≤0.001, ****p≤0.0001. 
 
Th17 cell differentiation occurs in the presence of the polarizing cytokines IL-6 and TGF-
β [89, 90]. In addition, IL-23 mediates commitment to the Th17 subset [108], while autocrine 
production of IL-21 induces Th17 differentiation [109]. While much is understood about how 
Th17 cells differentiate in vitro and during primary immune responses, the requirements for 
Th17 recall responses in vivo, specifically upon Mtb recall challenge have not been well 
characterized. Thus, using the Th17 cell adoptive transfer model, we then addressed the role of 
IL-12, IL-23 and IL-21 in mediating effective Th17 recall responses and conferring protection 
upon Mtb challenge. IL-12 is a polarizing cytokine required for differentiation of Th1 responses 
[110, 111], and is thus critical for protective immunity against TB [112]. Accordingly, IL-12p35-
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/- control mice were more susceptible to Mtb challenge when compared to B6 control mice (Fig 
3A). Similar to B6 mice that received Th17 cells, adoptive transfer of Th17 cells into IL-12p35-/- 
mice resulted in reduction in lung Mtb burden (Fig 3A), suggesting that although IL-12 is 
required for protective primary immunity against TB, IL-12 is not required for protective Th17 
recall responses upon Mtb challenge. Interestingly, IL-12p35-/- mice that received Th17 cells also 
exhibited increased ESAT-6-specific IFN-γ-producing T cells (Fig 3B), and increased ESAT-6-
specific IL-17-producing cells (Fig 3C), when compared to cytokine-production in naïve B6 
mice (published data, [107]). IL-21 is a cytokine that is involved in the induction of Th17 cells 
[109]. As previously described [102], IL-21-/- mice challenged with Mtb did not have increased 
bacterial burden compared to B6 control mice (Fig 3D). Interestingly, Th17 adoptive transfer 
into IL-21-/- mice improved Mtb control, when compared to IL-21-/- mice that did not receive 
cells (Fig 3D). These results indicate a dispensable role for IL-21 in both primary immunity 
[102] as well as protective Th17 recall responses in TB. The protection afforded in the IL-21-/- 
mice coincided with generation of efficient Mtb-specific IFN-γ-producing (Fig 3E) and IL-17-
producing (Fig 3F) T cell responses. Interestingly, when we transferred in vitro-differentiated 
Th17 cells into IL-23p19-/- mice and evaluated their ability to confer protection upon Mtb 
challenge, we found that IL-23 was required for Th17-induced protection (Fig 3G). As shown 
before [104], IL-23p19-/- control mice are not more susceptible to Mtb infection, when compared 
to B6 control mice (Fig 3G). However, IL-23p19-/- mice that received Th17 cells had comparable 
lung bacterial burdens to IL-23p19-/- mice that did not receive T cells (Fig 3G), suggesting that 
despite a dispensable role for IL-23 in primary immunity to Mtb infection, IL-23 has a critical 
role in Th17 recall response mediated protection against Mtb infection. Incidentally, IL-23p19-/- 
mice that received Th17 cells and did not mediate early Mtb control also exhibited defective IL-
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17 responses (Fig 3I), although ESAT-6-specific IFN-γ responses were robust and at levels 
comparable to B6 Mtb-infected mice (Fig 3H). These data together project a critical role for IL-
23, but not IL-12 or IL-21 in Th17 recall responses in response to Mtb infection. In addition, 
these data clearly show that Th17 cells generated in vitro in the presence of IL-23, still required 
the presence of IL-23 for effective Th17 recall response following Mtb challenge. 
 
Figure 3. Th17 recall responses mediate Mtb control through an IL-12 and IL-21-independent but IL-23-
dependent mechanism. 
C57BL/6 (B6), IL-12p35-/-, IL-21-/-, or IL-23p19-/- mice were left untreated (-) or received 2x106 ESAT-6 TCR Tg 
Th17 cells by i.v. route, and were aerosol challenged with 100 CFU Mtb H37Rv. (A, D, G) Lung bacterial burden at 
40 dpi and (B, E, H) the number of IFN-γ or (C, F, I) IL-17-producing ESAT-6-specific CD4+ T cells were 
A                                        B                                            C 
D                                        E                                            F 
G                                        H                                            I 
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determined via peptide-driven ELISpot. The data points represent the mean (±SD) of values from 4 to 8 mice. 
*p≤0.05, **p≤0.01, ***p≤0.001. 
 
Transferred Th17 recall responses occur early upon Mtb challenge and produce 
both IFN-γ and IL-17 
To further understand the immune features of Th17 recall responses, we tracked Thy1.1+ 
Th1 or Th17 cells upon adoptive transfer in B6 Thy1.2+ congenic hosts. We found that 
adoptively transferred Th17 cells preferentially migrated to, and were retained in the lung 
compartment, when compared to similarly transferred Th1 cells (published data, [107]). To 
further delineate the early kinetics of Th17 recall responses upon Mtb challenge, we adoptively 
transferred naïve undifferentiated Thy1.1+ Th0 cells, in vitro generated Thy1.1+ Th17 cells or 
Th1 cells into B6 Thy1.2+ congenic mice, rested mice and then challenged them with Mtb, and 
early Thy1.1+ Mtb-specific recall responses were assessed on days 10, 12 and 14 post Mtb 
infection. Consistent with our observation that Th17 cells accumulate and are retained in the lung 
upon adoptive transfer and prior to Mtb challenge (published data, [107]), we observed that the 
number of Th17 cells increased in the lungs between days 12 and 14 post Mtb challenge 
(published data, [107]). This was in contrast to B6 mice that received Th0 cells or Th1 cells, 
where significantly fewer ESAT-6-specific Th cells were detected in the lungs at these early time 
points (published data, [107]). This is consistent with previous studies which have shown that 
Mtb-specific Th0 cells take 13-18 days to accumulate in the Mtb-infected lungs [101, 113, 114].  
Interestingly, in vitro differentiated Th17 cells which were primarily IL-17-producers at the time 
of transfer, produced IFN-γ following Mtb challenge, with or without IL-17 expression 
(published data, [107]). The majority of the adoptively transferred Mtb-specific Th17 cells were 
activated as detected by expression of CD44, suggesting that the ability to co-produce IFN-γ is 
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not due to in vivo priming of undifferentiated adoptively transferred T cells (published data, 
[107]). These data together show that antigen-experienced Mtb-specific Th17 cells accumulate 
early in the lungs following Mtb challenge when compared to naïve Th0 cells or antigen-
experienced Th1 cells. In addition, our new data demonstrate that in vitro differentiated Th17 
recall responses which confer protection upon Mtb challenge (Fig 3), can acquire the ability to 
co-produce IFN-γ during early recall responses.  
 
Mtb-specific Th cell subsets exhibit variable plasticity in an in vitro setting. 
Given the ability of Th17 cells to co-produce IL-17 and IFN-γ, we hypothesized that Mtb 
specific CD4+ T cells are plastic and can change their cytokine production in response to external 
cytokine stimuli. Thus, we assessed the plasticity of Mtb-specific in vitro generated T cell 
subsets. For this, CD4+ T cells purified from ESAT-6 TCR Tg mice [101], which recognize the 
immunodominant Mtb ESAT-61-20 antigen, were in vitro polarized to the Th1, Th2, Th17 or Tfh 
subsets and subsequently exposed to differentiation conditions that drive different Th subsets. 
We found that the in vitro generated Th17 and Tfh subsets constituted highly plastic subsets, 
with the potential to acquire IFN-γ secretion upon exposure to Th1 cytokines (Fig 4A). In 
addition, both in vitro generated Tfh as well as Th17 subsets increased IL-17 (Fig 4B) and IL-21 
production (Fig 4C) upon incubation under Th17 or Tfh skewing conditions, respectively. 
Additionally, in vitro-differentiated Th1 cells were less plastic, as they increased IL-21 
production in response to Tfh cytokines (Fig 4C), but did not upregulate IL-17 production under 
Th17 conditions (Fig 4B). Th2 cells only upregulated IL-21 under Tfh conditions (Fig 4C), but 
were unable to acquire IFN-γ (Fig 4A) or IL-17 production (Fig 4B) upon exposure to Th1 or 
Th17 skewing conditions. These data together indicate that in vitro primed Mtb-specific T cell 
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subsets are plastic, yet differ in their ability to acquire the cytokine secretion patterns of other 
subsets, with Th17 and Tfh cells demonstrating the most plasticity. 
 
Figure 4. Mtb-specific T cell subsets exhibit variable plasticity in an in vitro setting. 
ESAT-6 TCR Tg Th1, Th2, Th17 and Tfh cells were differentiated from naïve CD4+ T cells in vitro using cytokine 
cocktails (indicated as subset below the graph). Cells were then incubated with cDMEM (-), IL-12 (Th1 conditions); 
TGF-β, IL-6 and IL-23 (Th17 conditions); or IL-21 (Tfh conditions) for 6 days (indicated as restimulation below the 
graph). Cells were washed, incubated for 48 h with anti-CD3/CD28 beads and culture supernatants assessed to 
determine (A) IFN-γ, (B) IL-17 and (C) IL-21 protein levels. The data points represent the mean (±SD) of values 
from 3-5 samples. ***p≤0.0005.  
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In vivo primed, Mtb-specific T cell populations are plastic. 
We next addressed if in vivo differentiated lung CD4+ Th cells induced following chronic 
Mtb infection will also demonstrate plasticity and can respond to cytokine changes in the 
microenvironment. Thus, we purified CD4+ T cells from the lungs of Mtb-infected wild type 
C57BL/6 mice and ex vivo exposed them to different Th cell subset-skewing cytokine cocktails. 
We found that, in the absence of additional stimuli (Untreated), these cells produced IFN-γ, low 
levels of IL-17 and undetectable production of IL-4 (Fig 5A), suggestive of a Th1 subset [102]. 
In support of our hypothesis, exposure to Th2-skewing cytokines led to the inhibition of IFN-
γproduction and to the upregulation of IL-4 production (Fig 5A), indicating that under the right 
conditions, in vivo generated Mtb-specific T cells can also acquire the ability to produce IL-4. 
Additionally, these cells were able to acquire IL-17 production in response to Th17 cytokines 
(Fig 5A). Interestingly, such an increase in IL-17 production was accompanied by a coincident 
increase in IFN-γ production (Fig 5A). Such plasticity was observed at varying points during 
chronic infection, as analysis on day 30 and day 50 post Mtb infection revealed similar results 
(data not shown). Since total lung CD4+ T cells were used in these assays, it is possible that an 
undifferentiated T cell population was contributing to the plasticity observed. To address 
whether changes observed in cytokine production was due to plasticity of the Th1 subset or due 
to differentiation of uncommitted CD4+ T cells, we enriched CD4+ cells for IFN-γ-producing 
population by using a magnetic-activated cell sorting (MACS) approach. We observed that the 
enriched IFN-γ-producing CD4+ T cells were potent producers of IFN-γ, and upon exposure to 
the Th2 skewing cocktail, downregulated IFN-γ production and increased IL-4 production (Fig 
5B). However, the ability to produce IL-17 upon incubation with Th17-skewing conditions was 
lost in the IFN-γ-producing CD4+ T cell population, but was retained in the sorted IFN-γ 
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negative CD4+ T cell population (Fig 5B). To further confirm our findings using a highly pure 
IFN-γ-producing CD4+ T cell population, we infected IFN-γ-YFP reporter mice with M.bovis 
BCG via oropharyngeal aspiraton, and sorted CD4+CD44+YFP+ lung cells using a flow 
cytometric approach. Using this strategy, we obtained a ~90.1% pure IFN-γ-producing CD4+ T 
cell population, which upon exposure to Th2-skewing cytokine cocktail resulted in reduction in 
IFN-γ production accompanied by an increase in IL-4 production (Fig 5C). IL-17 production was 
undetectable after incubation under Th17 conditions, suggesting that IL-17 production in CD4+ T 
cells upon exposure to Th17-skewing conditions was likely from a naïve undifferentiated or a 
differentiated but IFN-γ negative CD4+ T cell population (Fig 5B). Taken together, our results 
indicate that mycobacteria antigen-specific CD4+ T cells, although predominantly committed to 
the Th1 subset in vivo, can be stimulated to acquire the cytokine secretion pattern of Th2 cells ex 
vivo. In addition, Mtb-specific Th17 cells differentiated in vitro can upregulate IFN-γ production 
in response to signals in the microenvironment. Implicating these findings to an in vivo setting, 
these results suggest that changes to the lung microenvironment that favor Th2 cell development 
may redirect the commitment of Mtb-specific Th1 cells to a subset with reduced ability to 
contain the infection. Similarly, Th17 cells may act as bifunctional T cells, producing both IL-17 
and IFN-γ.   
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Figure 5. In vivo primed, Mtb-specific T cell populations are plastic. 
(A) C57BL/6 mice were aerosol infected with ~100 cfu H37Rv Mtb and lung CD4+ T cells were purified 30 days 
post-infection. Cells were incubated with cDMEM for 6 days, in the presence of subset-skewing cytokine cocktails, 
ESAT-6 peptide and IL-2. Cells were washed, restimulated for 48 h with irradiated splenocytes and ESAT-6 peptide 
and culture supernatants assessed to determine IFN-γ, IL-4 and IL-17 protein levels. (B) IFN-γ-YFP (Yeti) reporter 
mice were aerosol infected with ~100 cfu H37Rv Mtb and lung CD4+ T cells were purified on day 50 post-infection. 
Subsequently, IFN-γ-secreting cells were enriched, leading to a 50% pure population. This IFN-γ+ cell population, 
as well as the remaining IFN-γ- cells, were cultured with cDMEM for 6 days, in the presence of subset-skewing 
cytokine cocktails, ESAT-6 peptide and IL-2. Cells were washed, restimulated for 48 h with irradiated splenocytes 
and ESAT-6 peptide and culture supernatants assessed to determine IFN-γ, IL-4 and IL-17 protein levels. (C) IFN-γ 
reporter mice were i.t. infected with BCG and lung CD4+ T cells were purified on day 30 post-infection. 
Subsequently, CD4+CD44+IFN-γ+ cells were purified by FACS, leading to a 91.1% pure population. This IFN-γ+ 
cell population was cultured with cDMEM for 6 days, in the presence of different subset-skewing cytokine 
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cocktails, Ag85 and IL-2. Cells were washed, restimulated for 48 h with irradiated splenocytes and ESAT-6 peptide 
and culture supernatants assessed to determine IFN-γ and IL-4 protein levels. The data points represent the mean 
(±SD) of values from 3-5 samples. *p≤0.05, **p≤0.01, ***p≤0.001, ND-not detectable.  
 
IFN-γ production by Th17 cells decreases the potency of recall protection against 
Mtb challenge 
Given the ability of adoptively transferred Th17 antigen-experienced cells to co-produce 
IFN-γ  (published data, [107]) and the capacity of in vitro-differentiated Th17 cells to produce 
IFN-γ in response to IL-12 treatment (Fig 4A), we next sought to determine whether IFN-γ or IL-
17 production by Th17 cells was mediating the control upon Mtb challenge. Thus, we transferred 
ESAT-6 TCR Tg IFN-γ-deficient Th17 cells into IL-12p35-/- mice which lack IFN-γ responses 
(Fig 3B), and determined lung bacterial burden following Mtb challenge. Surprisingly, not only 
was IFN-γ dispensable for Th17-induced protection, but IFN-γ deficiency in Th17 cells further 
increased protection in IL-12p35-/- mice, when compared to adoptive transfer of IFN-γ-sufficient 
Th17 cells (Fig 6A). Our recent work has demonstrated a critical role for IL-17 in induction of 
CXCL-13 and formation of ectopic lymphoid structures in the lung for early Mtb control [102, 
115]. Consistent with these findings, we found that adoptive transfer of IFN-γ-deficient Th17 
cells more efficiently induced localized CXCL-13 protein expression within lymphoid follicles 
(Fig 6B) and triggered the formation of well-organized B cell follicles in the lungs (Fig 6B,C), 
when compared to lungs of IL-12p35-/- mice that received IFN-γ-sufficient Th17 cells.  
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Figure 6. IFN-γ production in Th17 cells decreases the potency of recall protection against Mtb challenge. 
Th17 cells were differentiated in vitro from IFN-γ-sufficient and IFN-γ-deficient ESAT-6 TCR Tg mice. IL-12p35-/- 
mice received 2x106 ESAT-6 TCR Tg Th17 or IFN-γ-deficient Th17 cells i.v. or were left untreated (-), rested, and 
aerosol infected with Mtb. (A) Lung bacterial burden at 40 dpi was determined by plating on 7H11 agar plates. (B) 
Formalin-fixed, paraffin-embedded (FFPE) serial lung sections from the above groups were processed for 
immunofluorescence using antibodies specific for CXCL-13 or B220 and CD3. (C) The average (Avg.) size of B-
cell follicles and (D) the average (Avg.) area occupied by perivascular T-cell cuffing were calculated using the 
morphometric tool of the Zeiss Axioplan microscope. (E) IL-17-producing ESAT-6-specific CD4+ T cells were 
determined via peptide-driven ELISpot. The data points represent the mean (±SD) of values from 5 to 8 mice. 
*p≤0.05, **p≤0.01, ***p≤0.001, NS, not significant. 
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Increased ectopic B cell follicle formation also coincided with a reduction in T cell 
perivascular cuffing (Fig 6D), which is indicative of migration of T cells to areas containing 
Mtb-infected macrophages [102]. These findings together project that not only is IFN-γ 
production by Th17 cells dispensable for T cell recall immunity against TB, but in fact, presence 
of early IFN-γ is detrimental to recall immunity against Mtb challenge.  
M.bovis BCG, the current vaccine against TB, confers protection against pediatric cases 
of disseminated TB, but its efficacy against adult pulmonary TB ranges from 0 to 80%. Defining 
the requirements for induction of long-lasting protective immunity is therefore a key parameter 
in the development of more efficacious vaccines against TB. Thus, we next determined whether 
Th17-induced protection observed in the IL-12p35-/- mice (Fig 6) was prolonged and whether the 
absence of IFN-γ in adoptively transferred cells conferred any long-term advantage to Mtb 
control in hosts. Accordingly, we found that although IL-12p35-/- mice that received Th17 cells 
had short-term protection (Fig 6A), the IL-12p35-/- hosts that received Th17 cells lost the 
protective effects around 100 days post-challenge (Fig 7A). This was despite the fact that IL-
12p35-/- hosts which received Th17 cells had significantly larger B cell follicles (Fig 7B, C), 
increased localization of CXCL13 protein within follicles (Fig 7C), and decreased T cell 
perivascular cuffing (Fig 7D), when compared to IL-12p35-/- mice that did not receive Th17 
cells.  
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 Figure 7. IFN-γ-deficient adoptively transferred Th17 cells induce long-lasting protection against Mtb 
challenge.  
IL-12p35-/- mice received 2x106 ESAT-6 TCR Tg Th17 or IFN-γ-deficient Th17 cells i.v. or were left untreated (-), 
rested, and aerosol infected with Mtb. (A) Lung bacterial burden at 100 dpi was determined by plating on 7H11 agar 
plates. (B) FFPE serial lung sections from the above groups were processed for immunofluorescence using 
antibodies specific for CXCL-13, and B220 and CD3. (C) The average size of B-cell follicles and (D) the average 
area occupied by perivascular T-cell cuffing were calculated using the morphometric tool of the Zeiss Axioplan 
microscope. The data points represent the mean (±SD) of values from 5 to 8 mice. **p≤0.01, ***p≤0.001. 
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 Importantly, transfer of IFN-γ-deficient Th17 cells conferred sustained long-term 
protection in IL-12p35-/- mice (Fig 7A), and this coincided with significantly larger ectopic 
lymphoid follicles (Fig 7B,C) and decreased T cell perivascular cuffing (Fig 7D), indicating that 
the establishment of a certain threshold B cell follicle size may be required for long term Mtb 
containment. These data together for the first time suggest that the ability to produce IFN-γ by 
Th17 cells may compromise long-term protective ability of T cell recall responses following Mtb 
challenge. 
 
CXCR5 expression on adoptively transferred Th17 cells is critical for the protective 
recall responses against TB.  
We have recently demonstrated that CXCL-13 is a critical chemokine that is necessary 
for migration of CXCR5-expressing T cells into the lung parenchyma to localize in apposition to 
Mtb-infected macrophages [102]. Using Cxcr5-/- ESAT6 TCR Tg Th17 cells, we next determined 
whether expression of this receptor was required for Th17-driven protection in recall responses 
to Mtb challenge. Thus, we adoptively transferred either no cells, Th17 cells, IFN-γ-deficient 
Th17 cells or CXCR5-deficient Th17 cells into B6 mice and following a period of rest, 
challenged mice with low doses of Mtb. We found that similar to our data with IL-12p35-/- mice 
that received IFN-γ-deficient Th17 cells (Fig 6,7), absence of IFN-γ in Th17 cells conferred 
better recall protection even in B6 mice, when compared to B6 mice that received IFN-γ-
sufficient Th17 cells (Fig 8). Most importantly, we found that B6 mice that received CXCR5-
deficient Th17 cells exhibited impaired Mtb control, while B6 mice that received CXCR5-
sufficient Th17 cells conferred protection (Fig 8), suggesting that expression of CXCR5 on Th17 
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cells is critical for the protective recall responses mediated by Th17 cells. Cxcr5-/- mice do not 
form ectopic lymphoid structures and are more susceptible to Mtb challenge [102]. Thus, we next 
addressed if adoptive transfer of CXCR5-sufficient Th17 cells is sufficient to rescue ectopic 
structure formation and confer protective recall responses in Cxcr5-/- mice. We found that 
adoptive transfer of ESAT6 TCR Tg Th17 cells into Cxcr5-/- mice resulted in improved Mtb 
control (published data, [107]), suggesting that presence of CXCR5 on adoptively transferred 
Th17 cells was necessary to mediate recall responses in CXCR5-deficient hosts. This was 
associated with improved B cell follicle formation and diminished T cell perivascular cuffing 
(published data, [107]). Taken together, these results indicate that CXCR5 expression on Th17 
cells during recall responses is necessary for correct localization of T cells within the lung 
parenchyma near infected macrophages to mediate Mtb control.  
 
 
Figure 8. CXCR5 expression on Th17 cells is critical to mediate protective recall responses following Mtb 
challenge. 
C57BL/6 (B6) mice received 2x106 ESAT-6 TCR Tg wild-type (WT), IFN-γ-deficient or CXCR5-deficient Th17 
cells i.v. or were left untreated (-), rested, and aerosol infected with Mtb. Lung bacterial burden at 40 dpi was 
determined by plating on 7H11 agar plates. The data points represent the mean (±SD) of values from 5 to 8 mice. 
*p≤0.05, **p≤0.01, NS, not significant. 
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3.4 DISCUSSION 
The recent emergence of drug resistant Mtb strains [67], the spread of the HIV-TB co-
epidemic [67] and the disappointing efficacy data from the recent human clinical trials with 
MVA85A [71], together highlight the big gaps in our understanding of how protective recall 
responses function during Mtb challenge. If we want to reach the deadline of elimination of TB 
as a public health problem by 2050, the development of safe and more effective vaccines against 
TB is urgent and an area of top priority. Early studies projected Th1 responses and the cytokine 
IFN-γ in primary protection against TB [116], where it plays a role in the potentiation of 
macrophage killing mechanisms. Thus, most vaccines in the past have used induction of IFN-γ 
responses as a correlate for vaccine efficacy [117]. However, recent studies have demonstrated 
that while vaccine-induced protection occurs in the absence of IFN-γ, vaccine-induced recall 
protection is lost in the absence of IL-17 [64, 84, 105, 106]. Thus, it is now becoming clear that 
targeting Th17 cells rather than Th1 cells to improve vaccine-induced immunity may enhance 
the efficacy of future vaccine strategies against TB [117]. However, in order to improve Th17 
recall responses, we need to first understand the immune characteristics of Th17 recall responses 
that confer protection against Mtb challenge. Thus, using a Th17 cell transfer model, we have 
identified that Th17 recall responses are dependent on IL-23, while endogenous IL-12 and IL-21 
are not required for effective Th17 recall responses. In addition, we demonstrate that upon Mtb 
challenge, Th17 recall responses appear earlier than naïve or Th1 cells and acquire the ability to 
produce IFN-γ. This was in line with our demonstration that, in vitro, Mtb-specific Th17 cells are 
plastic, and can increase IFN-γ production in response to culture under Th1 conditions. 
Importantly, the ability to produce IFN-γ is in fact detrimental to long term protective recall 
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responses against TB, while expression of CXCR5 by Th17 cells is necessary to mediate 
strategic positioning of Th17 recall responses within the lung to promote early Mtb control. 
Thus, identification of new immune characteristics of Th17 cells as described in this paper, are 
critical to harness novel pathways to enhance Th17 recall responses for design of more effective 
vaccines against TB.  
Our new data show that adoptive transfer of ESAT-6-specific Th17 cells into naïve hosts 
followed by a period of rest and Mtb challenge, results in similar levels of protection as prior 
parenteral vaccination with ESAT-61-20 antigen in adjuvant. IL-23 is as an important factor in 
differentiation of effector Th17 cells [108]. Accordingly, our early work showed that IL-23p19-/- 
mice vaccinated with parenteral Mtb antigen vaccine had reduced priming of Th17 responses and 
demonstrated loss of vaccine-induced protection upon Mtb challenge, suggesting that IL-23 was 
critical for initiation of vaccine-induced Th17 responses [84]. However, because IL-23p19-/- 
vaccinated hosts have defects in initiation of Th17 responses, we cannot use IL-23 deficient 
hosts to specifically address if IL-23 has a role to play in Th17 recall responses upon Mtb 
challenge. Thus, our studies in the present paper demonstrate for the first time that Th17 cells 
primed in vitro in the presence of IL-23 also require the presence of IL-23 for effective Th17 
recall responses that contribute to protection upon Mtb challenge. This is consistent with a recent 
study that showed an important role for IL-23 in activation of memory Th17 cells in a model of 
Experimental Autoimmune Encephalomyelitis (EAE) [118]. Interestingly, immune pathways that 
are important for primary immunity against TB such as IL-12 and IFN-γ are dispensable for 
Th17 recall responses. Thus, our data show a critical role for IL-23, but not IL-12 and IL-21, in 
activation of Th17 recall responses for protection against Mtb challenge, projecting IL-23 as a 
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key target pathway in both generation of Th17 responses [84] and activation of Th17 recall 
responses upon Mtb challenge.  
Our previous data showed that parenteral vaccination induces a population of antigen-
specific Th17 cells in the lungs, which are required for vaccine-induced protection against Mtb 
challenge [84]. Our current data support these findings as they show that adoptive transfer of 
Th17 cells also results in accumulation and persistence of Th17 cells in the lung compartment, 
suggesting that specific chemokine receptor expression such as CCR4 on Th17 cells [84], may 
regulate the preferential accumulation in mucosal compartments. Consistent with these findings, 
improving lung Th17 populations by mucosal immunization strategies enhances protection 
against Mtb challenge [64, 106]. Our data show that upon Mtb challenge, accumulation of Th17 
recall responses occurs prior to accumulation of either Th1 recall responses or Th0 cells in the 
lungs of Mtb-infected mice, suggest that the preferential location of Th17 cells in the mucosal 
compartment may serve an advantage and improve protection upon pulmonary Mtb challenge. In 
addition, although it is interesting that the early accumulation of Th17 recall responses upon Mtb 
challenge coincides with production of IFN-γ, this is not a completely unexpected finding. 
Several recent studies have projected Th17 cells as inherently plastic and have shown that they 
can readily acquire the ability to co-produce IFN-γ, especially in inflammatory models [97, 118, 
119]. In agreement with our findings, in observing long term vaccine-induced Th17 recall 
responses to Mtb challenge, it was found that not only did IL-17-producing CD4+ T cells 
accumulate in the lung earlier than IFN-γ-producing T cells, but IL-17-producing CD4+ T cells 
also co-produced IFN-γ [85]. However, it is surprising that adoptive transfer of IFN-γ-deficient 
Th17 cells into host mice results in more protective and long-term control of Mtb, suggesting a 
detrimental role for IFN-γ in recall responses against Mtb challenge. As IFN-γ production has 
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been shown to limit IL-17 production in T cells [120], it is thus possible that IFN-γ deficiency in 
Th17 recall responses improves IL-17 production and downstream induction of chemokines and 
enhancement of Mtb control. In addition, the increased protection afforded by adoptive transfer 
of IFN-γ-deficient Th17 cells holds true irrespective of whether IFN-γ-deficient Th17 cells are 
transferred into B6 mice or IL-12 deficient mice, suggesting that early IFN-γ production by Th17 
recall responses is detrimental to Mtb control. Our findings are supported by a recent study that 
used both experimental and mathematical approaches to demonstrate that the control of Mtb 
burden in the lung was not immediate after onset of IFN-γ responses in the lung [121]. As IFN-γ 
production has been conventionally used as a correlate for vaccine efficacy against TB, our 
findings instead project an important role for targeting IL-17 while limiting IFN-γinvaccine 
design for TB, and as such needs to explored in different preclinical vaccine models. 
IL-17 induces expression of the homeostatic chemokines CCL-19 and CXCL-13 [122], 
which orchestrate the formation of ectopic B-cell follicles within inducible Bronchus-Associated 
Lymphoid Tissue (iBALT). Similarly, our recent findings in vaccine models of TB demonstrate 
that early vaccine-induced Th17 cells produce IL-17 to mediate expression of CXCL-13 in lung 
stromal cells, enabling CXCR5-expressing T cells to localize near Mtb-infected macrophages 
[64]. Accordingly, our data show that effective Th17 recall responses coincide with localized 
CXCL-13 expression within lymphoid follicles, improved T cell localization and B cell follicle 
formation for enhanced Mtb control, while CXCR5 deficiency on Th17 cells abrogates the 
protective effects of Th17 recall immune responses. Similarly, although IL-17 and IL-23 are 
dispensable for primary immunity against lab adapted strains such as Mtb H37Rv, long-term 
control of Mtb is dependent on IL-23, and failure to contain Mtb infection in IL-23-deficient 
mice is associated with reduced B cell follicle formation [123]. More recently, we have shown 
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that IL-17 is required for protective primary immunity and formation of B-cell follicles upon 
challenge with emerging clinical strains of Mtb, i.e. hypervirulent W-Beijing strains [124], 
suggesting that design of vaccines for emerging Mtb strains must target the generation of Th17 
cells for effective long term protection against TB. However, excess IL-17 production has been 
associated with severe lung pathology during TB [125, 126]. Thus, optimization of antigen 
delivery strategies that promote the generation and maintenance of lung resident Th17 cells, 
while minimizing potentially pathological effects of IL-17 should be carefully evaluated in 
preclinical models. In addition, our T cell plasticity studies demonstrate that Th1 cells primed in 
vivo during mycobacterial infections can acquire Th2 cytokine production upon ex vivo 
restimulation. These findings highlight the interesting notion that a Th2-dominant environment, 
such as that which arises during helminth infection, may alter Th1 responses and bacterial 
containment. This will be explored in the next chapter. 
In conclusion, given the urgency for the development of safe and effective vaccines 
against TB, identification of immune characteristics of Th17 recall responses as described here 
can provide novel insights into pathways that can be targeted to improve vaccine design against 
TB. Our studies suggest that targeting Th17 cells, enhancing expression of CXCR5, or 
suppressing IFN-γ production in Th17 recall responses may all provide novel avenues and 
pathways to improve Th17 cell function and improve vaccine efficacy against TB. 
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4.0  CO-INFECTIONS SHAPE DISEASE OUTCOME DURING TB 
4.1.1 Co-endemicity of diseases with TB 
The immune requirements for primary control of TB and the optimal responses for vaccine-
mediated immunity remain incompletely understood. However, an additional layer of complexity 
is added by the fact that TB in natural human populations rarely occurs in isolation [127]. For 
example, in sub-Saharan Africa, HIV, malaria, TB and multicellular parasite infections each 
cause significant morbidity and mortality [127]. This highlights the notion that in many regions 
of the world, individuals may display concurrent immune responses to several pathogens, which 
can affect one another.  
Perhaps the best studied co-infection between Mtb and another pathogen is the HIV-TB 
syndemic [128]. HIV infection is the major risk factor for progression to active TB, increasing 
the risk for TB reactivation by 20 to 30-fold [14]. In turn, TB is the most common single cause 
of death in individuals with AIDS, accounting for 26% of AIDS-related deaths [129]. It has been 
estimated that about 14 million individuals are co-infected with HIV and Mtb [130], which 
greatly adds to the mortality and impact of each individual pandemic. The reduction of CD4+ cell 
counts associated with progression to AIDS contributes to the increased reactivation rates in 
HIV-Mtb co-infected individuals [131, 132]. Additional immune changes, such as impairment of 
CD8+ T cell responses, up-regulation of Mtb receptors in macrophages [133], changes in 
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macrophage killing capacity [134] and impaired chemotactic mechanisms [135] may all 
contribute to less efficient TB control in HIV-infected individuals. 
Malaria causes approximately 200 million new infections and over 500 000 deaths every 
year. It is an arthropod-borne disease, spread by female mosquitoes of the genus Anopheles, and 
can be caused by five species of parasites of the genus Plasmodium [136]. Similar to TB, it is 
endemic in tropical and developing regions of the world, and its effect on Mtb control has been 
explored in several studies. Co-infection between Mtb and Plasmodium exacerbated Mtb 
bacterial burden and led to increased mortality in a mouse model [137]. More recently, a 
different study showed that Plasmodium infection increased Mtb bacterial burden, while 
enhancing lung pathology and dysregulating T cell responses in mice [138]. Importantly, a study 
conducted in a hospital in Guinea-Bissau showed that increasing preventive measures for 
malaria, including bed nets, vector control and anti-malaria prophylaxis reduced the mortality in 
TB patients [139]. Together, these findings indicate that malaria may hinder TB control and 
promote reactivation in co-infected patients. 
The outcome of co-infection on TB disease control, however, is not always detrimental to 
the host. Helicobacter pylori, which infects the gastric mucosa and epithelial lining of the 
stomach, and is the leading cause of gastric cancer and peptic ulcers, infects about 80% of 
individuals in TB-endemic regions [140]. Similar to Mtb, H. pylori induces the secretion of 
numerous proinflammatory cytokines, including IFN-γ, TNF-α, IL-1β and IL-6 [141]. In 
addition, high IL-12 production leads to the differentiation of Th cells to the Th1 subset [142]. 
Interestingly, a recent study has shown that a cohort of individuals from California who were 
seropositive for H.pylori and PPD positive had enhanced IFN-γ production in response to TB 
antigens. In addition, H. pylori-infected individuals were less likely to progress to active TB in a 
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separate Gambian cohort, and these findings were validated in a NHP model [143]. Together, 
these results suggest that H. pylori co-infection may play a beneficial role in Mtb containment.  
4.1.2 Helminth modulation of host immune responses 
Helminth parasites constitute a broad group of organisms that can cause pathology in vertebrate 
hosts. It is estimated that approximately 1 billion people living in developing regions of the 
world are infected with one or more helminths [144]. Although rarely lethal, helminths tend to 
establish chronic infections, which limit cognitive development and lead to stunted growth in 
children [145], and contribute to morbidity in adults. Their complex life cycle involves invasion 
of intermediate and definitive hosts, which in humans often occurs via the oral or skin route. 
Following invasion, parasites can establish themselves in different organs of the definitive host, 
which can range from the gastrointestinal tract, to the lungs, liver, circulatory system and brain 
[146].  
However, despite evolutionary divergence, immune responses against such parasites are 
strikingly conserved, and greatly differ from those induced by viruses and bacteria. Adaptive 
immune responses against helminths are characterized by the activation of Th2 cells, which 
secrete IL-4, IL-5 and IL-13 and antagonize Th1 responses [147]. These mediators lead to the 
activation of several effector mechanisms, including antibody class switch to IgE, activation of 
eosinophils, mast cells and basophils, increased smooth muscle contractility and mucus secretion 
[146]. The relative contribution of each mechanism to host defense against helminths varies 
depending on the specific infecting species.  
In addition, although these responses are well adapted to parasite elimination, they often 
contain a regulatory component, elicited by the parasite, which compromises clearance of the 
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parasite but protects the host from excessive damaging immunopathology [147, 148]. This is 
particularly important as helminths generally establish chronic infections, each individual worm 
having a lifespan that can range from months (in the case of gastrointestinal nematodes) to 
decades (in the case of schistosomes). Regulation of inflammation is one of the mechanisms 
through which these parasites can ensure their continued survival in their definitive host, and this 
can occur at multiple levels. Macrophages acquire an alternatively activated phenotype in 
response to helminth molecules, which is characterized by increased Arginase-1, Ym-1 
(chitinase-3-like-3) and RELM-α (resistin-like molecule α) expression [147]. Together, these 
molecules can regulate tissue repair processes, and are involved in extracellular matrix repair, 
wound healing and fibrosis. In addition, alternatively activated macrophages (AAMs) can secrete 
anti-inflammatory cytokines, including IL-10 and TGF-β. Unlike classic macrophage activation, 
AAMs possess decreased iNOS expression, inhibit T cell proliferation in vitro and mediate 
fibrosis. Helminth products similarly affect other cells of the innate immune system. DCs 
exposed to helminth antigens possess decreased expression of costimulatory molecules, 
including CD40, CD80 and CD86, and preferentially drive Th2 and Treg differentiation [149]. 
Further, parasite-specific T cell responses are inhibited in chronic helminth infections, as 
evidenced by the antigen-specific hyporesponsiveness of blood T cells following in vitro 
restimulation PBMCs of patients with Schistosomiasis [150]. Interestingly, such effects were 
reversible, and dependent on parasite persistence, as antihelminthic drug treatment abolished the 
inhibition [150]. Finally, helminths can lead to the activation and accumulation of several 
regulatory cell types, including Foxp3+ Tregs [151], IL-10-producing Tr1 cells [152] and 
regulatory B cells (Bregs) [153] in Schistosoma infections.  
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4.1.3 Tuberculosis and helminth co-infections 
As we described in the previous section, helminth parasites skew the immune response to a Th2 
response and simultaneously limit the establishment of immune responses that would lead to 
their elimination. These immune changes, however, are not confined to parasite-specific 
responses, as helminth infections have been linked to impaired immune responses to vaccines 
[154] and co-infecting pathogens [155]. Interestingly, these regulatory mechanisms can be 
beneficial in conditions of pathologic inflammation, including allergy [153] and autoimmunity 
[156, 157]. 
The single factor that most strongly impacts efficacy of the BCG vaccine is geographical 
latitude. Indeed, protection from adult pulmonary TB is lowest in developing countries found 
within 30 degrees latitude of the equator. In addition, the death rates from TB during the first 2 
months of antibiotic regime initiation are high in developing countries. Despite the presence of 
confounding factors, including co-infection with HIV, difficulty in access to health care and 
disease severity at the time of diagnosis, death rates remain higher even when these factors are 
taken into account. Among the proposed hypotheses to explain this phenomenon is modulation 
of anti-mycobacterial immune responses by co-infecting helminths. Indeed, several studies 
suggest that infection with parasitic worms hinders the ability to mount efficient anti-
mycobacterial responses.  
Human studies on co-infected individuals suggest that infection with helminths 
compromises protection conferred by M. bovis Bacillus Calmette-Guerin (BCG) vaccination 
[158-160], and may be associated with increased TB reactivation rates in HIV-infected patients 
[161]. In addition, antihelminthic treatment of individuals who were immunized with BCG 
vaccination resulted in increased proliferation and IFN-γ production by peripheral blood 
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mononuclear cells (PBMC) in response to PPD stimulation [162]. In experimental models, mice 
chronically infected with Schistosoma mansoni have increased susceptibility to M. bovis BCG 
systemic infection, accompanied by decreased M. bovis BCG-specific Th1 responses [163].  
Additionally, S. mansoni-infected mice vaccinated with M. bovis BCG demonstrate reduced 
protection upon subsequent Mtb systemic challenge [164]. In a mouse model of Mtb infection, 
repeated infections with Nippostrongylus brasiliensis led to a significant increase in bacterial 
burden. This effect correlated with AAM accumulation, but T cell responses were unaltered 
[165]. Thus, the prevailing models suggest that Th2 responses or their effector mechanisms, 
induced due to helminth co-infections, impair Th1 immune responses and Mtb control.  
4.1.4 Schistosoma mansoni 
Approximately one billion people are infected with one or more helminths, of which 
schistosomiasis, caused by trematodes of the genus Schistosoma, affects about 207 million 
individuals [166]. S. mansoni leads to about 130,000 deaths ever year and is a significant cause 
of morbidity in many infected individuals, causing diarrhea in 780,000 individuals, blood in stool 
in 4.4 million and hepatomegaly in 8.5 million [167]. Two main clinical conditions can be 
observed in S. mansoni-infected individuals- acute or chronic schistosomiasis. The former, also 
known as Katayama fever, occurs during the first 6 to 8 weeks of infection, and is characterized 
by elevated levels of serum TNF, IL-1 and IL-6. Interestingly, it most frequently presents in 
individuals who are traveling to endemic areas and mount strong Th1 rather than Th2-skewed 
immune responses [168]. Chronic schistosomiasis, in turn, can present in its most severe form as 
hepatosplenic disease with hepatic fibrosis, hepatosplenomegaly and portal hypertension, which 
arises from persistent immune granulomatous responses to S. mansoni eggs that become lodged 
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in the liver [169, 170]. Efforts to control this disease include elimination of the snail intermediate 
host, the prevention of sewage waste contamination of freshwater, avoiding human contact with 
water containing infected snails and treatment of infected individuals. In this regard, praziquantel 
is the most widely used drug against S. mansoni. Several factors have contributed to its 
widespread use, including its effectiveness after only one oral dose, lack of toxicity and low cost 
(US$ 0.15 per child and US$ 0.30 per adult) [171]. Its exact mechanism of action remains 
unknown, but is thought to involve activation of calcium channels and disruption of adenosine 
absorption from the host, a process that is essential for parasite survival. In addition, praziquantel 
has been shown to increase antigen expression on the worm surface, increasing S. mansoni 
targeting by host antibodies [171].   
Flukes of the Schistosoma genus differ from other helminths in four ways: they have only 
two hosts, are non-hermaphroditic, they infect their definitive hosts through breaching the skin 
barrier rather than via ingestion, and reside in the circulatory system [168]. Schistosoma 
mansoni’s life cycle is shown in Figure 9. Schistosoma mansoni eggs are eliminated in the feces 
of infected individuals, which can reach freshwater reservoirs if there is contamination with 
human sewage (Fig 9A). These eggs hatch, releasing miracidia (Fig 9B), which can swim by 
ciliary movement until they invade an intermediate snail host (Fig 9C). Within the snails, 
miracidia develop into sporocysts, which have the potential of giving rise to thousands of 
cercariae (Fig 9D). Cercariae are then liberated into freshwater, where they can then swim and 
penetrate the skin of a definitive vertebrate host (Fig 9E). Upon entry, these parasites shed their 
tails and become schistosomulae, and migrate predominantly to the mesenteric veins of the large 
intestine and develop into male or female adult parasites (Fig 9F). Upon pairing, adult males and 
females reproduce, each couple producing up to 300 eggs per day (Fig 9G). The released eggs 
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pierce their way through the intestinal wall into the lumen and are excreted in the feces (Fig 9H), 
thereby completing the cycle. 
 
Figure 9. Schistosoma mansoni life cycle. 
(A) S. mansoni eggs are eliminated in the feces of infected individuals, which can reach freshwater reservoirs if 
there is contamination with human sewage. (B) These eggs hatch, releasing miracidia, which swim by ciliary 
movement (C) until they invade an intermediate snail host. (D) Within the snails, miracidia develop into sporocysts, 
which have the potential of giving rise to thousands of cercariae. (E) Cercariae are then liberated into freshwater, 
where they can then swim and penetrate the skin of a definitive vertebrate host. (F) Upon entry, cercariae shed their 
tails, becoming schistosomulae, which migrate predominantly to the mesenteric veins of the large intestine and 
develop into male or female adult parasites. (G) Upon pairing, adult males and females reproduce, each couple 
producing up to 300 eggs per day. (H) The released eggs pierce the intestinal wall into the lumen and are excreted in 
the feces, thereby completing the cycle. Figure was produced using Servier Medical Art (www.servier.com). 
 
 
 53 
The nature of the immune response to S. mansoni is thought to proceed through three 
phases [168]. During the initial 3-5 weeks, prior to the development of adult worms, T cells 
mainly develop into the Th1 subset. However, at the onset of egg production between 5-6 weeks 
post-infection, the immune response switches toward a Th2 type. Interestingly, egg deposition 
has been shown to trigger this Th2 differentiation, and numerous studies have used Schistosoma 
egg antigens (SEA), an egg lysate, to explore the mechanisms driving this immune response in 
the absence of the tissue damage caused by the presence of the live parasite. Subsequently, as the 
infection reaches its chronic phase, a regulatory component arises, dampening Th2 inflammation. 
In this work, we have studied the effect of S. mansoni infection on a subsequent Mtb 
infection using a mouse model. Our previous findings showed that T cells in Mtb infection are 
plastic, with Mtb-specific Th1 cells being able to acquire Th2 cytokine production after in vitro 
treatment under Th2-skewing conditions. In addition, several studies have shown that innate 
immune cells differ between Mtb and helminth infections. This suggests that immune changes 
induced by helminth infections may reduce the effectiveness of anti-Mtb immune responses. 
Importantly, this posits the interesting notion that deworming may serve as a simple, cost-
effective strategy to improve Mtb control and limit TB reactivation in individuals living in areas 
of high TB and helminth co-endemicity. 
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5.0  THE EFFECT OF SCHISTOSOMA MANSONI CO-INFECTION AND 
ANTIGENS ON TUBERCULOSIS 
5.1 SUMMARY 
Helminths are endemic in populations where tuberculosis (TB) prevalence is highest. 
Human studies suggest that helminth co-infections contribute to increased susceptibility to TB 
and increased rates of TB reactivation. The prevailing models suggest that Th2 responses 
induced due to helminth co-infections impair Th1 immune responses and limit Mycobacterium 
tuberculosis (Mtb) control. Using a pulmonary mouse model of Mtb infection, we show that 
Schistosoma mansoni co-infection or treatment with S.mansoni egg antigens can reversibly 
impair Mtb-specific T cell responses without affecting macrophage mediated Mtb control. 
Instead, S. mansoni infection results in accumulation of high arginase-1-expressing macrophages 
in the lung, forming type 2 granulomas and mediating exacerbated inflammation in Mtb-infected 
mice. In a Mtb-infected genetically diverse mouse population, increased lung inflammation is 
also associated with enhanced arginase-1 activity. Most importantly, increased serum activity of 
arginase-1 in human pulmonary TB patients correlates with lung damage, and serum arginase-1 
activity is increased in TB patients co-infected with helminths. Thus, helminth co-infections 
induce arginase-1-expressing type 2 granulomas and increase inflammation and TB disease 
severity; effects that can be reversed by treatment with anti-helminthics. Thus, our data provide 
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novel insights into the mechanisms by which helminth co-infections drive increased 
susceptibility, disease progression and severity in TB. 
5.2 METHODS 
Human tissue samples and patient diagnosis.  
Fresh blood samples from ATB patients were obtained from patients recruited to the 
Tuberculosis Outpatient Clinic, INER, Mexico or NIH-NIRT-ICERT, Chennai, India. Serum 
samples from all patients with ATB were collected prior to anti-Mtb treatment and did not 
present co-morbidities such as diabetes, HIV, cancer and COPD. For ATB patients, chest 
radiographs were assessed for the presence, distribution and extent of pulmonary abnormalities, 
such as airway consolidation and fibrosis, lung distortion, traction bronchiectasis, irregular 
interfaces and parenchymal bands. We developed a quantitative scale for measuring the degree 
of lung damage, according to the profusion of pulmonary abnormalities. The pulmonary 
parenchyma was evaluated in four quadrants with the division between the upper and lower lung 
in both sides being arbitrarily set at the carina section. Each quadrant was scored from 0 to 5, 
where 0 denotes absence of lesions and 5 is the maximum affection. The score represented the 
percentage of lung parenchyma involvement. The maximum score for the four lung zones was 20 
[126]. The images were blinded and the same image was read twice separately by an experienced 
observer (pulmonologist researcher). The reported score is the mean of two measurements.  
Buffy coats from 20 mL of EDTA anticoagulated peripheral blood from ATB and LTB 
patients, who signed an informed consent letter, were obtained at the Tuberculosis clinic of the 
INER. Total peripheral blood mononuclear cells (PBMCs) were obtained by density gradient 
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centrifugation using Lymphoprep (Axis-Shield, Oslo, Norway). CD14+ monocytes were purified 
using magnetic beads (Miltenyi, Auburn, CA, USA). Purity of isolated monocytes was assessed 
by flow cytometry using anti-human monoclonal antibodies: CD14-FITC and CD3-PE-Cy7 
(BioLegend, San Diego, CA, USA), obtaining > 97% purity. Total RNA was isolated from 
monocytes for real time RT-PCR expression assays using validated TaqMan assays.  
In samples collected from NIH-NIRT-ICER, Chennai, India, we studied a group of 44 
individuals with active pulmonary TB, 22 of whom were infected with the helminth 
Strongyloides stercoralis. Active pulmonary TB was diagnosed microbiologically on the basis of 
being at least culture positive for Mtb by solid cultures in LJ medium (some were also sputum 
smear positive). Strongyloides infection was diagnosed by the presence of IgG antibodies to the 
31-kDa recombinant NIE antigen by the Luciferase Immunoprecipitation System Assay, as 
described previously [172]. 
Animals.  
C57BL/6 mice were purchased from Taconic Labs, and IFN-γ-YFP reporter mice were 
obtained from Dr. Markus Mohrs, Trudeau Institute [173].  ESAT-6 (Early Secreted Antigenic 
Protein 6) transgenic (Tg) mice, expressing the αβ TCR specific for the IAb-presented ESAT-61-
20 peptide were kindly provided by Dr. G. Winslow (Wadsworth Center, Albany, NY) and Dr. D. 
Woodland (Trudeau Institute, Saranac Lake, NY) [101]. The ESAT-6 TCR Tg mice were 
maintained on the Rag1-/- background. Yarg (Arginase-1 eYFP reporter mice), C57BL/6.SJL and 
DO mice were purchased from Jackson Labs. Tie2CreArg1flox/flox bone marrow as well as 
Arg1flox/flox (WT) mice were used as before [174]. Mice strains were bred and maintained in 
house either at the University of Pittsburgh or Washington University in St.Louis. Experimental 
mice were age-and sex-matched and used between the ages of 6-8 wks in accordance with 
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Animal Care and Use Committee guidelines.  
Mtb aerosol infection, S.mansoni infection and and immunizations.  
Mtb strain H37Rv was cultured in Proskauer Beck medium containing 0.05% Tween 80 
to mid-log phase and frozen in 1 ml aliquots at -80°C. For Mtb infections, animals were aerosol 
infected with ~100 Colony Forming Units (CFU) of bacteria using a Glas-Col airborne infection 
system. At given time points, organs were harvested, homogenized and serial dilutions of tissue 
homogenates plated on 7H11 agar plates supplemented with OADC. Additionally, lung samples 
were processed for RNA extraction, histology and cytokine determination. For S. mansoni, Mtb 
co-infections, mice were infected by percutaneous exposure to 55 S. mansoni cercariae (Puerto 
Rican strain, Naval Medical Research Institute) 6 weeks prior to Mtb aerosol challenge. 
S.mansoni liver egg burden was determined by overnight digestion of the liver in 4% KOH at 
37ºC. Eggs were enumerated by microscopic observation of the liver suspensions. SEA was 
prepared as described before [175]. For immunizations, 50μg of SEA, BSA or PPD were 
subcutaneously administered to mice as described before [175]. 
Antihelminthic treatment.  
S.mansoni treatment was performed by oral gavage with 6.25 mg of praziquantel in a 
volume of 300μL [176]. S.mansoni, Mtb co-infected mice received 3 doses of praziquantel, 24, 
72 and 120 hrs following Mtb infection. Control mice instead received 300μL of PBS. 
Generation of BMC mice.  
To generate BMC mice, we treated C57BL/6.SJL mice with Sulfamethoxazole and 
Trimethroprim (Hi-Tech Pharmacal) in the drinking water for 2 weeks prior to irradiation. Mice 
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were sublethally irradiated with 1000 rad and were reconstituted with 5-10x106 bone marrow 
cells from either WT control (Arg1flox/flox ) or Tie2cre Arg1flox/flox mice via i.v. injection as before 
[102]. Mice were allowed to reconstitute for 6 weeks while continuing to receive antibiotic 
water, after which they were used in experimental procedures. Bone marrow reconstitution was 
verified by flow cytometric analysis of peripheral blood cells.  
Modified Cornell mouse model of latent tuberculosis.  
C57BL/6 mice were aerosol infected with ~100 CFU of Mtb H37Rv using a Glas-Col 
airborne infection system and rested for 30 days. Mice were subsequently treated for 6 weeks 
with rifampicin (100mg/L) and isoniazid (200mg/L) in the drinking water [126]. After a 2 week 
period, mice received either 2 subcutaneous immunizations of 50μg SEA or PBS. Lung and 
spleen bacterial burden was determined 2 weeks after the second immunization, as described 
above. 
CD4+ T cell isolation, in vitro T cell differentiation and restimulation.  
Single cell suspensions from DNAse/collagenase-treated lung tissue or spleen were 
prepared as previously described [84]. CD4+ T cells from secondary lymphoid organs of ESAT-6 
TCR Tg mice or from the lungs of Mtb-infected mice were isolated using magnetic CD4+ beads 
(GK1.5, MiltenyiBiotech), according to the manufacturer’s instructions. For SEA treatment, cells 
were incubated in the presence of irradiated splenocytes, 5μg/ml ESAT-6 peptide, 10U/mL IL-2 
with 50μg/ml SEA. T cells were incubated for six days at 37°C and 5% CO2 and supplemented 
with an equivalent volume of media containing IL-2 (10U/ml) on day 3. Control cells were 
incubated using the same peptide and cytokine concentrations in the absence of SEA. After 6 
days, T cells were restimulated with irradiated splenocytes and 5µg/mL ESAT-6 peptide for 48h. 
 59 
Tissue culture supernatants were then harvested and used in ELISA, while cell pellets were 
processed for RNA extraction.  
Arginase-1 activity determination.  
Arginase-1 activity in serum or lung homogenates was determined using the 
QuantiChrom Arginase Assay Kit (BioAssays Systems, Hayward, CA). For serum samples, urea 
was eliminated by performing 2 washes with PBS through Amicon Ultra 0.5 (10kDa cutoff, 
Millipore). For lung homogenates, protein concentration was adjusted to 100μg/mL. 40μL of 
sample was incubated at 37°C for 120 minutes in the presence or absence of 10μL of 5X assay 
reagent. Urea levels were subsequently detected and calculated according to the manufacturer’s 
instructions. Arginase-1 activity is expressed as U/L of sample. 
Cytokine and chemokine protein determination.  
Culture supernatants or lung homogenates were generated and cytokine and chemokine 
concentrations were determined by sandwich ELISA (Mouse DuoSet ELISA-R&D Systems) or 
Luminex (Millipore), according to the manufacturer’s instructions. 
Flow cytometry.  
Single-cell lung suspensions from lung tissue were stained with fluorochrome-labeled 
antibodies specific for CD3 (145-2C11), CD4 (RM4-5), CD44 (IM7), CD11c (HL3), CD11b 
(M1/70), MHC class II (M5/114.15.2) or isotype control antibodies (BD Biosciences). For 
intracellular cytokine staining, lung cell suspensions were stimulated with 50ng/mL PMA 
(Sigma-Aldrich), 750ng/mL ionomycin (Sigma-Aldrich) and GolgiStop (BD Biosciences) for 5 
hours at 37°C.  Following Fc block incubation (BD Biosciences), surface staining was carried 
out. Cells were then permeabilized with Cytofix-Cytoperm solution (BD Biosciences), and 
stained with anti-IFN-γ(XMG1.2) or anti-IL-4 (11B11) (BD Biosciences). Cells were analyzed 
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using a Becton Dickinson LSR II flow cytometer using FACS Diva software. Cells were gated 
based on their forward by side scatter characteristics and the frequency of specific cell types was 
calculated using FlowJo (Tree Star, CA). Mean fluorescence intensity was also determined to 
define expression levels of different molecules using FlowJo. 
Real-time PCR.  
RNA was extracted using the RNeasy kit (Qiagen) and cDNA was then amplified with 
FAM-tagged probes and PCR primers on a Viia7 thermocycler. Specific gene expression was 
calculated relative to Gapdh expression. Primer and probe sequences targeting specific genes 
were commercially purchased (ABI Biosystems). 
Detection of IFN-γ-producing cells by ELISpot.  
ESAT-61-20-specific IFN-γ-producing CD4+ T cells from infected lungs were quantified 
using peptide-driven ELISpot. Briefly, 96-well ELISpot plates were coated with monoclonal 
anti-mouse IFN-γ (R46A2, eBioscience) in phosphate-buffered saline and blocked with media 
supplemented with 10% FBS. Cells from lungs were plated at an initial concentration of 5x105 
cells/well and serial two-fold dilutions were made. Restimulation was carried out in the presence 
of 1x106 cells/well C57BL/6 irradiated splenocytes, ESAT-61-20 peptide (10µg/mL) and mouse 
rIL-2 (10U/mL). After 24 hours, plates were washed and probed with biotinylated anti-mouse 
IFN-γ (XMG1.2, eBioscience). Spots were enumerated using a CTL-immunospot S5 
MicroAnalyzer. No spots were detected in cultures lacking antigen. 
RNA seq.  
Total RNA was isolated using the RNEasy Mini kit (Qiagen, Hilden, Germany) and RNA 
integrity was determined with the Agilent 2100 Bioanalyzer (Carlsbad, CA). Briefly, mRNA was 
purified from 2–5 μg of total RNA using Sera-Mag Oligo(dT) Beads, fragmented with 
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magnesium-catalyzed hydrolysis and reverse transcribed into cDNA using random primers 
(Superscript II; Invitrogen). Then, cDNA underwent end repair with T4 DNA polymerase and 
Klenow DNA polymerase, followed by the addition of ‘A’ bases to the 3′ end, and ligation to 
adaptor oligos. Products from the ligation were run on a 2% agarose gel. A gel slice consisting of 
the 200 bp region (+/−25 bp) was excised and used as a template for PCR amplification. The 
final PCR product was purified, denatured with 2 N NaOH, and diluted to 10–12 pM prior to 
cluster amplification on a single-read flow cell v4, as outlined in the Single Read Cluster 
Generation Kit v4 (Illumina). The flow cell was sequenced on an Illumina Genome Analyzer II. 
We mapped reads to Mus musculus (mm9) reference transcriptome from GenBank using 
the bwa alignment tool. For sample-wise data normalization, we applied DESeq using R 
statistical software. To achieve more reliable results, we applied 3 popular methods for detecting 
differentially expressed genes (DEGs) using RNAseq data: edger, DESeq and baySeq. We 
considered genes detected by at least 2 methods as DEGs when they had a q-value (FDR) less 
than 0.05. Pathway analysis was performed using Ingenuity IPA. P-values from Fisher’s exact 
test were adjusted by Benjamini-Hochberg multiple testing correction.   
Morphometric analysis and Immunofluorescence.  
Lungs from Mtb-infected mice were inflated with 10% neutral buffered formalin and 
paraffin embedded. Lung sections were stained with H&E stain (Colorado Histo-Prep) and 
processed for light microscopy. To visualize collagen deposition, Gomori’s trichrome staining 
(Sigma Aldrich, MO) was performed according to the manufacturer’s instructions. Mucus was 
detected by Periodic acid-Schiff (PAS) stain. Slides were prepared for immunofluorescent 
staining by deparaffinization and subsequent rehydration by washes with xylene, alcohol and 
PBS. Antigen retrieval was performed using a DakoCytomation Target Retrieval Solution, 
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followed by blocking with 5% (v/v) normal donkey serum and Fc block (5ug/mL, 2.4G27). 
Endogenous biotin was neutralized with avidin followed by biotin (Sigma-Aldrich). Sections 
were stained with goat anti-mouse CD3ε (M-20; Santa Cruz Biotechnology), rat anti-mouse 
B220 (RA3-6B2; BD Pharmingen), inducible NO synthase (goat anti-mouse, M-19; Santa Cruz 
Biotechnology), F4/80 (MCA497GA, Serotec), Arginase-1 (rabbit anti-Arginase I, H-52, Santa 
Cruz Biotechnology) and biotin monoclonal mouse anti-mouse Muc5AC (45M1; Abcam). 
Primary antibodies were detected with secondary antibodies conjugated to Alexa fluor 568 for 
iNOS and CD3 (A-11057, Life Technologies). Donkey anti-rat Ab conjugated to Alexa Fluor 
488 was used to visualize B220 (A-21208, Life Technologies), donkey anti-rabbit conjugated to 
FITC was used to visualize Arginase-1 (711-095-152, Jackson Immunoresearch laboratories). 
Streptavidin-Alexa Fluor 488 was used to visualize Muc5AC (Life Technologies). Slow fade 
gold antifade with DAPI (Life Technologies) was used to counterstain tissues and to detect 
nuclei. Images were obtained with a Zeiss Axioplan 2 microscope and were recorded with a 
Zeiss AxioCam digital camera. Caudal lobes underwent morphometric analysis in a blinded 
manner using the morphometric tool of Zeiss Axioplan microscope, which determines the area 
defined by the squared pixel value for each granuloma and B cell follicle [102].  
In vitro Mtb-killing assay.  
Bronchoalveolar lavage was performed on euthanized naïve C57BL/6 mice with sterile 
PBS containing 0.2 mM EDTA. Following centrifugation, cells were incubated for 1 h at 37oC, 
after which adherent cells were used for subsequent studies. CD4+ T cells from Mtb-infected 
mice were sorted as previously described and treated in the presence or absence of SEA for 6 
days. Following restimulation, T cells were washed extensively and then layered over Mtb-
infected alveolar macrophages (MOI 1:1) for 6 days. At the end of the culture period, 
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macrophages were washed twice with PBS, lysed by a 5 min incubation with 0.05% SDS. 
Following SDS neutralization with 10% BSA, intracellular Mtb burden was determined by 
plating of serial dilutions on 7H11 plates. 
Detection of nitrites by the Griess reaction.  
Culture  supernatants were assessed for nitrite production by using the Griess Reagent 
System Kit (Promega, Madison, WI), according to the manufacturer’s instructions. 
Statistical Analysis.  
Differences between the means of multiple experimental groups were analyzed using 
one-way ANOVA with Tukey’s post-hoc test. For all other analyses, we used the two-tailed 
Student’s t-test. Correlation between variables was determined by calculating Pearson’s 
coefficient using a two-tailed analysis. Differences were considered significant when p≤0.05. For 
all figures, data represent mean ± SD. All analyses were performed using GraphPad Prism 
Software. 
Study approval.  
All individuals were examined as part of a clinical research protocol approved by the 
Institutional Review Board of the Tuberculosis Outpatient Clinic, INER, Mexico or NIH-NIRT-
ICERT, Chennai, India and informed written consent was obtained from all participants. All 
mice were used following the National Institutes of Health guidelines for housing and care of 
laboratory animals and in accordance with University of Pittsburgh and Washington University 
in St. Louis Institutional Animal Care and Use Committee guidelines. All efforts were made to 
minimize suffering and pain as described in these approved protocols. 
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5.3 RESULTS 
S. mansoni co-infection induces lung fibrosis and exacerbates inflammation during 
TB 
Although helminth co-infections are thought to increase susceptibility to Mtb infection, 
the mechanisms underlying this association remain poorly understood. To experimentally model 
helminth and Mtb co-infection, we infected C57BL/6 Arginase-1 Yellow Fluorescent Protein 
(YFP) reporter mice (Yarg mice) with S. mansoni and allowed helminth infection to progress for 
6 weeks, a period associated with induction of potent Th2 responses [177]. Following this, mice 
were infected with low doses of aerosolized Mtb and TB disease progression was monitored. 
Mice co-infected with S. mansoni and Mtb had larger inflammatory granulomas in the lungs (Fig 
10A and 11A-upper panel), which contained both eosinophils and neutrophils (Fig 11A-lower 
panel). In contrast, smaller and more lymphocytic granulomas were detected in the lungs of Mtb-
infected mice (Fig 10A and 11A). The increased inflammatory response coincided with a 
significant increase in the number of arginase-1-expressing macrophages in S. mansoni, Mtb co-
infected mice, when compared to Mtb-infected mice (Fig 10B). In addition, increased pulmonary 
mRNA expression for Arg1, and increased arginase-1 activity in the serum of S. mansoni, Mtb 
co-infected mice was detected, when compared to Mtb-infected mice (Fig 10B). Interestingly, in 
co-infected lungs, we found that type 2 granulomas containing high arginase-1 expressing 
macrophages were distinct (55% of granulomas) and in close proximity to type 1 granulomas 
(45% of granulomas) typically containing macrophages expressing high inducible nitric oxide 
synthase (iNOS) (Fig 10C,D), while no type 2 granulomas were observed in Mtb-infected lungs.  
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Figure 10. S. mansoni induces arginase-1-expressing type 2 granulomas and exacerbates inflammation during 
co-infection with Mtb. 
S. mansoni-infected (Mtb+Sm) or control Yarg mice (Mtb) were aerosol infected with Mtb. (A) On D30 post 
infection, pulmonary inflammation was assessed on FFPE lung sections stained with H&E. 100X magnification. 
Total area occupied by inflammatory lesions per lobe was quantified. (B-left panel) Arginase-1 reporter expression 
in lung macrophages was detected by flow cytometry. (B-middle panel) Arg1 mRNA expression in total lung was 
assessed by RT-PCR and expression relative to Gapdh expression shown. (B-right panel) Arginase-1 activity was 
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quantitated in the serum of infected mice. (C) FFPE sections from infected mice underwent immunofluorescence 
staining using antibodies specific for arginase-1, iNOS and F4/80. 4X4 mosaics of 200X magnification fields are 
shown. “Type 1” granulomas (red selection), “type 2” granulomas (green selection) and interstitial macrophages 
(arrows) are shown. (D) The number of high iNOS+ and high arginase-1-expressing F4/80+ cells per 200X field were 
counted and ratio of high arginase-1-expressing cells to high iNOS-expressing cells per field is shown. n=4-5 mice 
per group. Lungs of all mice were included in the analysis, one representative image per group is shown. Lungs of 
all mice were included in the analysis, one representative image per group is shown. *p≤0.05, ***p≤0.001, 
****p≤0.0001 unpaired, two-tailed Student’s t-test (A, B) or one-way ANOVA with post-hoc Tukey (D). Results 
are representative of 3 independent experiments. 
 
In addition, arginase-1-expressing macrophages were also localized within the lung 
interstitium of S. mansoni Mtb-co-infected mice, but not in the lungs of Mtb-infected mice (Fig 
10C,D). Interestingly, mice infected with S. mansoni alone also exhibited increased 
inflammation, when compared to either uninfected lungs or Mtb-infected lungs and exhibited 
increased accumulation of arginase-1-expressing macrophages (Fig 11B,C).  Together, these data 
demonstrate that S. mansoni infection results in accumulation of arginase-1-expressing 
macrophages in the lung, and upon infection with Mtb promotes exacerbated inflammation and 
increased TB disease severity. 
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Figure 11. S. mansoni co-infection leads to increased lung pathology during TB. 
S. mansoni-infected or control Yarg mice were either left untreated or aerosol infected with Mtb. (A) On day 30 
post-infection, pulmonary inflammation in Mtb-infected (Mtb) or co-infected (Mtb+Sm) mice was assessed on FFPE 
lung sections stained with H&E. Upper panel, 200X magnification, lower panel, 400X magnification. (B) Additional 
FFPE lung sections from uninfected (Un), S. mansoni (Sm)-infected, Mtb-infected or co-infected mice were stained 
with H&E. Total area occupied by inflammatory lesions per lobe was quantified. (C) Arginase-1 reporter expression 
in lung macrophages was determined by flow cytometry. n=4-5 mice. Lungs from all mice were included in the 
analysis, one representative image per group is shown. *p≤0.05, ***p≤0.001, ND-not detectable, one-way ANOVA 
with post-hoc Tukey. 
 
Coincident with increased accumulation of arginase-1-expressing macrophages, we also 
found increased expression of Th2 cytokines such as Il4 and Il13 mRNA in the lungs of S. 
mansoni, Mtb co-infected mice (Fig 12A). This also coincided with increased expression of 
mRNA for matrix metalloproteases such as Mmp13, and neutrophil derived products such as 
 68 
myeloperoxidases (Mpo) in S. mansoni, Mtb co-infected lungs (Fig 12A). Furthermore, lungs 
from S. mansoni, Mtb co-infected mice showed increased numbers of Muc5AC+ goblet cells, 
increased staining for mucins and glycogen in Periodic acid-Schiff (PAS) stained lung sections, 
as well as increased collagen deposition within type 2 granulomas (Fig 12B). These data together 
suggest that helminth infection drives accumulation of high arginase-1-expressing macrophages 
inside type 2 granulomas and interstitial areas, induces mucus production, local fibrosis, and 
exacerbates pulmonary inflammation in Mtb co-infected mice.  
Our recent studies have demonstrated that in TB, protective granulomas contain distinct 
B cell lymphoid follicles harboring T cells and macrophages, while inflammatory granulomas 
lack well-formed B cell containing lymphoid follicles, and instead contain neutrophils that 
mediate inflammation [102, 126]. Thus, we next measured the area occupied by lymphoid B cell 
follicles and found that S. mansoni co-infection in Mtb-infected mice, resulted in decreased and 
poorly formed B cell follicles (Fig 12C). Consistent with reduced B cell follicle formation, we 
also found that T cell accumulation was decreased within the lymphoid follicles, and T cells 
instead formed perivascular cuffs (Fig 12D). These data suggest that the majority of granulomas 
formed in S. mansoni, Mtb co-infected lungs are preferentially composed of granulocytes, and 
loosely organized B cell lymphoid follicles, a feature associated with non-protective 
inflammatory granulomas [102].  
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Figure 12. S. mansoni co-infection leads to increased lung pathology, impaired Th1 responses and increased 
susceptibilty to Mtb infection. 
S. mansoni-infected (Mtb+Sm) or control Yarg mice (Mtb) were infected with Mtb. (A) On D30 post-infection, lung 
expression of Il4, Il13, Mmp13 and Mpo mRNA relative to Gapdh was determined by RT-PCR. (B) FFPE sections 
were processed for immunofluorescence using antibodies for Muc5AC and CD3; mucus and glycogen accumulation 
by the PAS stain, and collagen deposition by Gomori’s Trichrome stain. 200X magnification. Arrows indicate areas 
of positive staining. (C) Immunofluorescence staining for B220 and CD3 was also performed. 200X magnification. 
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The average size of B cell follicles within granulomas and (D) the average area of perivascular T cell cuffing were 
calculated. (E) The percentage of IFN-γ- and (F) IL-4-producing activated T cells (CD4+CD44+IFN−γ+ and 
CD4+CD44+IL-4+, respectively) were determined by flow cytometry. (G) MHC class II expression on lung 
macrophages was determined by flow cytometry. (H) The percentage of ESAT-61-20-specific, IFN-γ-producing cells 
in the lungs was determined by antigen-driven ELISpot. (I) Lung bacterial burden was determined by plating. n=4-9 
mice per group. Lungs from all mice were included in the analysis, one representative image per group is shown. 
#p=0.0616, *p≤0.05, ***p≤0.001, ns-not significant, unpaired, two-tailed Student’s t-test (A, C-I). Results are 
representative of 2 independent experiments. 
  
S. mansoni co-infection reversibly impairs Th1 responses and limits Mtb bacterial 
control 
Accumulation of IFN-γ−expressing Th1 cells is critical for protective immunity against 
Mtb infection [116]. We found that accumulation of IFN-γ-producing activated CD4+ T cells was 
impaired in S. mansoni, Mtb co-infected lungs (Fig 12E), and this coincided with a trend in the 
increase in IL-4-producing CD4+ T cells (Fig 12F), and no differences in accumulation of 
Foxp3-expressing T regulatory cells (data not shown). In addition, the impaired Th1 response 
was associated with decreased activation of macrophages, as measured by MHC Class II 
expression (Fig 12G). Interestingly, the small but significant impairment in production of IFN-
γby lung CD4+ T cells in S. mansoni Mtb-co-infected mice was reversible, as the number of 
Mtb-specific IFN-γ-producing CD4+ T cells measured by in vitro overnight antigen-driven 
ELISpot assay was comparable between S. mansoni, Mtb co-infected mice and Mtb-infected 
mice (Fig 12H). Furthermore, we found that the impairment in Th1 responses ex vivo coincided 
with a significant but slight increase in lung Mtb burden in S. mansoni, Mtb-co-infected mice, 
when compared to Mtb-infected mice (Fig 12I). Unexpectedly, our data thus suggest that the Th2 
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responses induced by helminth infection have reversible effects on Th1 immunity and minimal 
effect on mycobacterial control, but more prominently affect lung inflammation. 
 
Treatment of S. mansoni, Mtb co-infected mice with an anti-helminthic can reverse 
TB disease severity 
Praziquantel is an anti-helminthic used for treatment of human schistosomiasis [178]. Thus, we 
next addressed if treatment with an anti-helminthic such as praziquantel can be used to limit 
disease severity in S. mansoni, Mtb co-infected mice. Mice were infected with S. mansoni and 
co-infected with Mtb, following which one group was treated with praziquantel, while the 
control co-infected group was treated with PBS. Treatment with praziquantel resulted in 
significantly decreased S. mansoni egg burden in the liver (Fig 14A). As before, S. mansoni, Mtb 
co-infected control mice exhibited increased disease severity (Fig 13A,B) and increased collagen 
deposition (Fig 14B), when compared to Mtb-infected mice. Importantly, co-infected mice 
treated with praziquantel significantly reversed exacerbated inflammation (Fig 13A,B), 
decreased collagen deposition within pulmonary granulomas (Fig 14B), decreased staining for 
Muc5AC+ goblet cells as well as decreased accumulation of mucins and glycogen (Fig 14C,D). 
The decreased inflammation in praziquantel treated co-infected mice coincided with a reduction 
in serum arginase-1 activity (Fig 13C), and decreased accumulation of high arginase-1-
expressing macrophages within the type 2 granulomas in the lungs (Fig 13D,E). This also 
coincided with increased activation of lung macrophages (Fig 13F) and improved Mtb control 
(Fig 13G) in praziquantel treated co-infected mice, when compared to control co-infected mice. 
Together, these data provide formal evidence that use of anti-helminthics can reverse the 
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accumulation of arginase-1-expressing macrophages in the lung to prevent exacerbated 
inflammation and decrease disease severity in S. mansoni, Mtb co-infected hosts.  
 
Figure 13. Praziquantel treatment of S.mansoni infection reverses the increased inflammation seen in Mtb-S. 
mansoni co-infected mice.  
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S. mansoni-infected (Mtb+Sm) or control C57BL/6 mice (Mtb) were aerosol infected with Mtb and treated with 
praziquantel (Mtb+Sm+PZQ). (A) On D30 post infection, pulmonary inflammation was assessed on FFPE lung 
sections stained with H&E. 200X magnification. (B) Total area occupied by inflammatory lesions per lobe was 
quantified. (C) Arginase-1 activity was quantitated in the serum of infected mice. (D) FFPE sections from infected 
mice underwent immunofluorescence staining using antibodies specific for arginase-1, iNOS and F4/80. 4X4 
mosaics of 200X magnification fields are shown. “Type 1” granulomas (red selection), “type 2” granulomas (green 
selection) and interstitial macrophages (arrows) are shown. (E) The number of high arginase-1-expressing F4/80+ 
cells per 200X field was determined. (F) MHC class II expression on lung macrophages was determined by flow 
cytometry. (G) Lung bacterial burden was determined by plating. n=4-5 mice per group. Lungs from all mice were 
included in the analysis, one representative image per group is shown. **p≤0.01, ***p≤0.001, **** p≤0.0001, ns-
not significant, one-way ANOVA with post-hoc Tukey (B,C,E-G). 
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Figure 14. Praziquantel treatment of Mtb-S.mansoni co-infected mice reduces Schistosoma egg burden and 
leads to decreased lung pathology upon Mtb infection. 
S. mansoni-infected (Mtb+Sm) or control C57BL/6 mice (Mtb) were infected with Mtb and treated with 
praziquantel (Mtb+Sm+PZQ) or PBS. (A) Liver Schistosoma egg burden was determined. (B) FFPE sections were 
processed for collagen deposition analysis using Gomori’s Trichrome stain. 100X magnification. (C) FFPE sections 
were processed for immunofluorescence using antibodies for Muc5AC. 100X magnification. (D) Mucus and 
glycogen accumulation were evaluated by the PAS stain. 100X magnification. Arrows indicate areas of positive 
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staining. n=4-5 mice per group, one representative image per group is shown. *p≤0.05, one-way ANOVA with post-
hoc Tukey (A), ND-not detectable. 
 
Arginase-1 expression drives exacerbated inflammation in helminth Mtb co-infected 
hosts 
Our data thus far suggest that S. mansoni infection induces the accumulation of arginase-1 
expressing macrophages within the lung, which upon Mtb infection mediate exacerbated 
inflammation and increased TB disease. To mechanistically address if arginase-1 expression in 
macrophages mediates the exacerbated disease seen in helminth Mtb co-infected mice, we then 
generated bone marrow chimeric mice (BMC). C57BL/6.SJL host mice received either WT bone 
marrow (WT BMC-Arg1flox/flox) or bone marrow from arginase-1-deficient mice where 
macrophages are devoid of arginase (Tie2cre Arg1flox/flox BMC) [174]. Upon complete 
reconstitution, BMC mice were infected with S. mansoni, followed by co-infection with Mtb as 
before. Under these conditions both WT BMC and Tie2cre Arg1flox/flox BMC co-infected mice 
exhibited a slight but significant increase in bacterial burden when compared to Mtb-infected 
WT BMC mice (Fig 15A). In contrast, Tie2cre Arg1flox/flox BMC co-infected mice exhibited 
decreased lung inflammation (Fig 15B,C), increased formation of protective B cell follicles 
within TB granulomas (Fig 15D), and decreased T cell perivascular cuffing when compared to 
WT BMC co-infected mice (Fig 15E). This coincided with the absence of arginase-1-expressing 
macrophages within the lungs of Tie2cre Arg1flox/flox co-infected mice, when compared to 
accumulation of high arginase-1-expressing macrophages in lungs of WT BMC co-infected mice 
(Fig 15F). These new data provide direct evidence that accumulation of arginase-1-expressing 
macrophages in the lungs following S. mansoni infection mediates exacerbated inflammation and 
disease severity during Mtb co-infection, without affecting mycobacterial control.  
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Figure 15. Tie2Cre Arg1flox/flox BMC co-infected mice have reduced lung pathology. 
WT BMC or Tie2Cre Arg1flox/flox BMC mice were S.mansoni-Mtb-co-infected (Mtb+Sm) or infected with Mtb alone 
(Mtb). (A) On D25 post-infection, lung bacterial burden was determined by plating. (B) Pulmonary inflammation 
was assessed on FFPE lung sections stained with H&E. 100X magnification. (C) Total area occupied by 
inflammatory lesions per lobe was quantified. (D) FFPE sections were processed for immunofluorescence using 
antibodies for B220 and CD3. 200X magnification. The average size of B cell follicles within granulomas was 
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determined. (E) The average area of perivascular T cell cuffing in B220 and CD3-stained sections was calculated. 
(F) FFPE sections were stained with antibodies specific for arginase-1, iNOS and F4/80. 200X magnification. The 
number of high arginase-1-expressing F4/80+ cells per 200X field was determined. n=3-10 mice per group. Lungs of 
all mice were included in the analysis, one representative image per group is shown. *p≤0.05, **p≤0.01, 
***p≤0.001, ns-not significant, ND-not detectable, one-way ANOVA with post-hoc Tukey (A, C), unpaired, two-
tailed Student’s t-test (D-F). 
 
SEA immunization exacerbates lung inflammation during Mtb infection  
In addition to the generation of type 2 granulomas, S. mansoni co-infection in Mtb-
infected mice may also alter tissue architecture due to the physical presence of the parasite and 
thus exacerbate lung pathology. Thus, we sought to determine whether exposure to the helminth 
product S. mansoni egg antigen (SEA), which contains the major antigens that induce Th2 
responses during infection [177], is by itself sufficient to exacerbate lung inflammation in TB. 
Thus, C57BL/6 mice were aerosol infected with low doses of Mtb and were immunized with 
SEA at day 15 post infection, a time when Mtb-specific T cell responses are initiated in the 
mouse model of TB [114]. We found that mice that were SEA immunized and Mtb infected, 
demonstrated increased lung inflammation (Fig 16A), and type 1 granulomas harbored fewer 
iNOS-expressing macrophages (Fig 16B). In contrast to S. mansoni, Mtb-infected lungs, we did 
not observe distinct arginase-1-expressing macrophage containing type 2 granulomas in the 
lungs of SEA-immunized Mtb-infected mice (data not shown), but nevertheless found increased 
expression of Arg1 mRNA in sorted lung CD11c+ cells from SEA immunized Mtb-infected mice 
(Fig 16C). Similarly, we found that the formation of B cell follicles was reduced and less 
organized in SEA immunized Mtb-infected mice (Fig 16D), and this coincided with decreased 
accumulation of T cells within lymphoid follicles, which instead accumulated as T cell 
perivascular cuffs (Fig 16E).  
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Figure 16. SEA immunization increases susceptibility to Mtb infection. 
C57BL/6 mice were aerosol infected with Mtb and immunized with SEA (Mtb+SEA) or saline (Mtb) on D15 post-
infection. (A) Pulmonary inflammation was assessed on D30 post-infection on H&E stained FFPE lung sections. 
40X magnification for H&E sections. Total area occupied by inflammatory lesions per lobe was quantified. (B) 
FFPE sections from infected lungs were processed for immunofluorescence using antibodies specific for iNOS and 
F4/80, and the number of iNOS-expressing F4/80+ cells per 200X field was counted. (C) CD11c+ cells were sorted 
from the lungs of SEA-treated, Mtb-infected mice, as well as Mtb-infected mice and level of Arg1 mRNA relative to 
Gapdh was determined by RT-PCR. (D) FFPE lung sections were also stained using antibodies specific for B220 
and CD3. 200X magnification. The average size of B cell follicles within granulomas, as well as (E) the average 
area occupied by perivascular T cell cuffing were calculated. n=4-8 mice per group. Lungs of all mice were included 
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in the analysis, one representative image per group is shown. *p≤0.05, ***p≤0.001, unpaired, two-tailed Student’s t-
test (A-E). Results are representative of 2 independent experiments. 
 
Importantly, mice similarly immunized with a control antigen such as Bovine Serum 
Albumin (BSA) or a Th1 promoting antigen such as Purified Protein Derivative (PPD) did not 
promote lung inflammation, instead limiting inflammation (Fig 17A,B). In addition, mice 
immunized with either BSA or PPD did not affect Mtb burden (Fig 17C). Together, these data 
suggest that exacerbated lung inflammation and decreased formation of protective B cell follicles 
can be recapitulated by immunization with SEA in Mtb-infected mice, suggesting that the 
inflammatory effects of the co-infection are due to the presence of Schistosoma antigens, and 
likely not due to tissue alterations caused by the physical presence of the helminth parasite.  
 
Figure 17. PPD and BSA immunization of Mtb-infected mice does not exacerbate lung inflammation and Mtb 
control. 
C57BL/6 mice were aerosol infected with Mtb and immunized with saline (Mtb), PPD (Mtb+PPD) or BSA 
(Mtb+BSA). (A) Pulmonary inflammation was assessed on D30 post-infection on H&E stained FFPE lung sections. 
50X magnification. (B) Total area occupied by inflammatory lesions per lobe was quantified. (C) Lung bacterial 
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burden was determined on D30 post-infection. n=5 mice per group. Lungs of all mice were included in the analysis, 
one representative image per group is shown. *p≤0.05, **p≤0.01, ns-not significant, one-way ANOVA with post-
hoc Tukey (B, C). 
 
SEA mediated inhibition of Th1 responses in Mtb infection is reversible 
Aerosol infection of mice with Mtb results in a chronic pulmonary infection which 
induces a predominantly Th1 immune response in the lung [114]. Consistent with this, we found 
that CD4+ T cells isolated from the lungs of chronically Mtb-infected wild type C57BL/6 mice 
strongly expressed mRNA for Ifng, Tnf, Stat1 and IL12rb2, which are associated with the Th1 
cell pathway (Table 1), but not canonical Th2 (Gata3, IL4ra), or Th17 genes (IL17a, Rorc). 
In vitro treatment of such isolated CD4+ T cells with SEA in the presence of irradiated 
APCs, inhibited both polyclonal (anti-CD3/CD28 bead stimulated) and Mtb-specific IFN-γ 
production (Fig 18A), without detectable IL-4 production in culture supernatants (data not 
shown). Upon analysis of gene expression in these cell pellets, we found genes associated with 
Th1 function (Ifng, Tbx21, Cxcr3), T cell signaling (Lck, Cd3g, Zap70, Lat), T cell costimulation 
(Cd40lg, Icos, Cd28) and T cell activation (Il2ra) were downregulated in SEA-treated cells 
(Table 2, Fig 18B), while expression of the Th2 cytokines Il4, Il5 and Il13 was below the 
threshold of detection. 
 
 
Table 1. Induction of genes associated with Th1 cell function in CD4+ T cells during Mtb infection. 
Gene Un 1 Un 2 Un 3 
Mtb 
1 
Mtb 
2 
Mtb 
3 
Fold 
Change edgeR DESeq baySeq 
Ifng 95.9 261 281 3700 2810 2620 14.3 3.18E-34 6.14E-25 0.000025 
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Il12rb1 86.5 139 106 501 568 517 4.79 1.26E-34 8.01E-24 0.00000218 
Il12rb2 71.5 56.5 60.1 395 320 301 5.4 6.74E-32 1.42E-19 0.00000178 
Stat1 32.9 21.9 27.3 102 94 96.9 3.57 8.17E-12 0.0000029 0.0000256 
Tnf 4.7 1.82 12 73.2 86.4 82.5 13 1.73E-22 3.36E-13 0.00000897 
Il1a 57.4 149 102 1110 870 897 9.32 2.36E-39 2.52E-35 0.0000056 
Gata3 638 458 447 79 71.7 75.3 -6.83 2.69E-40 8.31E-14 0.0000011 
Il4ra 3320 3550 2980 1940 2280 2080 -1.56 0.0000301 0.00488 0.00542 
Il13ra1 532 645 529 1430 1240 1370 2.36 3.74E-16 3.69E-10 0.0000211 
Il17a 4.7 9.11 4.01 13.5 4.9 3.2 1.21 0.837 0.957 0.23 
Rorc 70.5 72.9 79.4 30.8 14.7 17.6 -3.53 4.97E-10 0.00000137 0.000117 
Il17ra 3630 2210 2110 842 906 907 -2.99 1.75E-13 0.00157 0.0000757 
Il6ra 2140 1180 1130 272 387 411 -4.17 1.58E-15 0.00241 0.000816 
Il21 0 0 3.21 19.3 9.36 14.4 13.4 0.00000309 0.00607 0.00356 
Il10 4.7 10.9 8.02 63.6 61.5 61.6 7.89 4.5E-17 2.14E-09 0.00000538 
Tgfb1 1600 1450 1100 1240 1660 1480 1.06 0.732 0.501 0.305 
Ccl4 56.4 164 192 3830 3840 3490 27.1 7.07E-47 8.56E-110 0.000000605 
Ccl7 30.1 31 42.5 1410 767 821 29 3.52E-69 9.38E-10 0.000000908 
Cxcl3 5.64 1.82 9.62 214 148 138 29.2 2.28E-39 1.8E-16 0.00000314 
Cxcl9 16.9 23.7 24.1 1780 1540 1510 74.8 7.97E-179 6.30E-127 2.31E-09 
Cxcl10 23.5 56.5 48.9 1810 1400 1150 33.8 2.83E-87 1.53E-25 0.00000114 
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Table 2. Top down- and upregulated genes in CD4+ T cells from Mtb-infected mice following ex vivo treatment 
with SEA. 
Gene 
Mtb 
1 
Mtb 
2 
Mtb 
3 
Mtb 
+ 
SEA 
1 
Mtb 
+ 
SEA 
2 
Mtb 
+ 
SEA 
3 
Fold 
Change edgeR DESeq baySeq 
Top downregulated genes 
Klrc1 36.7 33.6 47.1 1.01 0 0 -116 2.13E-24 3.72E-15 0.000353 
Ccl1 316 263 367 4.05 1.4 3.49 -106 5.46E-114 6.33E-53 4.53E-07 
Ifng 4400 3370 3150 38.5 43.5 36.1 -92.5 0 2.38E-54 3.84E-13 
Themis 273 249 265 2.03 2.1 4.66 -89.5 9.08E-133 4.88E-94 2.57E-08 
Rgs16 1160 1310 1120 22.3 14.7 5.82 -83.8 0 1.39E-191 3.07E-08 
Cxcr6 2320 2110 2210 37.5 23.8 31.4 -71.6 0 0 7.12E-12 
Klrc2 11.5 15.5 22.1 0 
0.70
1 0 -70 5.99E-11 6.92E-06 0.00735 
Gzmc 22.9 34.7 10.6 1.01 0 0 -67.3 1.27E-09 1.34E-04 0.0518 
Trat1 57.3 39 43.3 1.01 0 1.16 -64.1 4.51E-25 1.23E-16 1.58E-04 
Lck 22.9 26.7 29.8 0 1.4 0 -56.6 2.61E-17 3.02E-09 6.63E-04 
Apol7e 91.6 66.7 70.2 3.04 1.4 0 -51.5 1.57E-39 6.47E-26 2.08E-05 
Cd40lg 156 106 105 2.03 2.81 2.33 -51.2 1.82E-51 7.97E-21 1.18E-06 
Ccr8 36.7 28.3 35.6 2.03 0 0 -49.6 3.93E-19 1.2E-11 0.000532 
B4galnt4 199 245 226 5.06 3.51 5.82 -46.6 6.82E-101 5.18E-77 2.19E-08 
Mmp3 1050 4.27 377 21.3 4.91 4.66 -46.5 1.13E-07 2.18E-01 0.00000104 
Fasl 128 115 114 6.08 3.51 0 -37.2 1.01E-59 1.45E-38 5.51E-07 
Cd5 559 629 631 18.2 12.6 19.8 -35.9 5.47E-213 1.92E-169 2.88E-09 
Ms4a4b 1630 1460 1480 48.6 37.9 43.1 -35.2 0 2.58E-308 1.28E-10 
Icos 887 734 797 26.3 21.7 21 -35 3.58E-231 4.64E-126 8.72E-09 
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Il18rap 314 288 270 12.2 6.31 6.99 -34.3 1.87E-119 1.52E-88 1.78E-08 
 Top upregulated genes 
Notch3 4.58 5.87 4.81 39.5 21.7 24.5 5.61 4.23E-07 4.33E-04 2.30E-03 
Mospd4 0 4.27 2.89 11.1 11.9 15.1 5.34 3.99E-04 1.16E-01 2.89E-02 
Slc32a1 4.58 9.61 3.85 23.3 40 28 5.06 1.41E-06 5.86E-04 5.18E-03 
Rpph1 0 11.7 4.81 25.3 28.8 25.6 4.81 1.55E-05 1.29E-02 6.24E-03 
Bfsp2 2.29 3.2 3.85 9.11 21 11.6 4.47 2.39E-03 4.03E-02 6.41E-02 
Vpreb3 11.5 16 9.62 47.6 49.1 43.1 3.77 3.24E-09 1.39E-04 5.08E-04 
Tecta 6.87 8.54 
0.96
2 17.2 27.4 16.3 3.72 1.54E-03 2.43E-02 5.35E-02 
Myh14 6.87 2.67 2.89 21.3 11.2 11.6 3.55 4.44E-03 4.37E-02 5.40E-02 
Dusp13 4.58 10.1 11.5 29.4 34.4 28 3.49 6.12E-06 7.75E-03 2.56E-03 
Cgn 2.29 9.08 5.77 23.3 17.5 16.3 3.33 1.80E-03 1.30E-01 2.79E-02 
Lingo4 4.58 5.87 7.7 19.2 23.1 17.5 3.3 4.64E-04 4.22E-02 8.67E-03 
Hspa5 9.16 39.5 20.2 59.8 91.9 67.5 3.18 2.04E-05 1.42E-02 5.97E-02 
Rtn4r 6.87 8.54 5.77 16.2 28.1 22.1 3.13 7.61E-04 3.75E-02 1.90E-02 
Dnah2 59.6 71 58.7 209 198 165 3.02 2.29E-19 5.51E-13 9.18E-05 
Gm11166 6.87 8.01 16.4 25.3 30.2 36.1 2.93 2.62E-04 1.53E-02 1.54E-02 
Cyp4f18 667 838 785 1870 2590 2160 2.89 3.03E-35 4.24E-09 1.37E-04 
Hspa5 16 46.4 31.8 73.9 121 72.2 2.84 2.05E-05 4.79E-02 1.39E-01 
Kctd19 22.9 16.6 17.3 49.6 65.9 45.4 2.84 5.60E-07 9.42E-05 2.59E-03 
Axdnd1 6.87 9.08 13.5 26.3 22.4 32.6 2.77 1.04E-03 5.27E-02 1.93E-02 
 
To further address if the inhibition of IFN-γ production occurs in Mtb-specific Th cells, 
we adoptively transferred naive CD4+ T cells isolated from the Mtb Early Secretory Antigenic 
target 6 (ESAT-6) T Cell Receptor (TCR) transgenic (Tg) mice into Cd4-/- mice, infected the 
mice with low doses of aerosolized Mtb, and isolated in vivo expanded Th cells from the lungs 
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on day 30 post infection. Consistent with our previous data, these isolated Th cells produced 
IFN-γ upon restimulation with ESAT-6, but in vitro SEA treatment in the presence of APCs 
inhibited the production of IFN-γ (Fig 18C), without inducing detectable levels of IL-4 (data not 
shown).  
Next, we assessed whether similar to Schistosoma infection, SEA immunization affects 
Th1 immunity in vivo. We found that total IFN-γ levels in lung homogenates were reduced in 
SEA immunized Mtb-infected mice when compared to Mtb-infected lungs (Fig 18D). Next, to 
assess the effect of SEA at the cellular level, using IFN-γ reporter mice (Yeti mice), we found 
that SEA immunization decreased both the accumulation of activated IFN-γ-producing CD4+ T 
cells in Mtb-infected animals (Fig 18E), and levels of IFN-γ reporter expression by activated 
CD4+ Th cells in the lungs of Mtb-infected mice (Fig 18F). Strikingly, assessment of IFN-γ Mtb-
specific T cell responses by restimulation with Mtb antigen in ELISpot assays, or following 
stimulation with PMA/Ionomycin, showed no differences between SEA treated and Mtb-infected 
groups (Fig 18G,H). These data together suggest that SEA-mediated inhibition of IFN-γ 
expression in CD4+ T cells evident in vitro (in cultured Th cells with SEA and APCs) and ex 
vivo (as assessed by reporter expression), can be reversed by in vitro culture in the absence of 
SEA (as assessed by ELISpot and intracellular staining). These data suggest that the effects of 
SEA on Th cell cytokine production and activation profile can be potent in in vitro cultures, but 
the effects are reversible upon removal of SEA. Additionally, activation of lung macrophages as 
measured by MHC-II expression, was reduced in SEA treated Mtb-infected mice (data not 
shown). Incidentally, decreased Th1 responses and decreased macrophage activation, coincided 
with a small but significant increase in bacterial burden in the lungs of SEA immunized Mtb-
infected mice (Fig 18I). Interestingly, immunization with SEA on day 15 but not day 1 in Mtb-
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infected mice, coincided with increased susceptibility to TB, suggesting that the presence of SEA 
during initiation of Mtb-specific T cell responses, but not earlier, affects protective outcomes 
during Mtb infection (Fig 18I). 
 
Figure 18. SEA treatment impairs Mtb-driven Th1 responses and increases susceptibility to Mtb infection. 
(A) Lung CD4+ T cells were purified from D30 Mtb-infected mice and incubated with (Mtb+SEA) or without SEA 
(Mtb) and APCs. Cells were restimulated with anti-CD3/CD28 beads or irradiated splenocytes and ESAT-61-20 
peptide and supernatant IFN-γ levels assessed. (B) Overall gene expression changes induced by SEA in cell pellets 
from (A) were assessed by RNAseq. Heat-map representation of significant genes is shown. (C) CD4+ cells sorted 
from ESAT-6 TCR Tg mice were transferred to Cd4-/- mice, which were Mtb-infected. On D30 post-infection, lung 
CD4+ cells were sorted, treated with SEA and restimulated with irradiated splenocytes and ESAT-61-20 peptide. 
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Supernatant IFN-γ levels were determined. (D) In some experiments, Mtb-infected C57BL/6 mice were immunized 
with SEA or saline on D15 post-infection. D30 lung IFN-γ levels were determined. (E) Mtb-infected Yeti mice were 
immunized with SEA on D15 post-infection and the percentage of lung CD4+CD44+YFP+ cells was determined by 
flow cytometry on D30. (F) IFN-γ MFI (YFP) within CD4+CD44+ T cells was determined. (G) The number of lung 
ESAT-61-20-specific, IFN-γ-producing cells was determined by ELISpot. (H) Lung CD4+CD44+IFN-γ+ cell numbers 
following PMA/ionomycin stimulation were determined. (I) C57BL/6 mice were infected with Mtb and immunized 
with SEA or saline on D1, D15 or both D1 and D15 post-infection and D30 lung bacterial burden determined. n=3 
samples (A,B) or n=5-9 mice per group (C-I). *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, ns-not significant, 
one-way ANOVA with post-hoc Tukey (A,E,F,G,I) or unpaired, two-tailed Student’s t-test (C,D,H). One experiment 
of two shown, Un- Uninfected controls. 
 
In vitro SEA treated CD4+ T cells from Mtb-infected lungs which demonstrated impaired 
T cell activation and IFN-γ production (Fig 18A,B), upon subsequent washes to remove SEA and 
further incubation with Mtb-infected alveolar macrophages, could now produce IFN γ and 
activate macrophages to induce iNOS (Fig 19A,B), which coincided with control of Mtb 
infection in infected alveolar macrophages, albeit not to the same level as CD4+ T cells isolated 
from Mtb-infected lungs (Fig 19C). Not surprisingly, naive lung CD4+ T cells isolated from 
uninfected mice, which demonstrated poor induction of IFN-γ production in T cells (Fig 19A) 
and decreased induction of iNOS (Fig 19B), exhibited reduced Mtb control in alveolar 
macrophages (Fig 19C). These data together with the improved Mtb control observed in 
praziquantel-treated co-infected mice (Fig 13G), indicate that although the presence of helminth 
antigens is sufficient to dampen Mtb-specific Th1 responses, these effects are reversible upon 
removal of the parasite and/or its products.  
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Figure 19. Impairment of Th1 responses in SEA treated Th cells is reversible. 
C57BL/6 mice were aerosol infected with Mtb and pulmonary CD4+ T cells were purified on D30 post-infection. 
Cells were then incubated for 6 days, alone (Mtb) or in the presence of SEA (Mtb+SEA) along with APCs. Cells 
were washed multiple times and restimulated for 48h with irradiated splenocytes and ESAT-61-20 peptide and then 
layered over Mtb-infected alveolar macrophages (MOI of 1) for 6 days. Alveolar macrophages that did not contain T 
cells (-) and alveolar macrophages incubated with T cells isolated from uninfected mice (Un) were included as 
controls. (A) Culture supernatants were assessed to determine IFN-γ levels and (B) nitrite production by 
macrophages was determined using the Griess reaction. (C) At the end of the culture period, macrophages were 
washed, lysed and intracellular Mtb burden determined by plating. n=4-6 samples. *p≤0.05, ***p≤0.001, 
****p≤0.0001, ns-not significant, one-way ANOVA with post-hoc Tukey (A-C). 
 
Helminth infections are associated with increased TB reactivation rates in HIV-infected 
patients [161]. Thus, based on our data that S. mansoni infection or immunization with SEA can 
exacerbate lung inflammation and increase Mtb susceptibility, we then tested whether SEA 
immunization would affect disease progression in mice undergoing TB reactivation. Using the 
Cornell model of Mtb reactivation [179], chronically Mtb-infected mice were treated with 
isoniazid and rifampicin until no cultivable lung bacteria were recovered [126], and mice were 
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immunized with SEA and spontaneously allowed to reactivate Mtb infection. We found that SEA 
immunized mice had higher lung and spleen bacterial burden when compared to control mice 
that also reactivated Mtb infection (Fig 20). These data for the first time provide experimental 
evidence that TB reactivation can be accelerated due to the presence of helminth products such 
as SEA, likely due to its effect on both Th1 responses, as well as due to decreased formation of 
lymphoid follicle-containing lung granulomas.  
 
Figure 20. SEA treatment increases TB reactivation in mice. 
C57BL/6 mice were aerosol infected with Mtb for 30 days, and were subsequently treated with rifampicin and 
isoniazid in the drinking water for 6 weeks. 2 and 4 weeks after antibiotic treatment cessation, mice were immunized 
with SEA (Mtb+SEA) or saline (Mtb) and lungs and spleen were harvested 2 weeks later. Lung and spleen bacterial 
burden were determined by plating on 7H11 agar plates. n=7 mice per group. *p≤0.05, **p≤0.01, unpaired, two-
tailed Student’s t-test. 
  
Arginase-1 expression is associated with exacerbated inflammation in TB 
Our data demonstrate that arginase-1 induced in response to S. mansoni infection and 
SEA immunization exacerbates inflammation in inbred C57BL/6 Mtb-infected mice. Inbred mice 
do not exhibit the heterogeneity in inflammatory responses seen in human TB. Thus, we recently 
used the Diversity Outbred (DO) mouse population to model heterogeneity in lung inflammatory 
and protective outcomes upon Mtb infection [126]. We next addressed if arginase-1 expression in 
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Mtb-infected DO hosts, even in the absence of helminth co-infection, was associated with 
exacerbated lung inflammation. Thus, we carried out RNA sequencing on lungs of individual 
genetically diverse DO mice that had severe inflammation (SI) and compared their 
transcriptional expression profile to individual DO mice that had enhanced control (EC), which 
coincided with formation of lymphoid follicle-containing granulomas and decreased Mtb burden 
[126]. Interestingly, we found that Arg1 mRNA was among the top 10 genes differentially 
expressed in mice with severe inflammation, when compared to genes expressed in lungs of mice 
with enhanced Mtb control (Table 3, Fig 21A). In support of recently published studies [126, 
180], mRNA for inflammatory molecules such as S100a8 and S100a9, and chemokines 
associated with neutrophilic accumulation were also significantly increased in the lungs of mice 
with severe inflammation at the mRNA level (Table 3).  
Table 3. Top 15 genes upregulated in lungs of DO mice with severe inflammation (SI) compared to mice 
with enhanced mycobacterial control (EC). 
Gene SI1 SI2 SI3 EC1 EC2 EC3 EC4 Fold Change 
Asprv1 3.25701 39.9014 86.26 1.2504 0.645684 0.937151 1.76856 -5.228739831 
Alb 14.4631 0.43517 0.218826 0.578426 0.0779802 0.0296708 0.0543738 -4.766670836 
Stfa2l1 19.0143 85.6295 392.37 5.72234 10.4689 7.36957 2.73549 -4.655391684 
Slfn4 8.08829 50.7014 13.174 0.232605 0.930751 1.13256 1.59585 -4.62380979 
Cxcl2 10.383 64.7287 129.571 3.29095 2.76533 2.26271 3.2902 -4.555087448 
Psca 1.00759 36.4841 0.113578 0.523481 0 0 1.63579 -4.537356052 
Arg1 11.1046 26.8485 149.778 10.0835 1.71299 1.59227 0.315004 -4.191061053 
Niacr1 32.5266 173.235 96.2922 5.97616 10.0292 9.74134 10.8565 -3.45980135 
S100a9 153.772 720.948 1968.91 26.5317 49.9857 223.773 76.2103 -3.332046807 
S100a8 322.557 643.468 1746.02 86.289 32.8266 198.995 47.2137 -3.307168991 
Cd163l1 0.06745 3.01754 2.17326 0 0.0564829 0.658925 0.124513 -3.061294999 
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05 
Il1b 99.8531 232.153 436.031 18.2768 17.5145 47.7993 40.5069 -3.044739449 
Ccl3 167.375 692.047 436.08 40.2995 96.735 32.3074 56.8208 -2.933115825 
Il1a 28.2172 54.4466 45.7485 3.11797 9.1227 4.55808 6.35482 -2.886514335 
Gzmb 54.0801 93.7295 62.1257 15.5687 11.7763 13.6951 6.64021 -2.55351675 
 
The increased expression of Arg1 mRNA was confirmed by RT-PCR (Fig 21B). 
Importantly, arginase-1 activity in lung homogenates of individual DO mice correlated with 
increased pulmonary inflammation (Fig 21C). Thus, we then addressed whether arginase-1 could 
be an inflammatory marker that correlates with the extent of lung damage in human ATB 
patients in a TB endemic setting. We found that levels of arginase-1 activity in the serum from 
ATB patients showed a positive linear correlation with the extent of lung inflammatory damage 
as assessed by chest radiographs (Fig 21D). This also coincided with increased relative 
expression of ARG1 mRNA in CD14+ monocytes isolated from peripheral blood of ATB 
patients, when compared to LTB patients (Fig 21E). Importantly, we also found increased serum 
arginase-1 activity in ATB patients with helminth co-infections, when compared to ATB patients 
without helminth co-infections (Fig 21F). These data provide new evidence that despite the well-
known role for arginase-1 in impairing Th1 responses, arginase-1 may have a new emerging role 
to play in mediating pulmonary inflammation in TB. 
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Figure 21. Arginase-1 expression during Mtb infection in genetically diverse mice and in humans correlates 
with increased inflammation and lung damage. 
Individual DO (n=40) mice were aerosol infected with Mtb and lung bacterial burden on D50 post-infection was 
determined. Total area occupied by inflammatory lesions per lobe was quantified in H&E stained FFPE lung 
sections. RNAseq was performed on lung RNA from individual DO mice with the most severe inflammation (SI) 
and individual DO mice with enhanced control (EC), which also correlated with improved formation of lymphoid 
follicles within the granulomas. (A) Heat-map representation of significant genes. (B) The levels of Arg1 mRNA 
expression relative to Gapdh in lungs of individual DO mice with SI or EC was determined by RT-PCR. (C) 
Arginase-1 activity was determined in lung homogenates of individual DO and linear correlation between arginase-1 
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activity and lung inflammatory area was determined (Pearson’s correlation, log2 scale). (D) Linear correlation 
analysis of arginase-1 activity in serum of patients with ATB and their lung damage score was carried out (Pearson’s 
correlation, n=13). (E) The levels of ARG1 mRNA expression relative to GAPDH in blood monocyte cDNA derived 
from LTB (n=5) and ATB (n=6) human donors were determined. (F) Arginase-1 activity in serum from ATB 
patients with helminth co-infection and those without helminth co-infections was measured (n=22 each). *p≤0.05, 
unpaired, two-tailed Student’s t-test (B,E,F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
5.4 DISCUSSION 
TB remains one of the largest global health threats, and it is estimated that, 5-10% of 
infected individuals will progress to ATB. However, the mechanisms leading to TB reactivation 
in otherwise immunocompetent individuals are largely undefined. As such, co-infection with 
helminths is considered a risk factor associated with increased TB reactivation rates and 
increased susceptibility to TB. However, thus far, the mechanisms behind this association remain 
poorly defined. In this study, we demonstrate that co-infection with S. mansoni, or presence of S. 
mansoni products such as SEA, can reversibly impair Th1 immune responses, but its effects on 
Mtb control are minimal. Unexpectedly, our data demonstrate that the more prominent effect of 
helminth infection during TB is the accumulation of high arginase-1-expressing macrophages 
within type 2 granulomas in the lung, mediating exacerbated inflammation and lung pathology 
during coinfection. Importantly, the effects driven by helminth-induced arginase-1-expressing 
macrophages on inflammation are reversible, as treatment with anti-helminthics can improve TB 
disease outcome. Our data in genetically diverse DO mice infected with Mtb, and humans with 
ATB, also show that increased arginase-1 activity correlates with increased inflammatory 
damage and disease severity during TB. Furthermore, helminth co-infection in ATB patients 
increases arginase-1 activity in serum. Together, our data suggest that contrary to the well-
known anti-inflammatory role for arginase-1 and its inhibitory effects on Th1 responses [181], 
arginase-1 has a new prominent role in driving inflammation and mediating lung damage during 
TB. 
Evidence suggests that a skewed Th2 response caused due to S. mansoni infection 
compromises protection conferred by M. bovis BCG vaccination in humans [158-160], and in 
mice systemically infected with Mtb [164]. Similarly, other models of helminth co-infections 
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such as Nippostrongylus brasiliensis, a rodent intestinal helminth that migrates to the lung, also 
drives Th2 responses and generation of alternatively activated macrophages in the lung, resulting 
in impaired resistance to Mtb [182]. Interestingly, while helminth co-infections increase M. bovis 
BCG [163] and Mtb [182] lung burden, the increase in mycobacterial burden is often transient 
[182], and moderate (about one log higher in co-infected hosts) [163] [182], suggesting that the 
effect of helminth co-infections on Mtb control is not profound enough to fully explain the 
increased severity of TB in helminth co-infected individuals observed in TB endemic regions. 
Furthermore, in some models of helminth Mtb co-infection, there are no differences observed in 
overall mycobacterial control [183, 184]. Our results support these published studies, as S. 
mansoni co-infection or immunization with SEA resulted in increased Mtb burden in the lung, 
but this effect was not profound, suggesting that Mtb control mechanisms are not completely 
suppressed in co-infected hosts. Furthermore, while some evidence suggests that Mtb-specific 
Th1 responses are impaired due to helminth co-infection [158, 163, 185], other studies have 
found that Mtb-specific Th1 responses are unaltered in the presence of helminth infections [182, 
184]. Our studies show that Mtb infection induces a potent Th1 signature in in vivo primed T 
cells isolated from the infected lung, and that in vitro treatment with SEA has an inhibitory effect 
on Th1 immune responses, as well as on cell activation pathways. Similarly, presence of SEA or 
S. mansoni during Mtb infection in vivo results in a significant inhibition of IFN-γproduction in 
T cells. This was associated with a trend towards increased levels of Th2 cells in co-infected 
mice, but no acquisition of a Th2 phenotype by Mtb-specific Th1 cells in vitro upon exposure to 
SEA. Whether these Th2 cells are S.mansoni-specific, or whether conversion of Mtb-specific  
Th1 cells to the Th2 subset occurs could be determined by transferring sorted Th1 cells from 
Mtb-infected ESAT-6 TCR Tg mice into uninfected or S.mansoni-infected controls. IL-4 is a 
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cytokine driving differentiation of Th cells upon priming, and its combination with IL-2 
signaling is sufficient for differentiation [186]. A previous study focusing on Th1 to Th2 
plasticity during Nippostrongylus brasiliensis infection established that conversion was 
enhanced, but not dependent on IL-4 signaling [187]. Whether this is also the case during Mtb-
S.mansoni co-infection could be addressed by co-infecting IL-4-deficient mice. Our in vitro 
studies revealed a marked suppression of gene expression associated with Th1 commitment and 
TCR signaling in Mtb-specific Th1 cells treated with SEA. This is reminiscent of the marked 
degradation of cytosolic RNA by the RNase omega-1, one of the main components of SEA, in 
DCs. Omega-1-driven RNA degradation in DCs leads to Th2 differentiation due to decreased 
TCR signal strength [188]. Whether in vitro, omega-1 is responsible for the marked suppression 
of Th1 function upon SEA treatment, and whether it participates in Th1 to Th2 conversion in 
vivo, will be addressed in future studies. 
In addition, we demonstrate that these effects on cytokine production by Th1 cells are 
transient and reversible, as evidenced by their comparable ability to produce IFN-γ following in 
vitro restimulation. In addition, removal of SEA restores IFN-γ production and the ability to 
activate alveolar macrophages to control Mtb infection. The discrepancy between our ex vivo 
flow cytometric analysis using reporter mice and our ELISpot results highlights the importance 
of directly analyzing immune cell function in the absence of additional restimulation in vitro. 
The differential assays used in the various studies, may in part be responsible for the variability 
in the impairment of Mtb-specific Th1 responses observed due to helminth infections across 
studies [158, 163, 182, 185]. Nonetheless, it is quite surprising that despite impairment of Th1 
responses by treatment with SEA in vitro, removal of SEA in culture conditions can reverse this 
impairment. This is further supported by our data that show that treatment of S. mansoni 
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infection with an anti-helminthic such as praziquantel, can reverse the accumulation of arginase-
1-expressing lung macrophages and decrease disease severity during TB. These findings are 
notable and underscore the potential for the broad application of antihelminthics as a cost-
effective strategy to overcome the effects of helminth driven arginase-1-mediated disease 
severity during TB, and to decrease the risk for TB reactivation in susceptible, co-infected 
individuals.   
 Our data demonstrate that while the effects of Schistosoma co-infection on Mtb control 
are small, its influence on Mtb-induced lung inflammation and pathology are dramatic. 
Considering that the Mtb burden was not profoundly different in co-infected mice when 
compared Mtb-infected mice, the exacerbated inflammation observed in co-infected hosts is 
likely not due to differences in the mycobacterial antigenic load. Instead, we demonstrate that 
helminth infection results in induction of high arginase-1-expressing macrophages within the 
lung, which are organized as type 2 granulomas, and are morphologically and functionally 
different from the type 1 granulomas containing high iNOS-expressing macrophages induced in 
response to Mtb infection. The induction of high arginase-1-expressing macrophages results in 
increased lung pathology in the S. mansoni Mtb-co-infected hosts, projecting an inflammatory 
role for arginase-1 in Mtb infection. These data are further supported by the increased expression 
of Arg1 mRNA expression in CD11c+ lung cells and increased inflammation observed in SEA 
treated Mtb-infected mice, suggesting that presence of Schistosoma antigens is sufficient to 
induce inflammation and lung pathology during Mtb infection. Our recent studies showed that 
the presence of B cell follicles harboring T cells interacting with macrophages within 
granulomas are associated with Mtb control during TB latency [102], while presence of 
granulocytes within the tubercle granulomas causes increased inflammation and exacerbates 
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disease severity in clinical disease [126]. Accordingly, the increased inflammation associated 
with Schistosoma co-infection and SEA immunization results in reduced formation of protective 
lymphoid follicles, with the concomitant formation of inflammatory granulomas containing both 
neutrophils and eosinophils. These data suggest that accumulation of helminth infection induced 
arginase-1-expressing macrophages in the lungs initiates the formation of “inflammatory” rather 
than “ protective” granulomas during TB. That S. mansoni, Mtb co-infected BMC mice that lack 
arginase-1-expressing myeloid cells exhibit decreased lung inflammation and increased 
formation of protective B cell follicles provides direct evidence that helminth induced arginase-1 
expression in myeloid cells mediates disease exacerbation in co-infected hosts. Interestingly, in a 
dermal Mtb infection model resulting in hypoxic lung granulomas, absence of arginase-1 in 
macrophages resulted in exacerbated inflammation in iNOS deficient mice [189]. It is possible 
that arginase-1 expression in macrophages can function to either limit or exacerbate 
inflammation depending upon the availability or absence of iNOS, and this needs to be carefully 
examined in the future. In the context of pulmonary Mtb infection, macrophages were found to 
express either iNOS, ariginase-1, or co-express both iNOS and arginase-1, with the arginase-1-
expressing macrophages localized to lymphocytic cuffs of granulomas in Mtb-infected macaques 
[190]. Accordingly, Mtb infection can induce arginase-1 expression in macrophages [174], and 
high levels of both arginase-1 and iNOS activity was detected in Mtb-infected macaque 
granulomas [190]. Consistent with these studies, the correlation between increased arginase-1 
expression and increased inflammation in genetically diverse outbred mice and humans with 
ATB in our study, further suggests that genetic factors that drive increased arginase-1 production 
may contribute to increased pathology and disease severity during TB. Importantly, similar to the 
mouse model of co-infection, we detected increased arginase-1 activity in the serum of ATB 
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patients co-infected with helminths when compared to ATB patients without helminth co-
infections. This is consistent with the presence of arginase-1-expressing macrophages within 
granulomas found within lungs of TB patients [190, 191], where arginase-1 is expressed both in 
granuloma associated macrophages [190, 191] and in type II pneumocytes [191]. Arginine is a 
crucial amino acid that modulates immune responses to Mtb, as it is a common substrate for both 
iNOS and arginase-1. Loss of arginase-1 in macrophages enhances protection against Mtb 
control, possibly due to increased availability of arginine for iNOS activity [174]. Interestingly, 
Mtb infection in mice deficient in arginase-1 expression within macrophages, also exhibit 
smaller, more lymphocytic granulomas [174], further supporting our hypothesis that arginase-1 
regulates inflammation within TB granulomas.  Based on these data, we propose that arginase-1 
induced due to helminth co-infections, helminthic products, and host genetics, mediates the 
formation of more inflammatory TB granulomas. Finally, increased reactivation of Mtb infection 
after SEA treatment, suggests that helminth co-infection likely facilitates increased TB 
reactivation rates.  
Arginase-1 has been implicated in models of lung injury, where increased expression of 
arginase-1 coincides with collagen deposition and fibrosis in pulmonary diseases such as asthma, 
cystic fibrosis, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease 
(COPD) [192]. In animal models of silicosis, another inflammatory lung disease characterized by 
fibrosis, arginase activity and arginase-1 expression are enhanced in alveolar macrophages [192]. 
In contrast, in S. mansoni induced Th2 driven inflammation, macrophage-specific arginase-1 was 
demonstrated to function as a suppressor of fibrosis [193]. Our studies demonstrate that in the 
lungs of mice co-infected with Schistosoma and Mtb, increased accumulation of arginase-1 
expressing macrophages organized as type 2 granulomas results in increased collagen 
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expression, increased Mmp13 and Ccl3 expression (data not shown), molecules implicated in 
lung fibrosis [192]. That accumulation of arginase-1-expressing macrophages coincide with 
exacerbated inflammation in a Th1 dominated disease such as TB is unexpected, as other models 
of acute and chronic Th2-mediated lung inflammation showed neither a pathogenic nor a 
protective role for myeloid-expressed arginase-1 [194]. In addition, our data show that 
praziquantel treatment in co-infected mice is able to control S. mansoni infection to fully reverse 
the increased inflammation and higher Mtb bacterial burden seen in co-infected mice, to levels 
seen in Mtb-infected mice. This is in contrast to the co-infection in BMC mice specifically 
lacking arginase-1 expression in myeloid cells, where increased inflammation is reversed but 
increased Mtb burden is unaffected. These data together suggest that while the increased 
inflammation seen in co-infected mice is helminth-driven and arginase-1-dependent, the increase 
in Mtb burden although helminth driven, is not directly dependent on arginase-1-expression in 
macrophages. Future studies delineating the specific mechanisms by which helminth induced 
responses drive the fibrosis and increased inflammation in a Th1 disease such as TB, will shed 
further light on the mechanisms of Mtb control, disease and TB reactivation in helminth-TB co-
infected populations. 
In conclusion, our data suggest that contrary to the well-known anti-inflammatory role for 
arginase-1 and its inhibitory effects on Th1 responses, arginase-1 has a prominent role in driving 
inflammation and mediating lung damage during TB. These novel data provide new insights into 
the mechanisms by which helminth co-infections drive increased susceptibility and disease 
progression in TB. In addition, our data show that the effects of helminth products on impairment 
of Th1 responses are reversible and support the use of antihelminthics as a cost-effective strategy to 
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improve M. bovis BCG vaccination, boost efficient immune responses against Mtb and to decrease 
the risk for TB reactivation in susceptible, co-infected individuals.  
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6.0  NTM DISEASE, AN EMERGING OPPORTUNISTIC INFECTION  
6.1.1 Non-tuberculous mycobacteria  
In previous chapters, we have focused on the effect of the cytokine milieu and helminth co-
infections in shaping immune responses against primary infection and recall responses to Mtb. 
The genus Mycobacterium, however, encompasses numerous organisms, some of which are 
emerging opportunistic pathogens. In particular, non-tuberculous mycobacteria (NTM) are a 
diverse group of environmentally ubiquitous organisms with the potential of causing a wide 
spectrum of disease in humans. Exposure to NTMs is thought to occur through different sources, 
and biofilm formation in household and public water sources, such as showerheads and plumbing 
systems, is thought to be one of the possible exposure mechanisms [196-198]. NTMs most 
commonly cause disease in people with structural lung abnormalities, including cystic fibrosis 
(CF) patients and patients with primary ciliary dyskinesia, where average prevalence rates of 
20% and 10%, respectively, have been reported [199]. In addition, female patients with a specific 
morphotype consisting of a thin body habitus, scoliosis, pectus excavatum and mitral valve 
prolapse, have been shown to have a higher rate of NTM infection. Similar to TB, immune 
suppression, and in particular treatment with TNF-α blockers [200], HIV infection and defects in 
IL-12 and IFN-γ are associated with serious cases of disseminated NTM disease [201].   
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Recently, concerns have been raised about the increasing rates of NTM infections in CF 
patients. The prevalence of chronic lung disease due to NTM is increasing and, in many areas of 
the US, exceeds that of Mtb. Indeed, it has been postulated that the true prevalence of NTM 
disease is higher than that of TB due to relative inefficacy of NTM treatments [202]. The most 
common NTM is the Mycobacterium avium complex (MAC), but other species, including 
Mycobacterium abscessus, are becoming particularly relevant in CF patients. M. abscessus 
infection accounts for 16% of NTM infections in CF patients and can cause a serious, life-
threatening disease. In addition, it constitutes one of the most clinically virulent and antibiotic-
resistant NTM species [203], and treatment can be rendered difficult by the discordance that 
often occurs between in vitro antibiotic susceptibility tests and clinical effectiveness [199]. In 
fact, M.abscessus treatment options are limited, with a treatment failure rate outcome of 50% for 
antibiotic treatment, and lung resection often being the sole option to treat disease [204]. The 
finding of NTM infection, and in particular M. abscessus, in CF patients is considered a 
contraindication for lung transplantation [205]. 
6.1.2 Host responses to NTM infection 
Despite the demonstration that NTM can cause disease over 60 years ago, host immunity to 
NTM has been understudied in comparison to other related mycobacteria, including Mtb and 
Mycobacterium leprae. NTM disease in humans can present in different manifestations. 
Hypersensitivity pneumonitis can occur via inhalation of NTM in aerosolized droplets from 
sources such as showerheads or baths, and is thought to be the main source of MAC infections in 
HIV patients in the USA. In addition, people with lung disease, smokers or previously Mtb-
infected individuals, can develop cavitary disease, with symptoms comparable to those seen in 
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TB. Finally, patients can develop nodular bronchiectasis, which is mostly observed in female 
patients with a thin body habitus.  
M.abscessus infection has been described in immunocompromised individuals and in 
patients deficient in IL-12 and IFN-γ [206], pointing toward a role of adaptive immunity and, in 
particular, the Th1 subset, in host control of infection. This resonates with findings in a mouse 
model of intratracheal M.abscessus infection, in which SCID mice exposed to 104 cfu of 
M.abscessus were more susceptible than wild type hosts, and presented with small areas of 
perivascular inflammation [207]. More recently, two studies demonstrated a role for IFN-γ in 
protection against M.abscessus intravenous or aerosol infection of mice [208, 209]. In the aerosol 
model of infection, which better reproduces the natural route of infection, wild type mice 
spontaneously clear the infection. In contrast, Ifng-/- mice were unable to control bacterial burden 
60 days after infection, and developed large pulmonary lesions with foamy cell formation [208]. 
Given that IFN-γ negatively regulates IL-17, Ifng-/- mice produce an intensified IL-17 response 
that mediates neutrophil recruitment and lung damage during other mycobacterial infections 
[210].  
Interestingly, a recent study showed that patients infected with M.abscessus exhibit 
decreased serum levels of Th1 markers and increased Th17 responses, and that low levels of the 
chemokines IP-10 and MIG are associated with successful sputum conversion after antibiotic 
treatment [211]. In addition, large numbers of neutrophils, one of the main cell types recruited in 
response to IL-17 signaling, accumulate in CF patients infected with M. abscessus. This points 
toward a potential role of the Th1/Th17 balance in M.abscessus infection outcome. However, the 
exact mechanisms leading to M.abscessus infection containment and the relative contributions of 
different Th subsets to M.abscessus pathology versus control remain poorly understood. 
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6.1.3 Co-infections during NTM infections in CF 
Mucus accumulation and inhibition of lung antimicrobial peptides through high ion 
concentration are thought to underlie the increased predisposition of CF patients to infection. 
Indeed, numerous pathogens can persist in the lungs of these individuals and contribute to the 
decline in respiratory function [212]. Importantly, this increased susceptibility to lung infections 
makes co-infections between NTM and other characteristic CF pathogens common. Indeed, a 
recent study has revealed the presence of Pseudomonas-derived genes in the genome of M. 
abscessus, and epidemiological data show that P. aeruginosa and M. abscessus frequently 
coexist in the lung environment [213]. Similarly, A. fumigatus can colonize the lungs in CF 
patients and induce allergic bronchopulmonary aspergillosis [212], and is associated with 
aggravation of NTM pathology [5].  
In this context, common CF co-infections may alter the course of NTM disease, and the 
nature and mechanisms behind such changes in NTM containment have not been studied in 
depth. A.fumigatus has been shown to induce Th17 signature cytokine production and 
neutrophilia [214], which have been associated with the development of pathology in a number 
of inflammatory conditions. These Th17 responses are beneficial for Aspergillus given that they 
inhibit the Th1 responses required to control infection and promote biofilm formation [214, 215]. 
Given the importance of Th1 immunity in mycobacterial control, a concomitant A.fumigatus 
infection may also be detrimental for mycobacterial containment. In addition, neutrophils have 
been shown to promote M.abscessus biofilm formation, thereby promoting bacterial persistence 
[216]. A. fumigatus has also evolved a number of strategies to evade the immune response, 
among which is TLR-2-dependent stimulation of IL-10 secretion [217]. In addition, PBMCs 
from CF patients secreted increased amounts of IL-10 when exposed to recombinant A.fumigatus 
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antigens, in comparison to PBMCs from healthy individuals [218]. Upon blockade of IL-10, Th1 
responses were enhanced, suggesting that IL-10 may play a role in inhibiting A.fumigatus T cell 
responses in CF [218]. This raises the question of whether such inhibition of the immune 
response by A.fumigatus may affect concomitant immunity to NTM infections and their 
associated pathology.  
 In this work, we have characterized the immune mechanisms required for M.abscessus 
control in a mouse model, and explored the participation of Th17 cells in M.abscessus infection 
containment. In addition, we have studied the effect of previous A.fumigatus infection, which 
induces a potent Th17 immune response, on a subsequent challenge with M.abscessus. Together, 
our data provide novel insights into how CF prevalent fungal diseases affect the pathology and 
control of emerging opportunistic NTM infections, such as M.abscessus.  
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7.0  THE EFFECT OF TH17-SKEWING INFECTIONS ON IMMUNITY TO NON-
TUBERCULOUS MYCOBACTERIA 
7.1 SUMMARY 
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene. Mutations in this chloride channel lead to 
mucus accumulation, subsequent recurrent pulmonary infections and inflammation, which is 
responsible for lung deterioration and failure. Recently, concerns have been raised about the 
increasing rates of nontuberculous mycobacterial (NTM) infections in CF patients. Of particular 
relevance is infection with Mycobacterium abscessus, which causes a serious, life-threatening 
disease and constitutes one of the most antibiotic-resistant NTM species. Interestingly, an 
increased prevalence of NTM infections associated with severe lung deterioration has been 
reported in CF patients that are also infected with P. aeruginosa or A. fumigatus. The latter 
infections are common in CF patients and induce Th17 signature cytokine production and 
neutrophilia. We studied the immune requirements for M.abscessus containment using a mouse 
model of infection, and found that adaptive immunity and IFN-γ, but not IL-17 receptor 
signaling, were required for containment of infection. In a model of co-infection with 
A.fumigatus, co-infected mice exhibited decreased bacterial burden when infected with an 
intermediate dose of M.abscessus. This increased control was mucus-independent, but dependent 
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on the presence of both Tbx21 and Rorc. In turn, co-infection using a high dose of M.abscessus 
did not significantly alter bacterial control, but reduced M.abscessus-driven lung pathology with 
a concomitant increase in IL-10 production and Treg lung infiltration. Together, our results 
demonstrate that CF-prevalent fungal infections can ameliorate M.abscessus control and 
pulmonary damage in a mouse model.   
7.2 METHODS 
Animals 
C57BL/6 (B6) animals were purchased from Taconic. Ifng-/- mice on the B6 background 
were purchased from The Jackson Laboratory (Bar Harbor, ME). IL17rc-/-, IL17ra-/-, Rag1-/-, 
Rag2-/-Il2rg-/-, Stat1-/- and Stat6-/- mice were maintained in the animal facility at the University of 
Pittsburgh. Experimental mice were age- and sex-matched and used between the ages of 6-8 
weeks. All mice were maintained and used in accordance with the approved University of 
Pittsburgh IACUC guidelines. 
Experimental infections 
Mycobacterium abscessus strain L948 was grown in Middlebrook 7H9 broth containing 
0.05% Tween-80 to mid-log phase and frozen in 1mL aliquots at -80°C. For M.abscessus 
infections, animals were oropharyngeally infected with 1000-1x106 (CFU) of bacteria using the 
tongue-pull method. Briefly, mice were anesthesized with 3% isoflurane, suspended by their 
front incisors, and the tongue was extended using forceps. The bacterial suspension was pipetted 
into the trachea, and the tongue was held until normal breathing resumed. In some cases, a 
second challenge was performed 1 week after the initial infection. Lung bacterial burden was 
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established by plating out organ homogenates on 7H10 agar plates. For co-infection with 
A.fumigatus, mice were oropharyngeally infected with 2.5x107 A.fumigatus conidia 3 days prior 
to M.abscessus challenge.   
Lung single-cell preparation and detection of cytokine-producing cells by ELISpot 
assay 
Lung suspensions from M.abscessus-infected mice were prepared as described previously 
[84] and were used in ELISpot assays as described below. Antigen-specific IFN-γ-producing and 
IL-17-producing cells were analyzed by ELISpot assay. Multi-screen HA filter plates (Millipore, 
Billerica, MA) were coated with anti-IFN-γ (BD Biosciences) or anti-IL-17 (R&D Systems) 
antibodies. Single cell suspensions were added to the plate at a starting concentration of 1x105 
cells/well and doubling dilutions made. Cells were cultured overnight in the presence of 1x106 
irradiated splenocytes and 10 µg/mL heat killed M.abscessus and 10 U/mL recombinant mouse 
IL-2. The following day, biotinylated anti-IFN-γ or anti-IL-17 antibody (both from eBioscience, 
San Diego, CA) was added and incubated overnight. Plates were developed by incubation with 
streptavidin-alkaline phosphatase (Vector Labs, Burlingame, CA) for two hours, followed by 
incubation with NBT/BCIP (Sigma Aldrich). Spots were enumerated using a CTL-ImmunoSpot 
analyzer (CTL, Shaker Heights, OH) and the frequency and total number of responding cells 
calculated as described before [84]. 
Detection of cytokine-producing cells by flow cytometry 
The presence of cells producing IFN-γ and IL-17, as well as additional immune 
populations, was determined by flow cytometry. Single cell suspensions were stimulated for five 
hours in the presence of 50 ng/mL phorbol-myristate acetate and 750 ng/mL ionomycin, as well 
as 5 µL/mL GolgiStop (BD Biosciences). Cells were treated with Fc Block (anti-CD16/CD32, 
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BD Biosciences) before surface staining for CD3, CD4 CD44, CD25, MHC class II, CD11c or 
CD11b. Cells were then fixed and permeabilized using the Cytofix/Cytoperm fixation 
permeabilization kit (BD Biosciences) before staining for IL-17 and IFN-γ, or according to the 
instructions for the Foxp3 Transcription Factor Staining Buffer Set (eBisocience) prior to Foxp3 
staining. Cell staining was analyzed on an LSRII (BD Biosciences), and results were processed 
using FlowJo (Treestar, Ashland, OR). 
Determination of protein concentration 
ELISA antibody pairs (DuoSet; R&D Biosystems) or Milliplex kits (Millipore) were used 
to detect cytokine levels in cell culture supernatants.  
Real-time PCR.  
RNA was extracted using the RNeasy kit (Qiagen) and cDNA was then amplified with 
FAM-tagged probes and PCR primers on a Viia7 thermocycler. Specific gene expression was 
calculated relative to Gapdh expression. Primer and probe sequences targeting specific genes 
were commercially purchased (ABI Biosystems). 
Morphometric analysis.  
Lungs from infected mice were inflated with 10% neutral buffered formalin and paraffin 
embedded. Lung sections were stained with H&E stain (Colorado Histo-Prep) and processed for 
light microscopy. Images were obtained with a Zeiss Axioplan 2 microscope and were recorded 
with a Zeiss AxioCam digital camera. Caudal lobes underwent morphometric analysis in a 
blinded manner using the morphometric tool of Zeiss Axioplan microscope, which determines 
the area defined by the squared pixel value for each inflammatory focus [102]. PAS staining was 
performed by the pathology core at Children’s Hospital of Pittsburgh of UPMC. 
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Generation of BMDMs (Bone Marrow-derived Macrophages) 
 
BMDMs were generated from the bone marrow of C57BL/6 mice. Cells were extracted 
from femurs and 1x107 cells were plated with 10 mL of cDMEM supplemented with 20 ng/mL 
mouse recombinant GM-CSF (Peprotech). Cells were cultured for 3 days at 37°C in 5% CO2, 
after which an additional 10 mL of cDMEM containing 20 ng/mL rmGM-CSF was added. On 
day 7, the adherent cells were collected by centrifugation and counted.  
In vitro Mtb-killing assay.  
For killing assays, BMDMs were pre-treated with medium or 100 µg/mL zymosan or 
curdlan for 24 h. BMDMs were then infected with M.abscessus at an MOI of 1 for 48 h. At the 
end of the culture period, macrophages were washed twice with PBS, lysed by a 5 min 
incubation with 0.05% SDS. Following SDS neutralization with 10% BSA, intracellular 
M.abscessus burden was determined by plating of serial dilutions on 7H10 plates. 
Detection of nitrites by the Griess reaction.  
Culture  supernatants were assessed for nitrite production by using the Griess Reagent 
System Kit (Promega, Madison, WI), according to the manufacturer’s instructions. 
Sputum processing 
Fresh sputum samples were collected from CF patients, weighed and incubated with a 
volume (mL) of 10% Sputolysin in PBS equivalent to the mass (g) of the sputum sample, for 15 
at 37°C with shaking. Following the incubation, cells were separated from the supernatant after 
centrifugation at 805 xg for 10 min. 
Statistical analysis 
Differences between the means of multiple experimental groups were analyzed using 
one-way ANOVA with Tukey’s post-hoc test. For all other analyses, we used the two-tailed 
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Student’s t-test. Differences were considered significant when p≤0.05. For all figures, data 
represent mean ± SD. All analyses were performed using GraphPad Prism Software. 
Study approval.  
All individuals were examined as part of a clinical research protocol approved by the 
Institutional Review Board of the University of Pittsburgh and informed written consent was 
obtained from all participants. All mice were used following the National Institutes of Health 
guidelines for housing and care of laboratory animals and in accordance with University of 
Pittsburgh and Washington University in St. Louis Institutional Animal Care and Use Committee 
guidelines. All efforts were made to minimize suffering and pain as described in these approved 
protocols. 
 
 
 
 
 
 
 
 113 
7.3 RESULTS 
The immune mechanisms required for containment of M.abscessus in a mouse model have not 
been extensively studied. In order to analyze the immune response induced by M.abscessus 
infection, we optimized an in vitro M. abscessus infection system. For that purpose, mouse bone 
marrow-derived macrophages (BMDMs) were infected with varying MOI of M. abscessus and 
cytokine production 48 and 120 hours post-infection was analyzed. Interestingly, IL-1β, an 
important cytokine that mediates production of IL-17 by γδ− and CD4+ T cells, was upregulated 
at high MOI 120 hours (Fig 22A) post infection.  
To delineate the immunological requirements for Mycobacterium abscessus control, we 
optimized a M. abscessus mouse infection model, adapted from a previous publication [208]. 
Briefly, 6-8 week-old C57BL/6 mice were oropharyngeally infected with M. abscessus L948 
strain. We studied the kinetics of infection in C57BL/6 mice with varying doses of M.abscessus 
and found that mice infected with M. abscessus rapidly control the infection, with complete 
bacterial clearance occurring at the 21 and 28 day time points for the 103 and 2x104 inoculums, 
respectively (Fig 22B). When mice received two weekly doses of 1x106 cfu of M.abscessus, 
bacterial burden was low, but not completely cleared by day 28 post-infection (Fig 22B). In 
immune competent mice, bacteria did not disseminate to the spleen, indicating that immune 
mechanisms elicited by the bacterium in immune competent wild type mice were sufficient to 
maintain the infection localized in the primary organ of infection (data not shown). This is also 
highlighted by the low degree of lung pathology observed in mice infected at the low 
M.abscessus doses, which consisted of small perivascular inflammatory foci, mostly composed 
of lymphocytic aggregates (Fig 22C). In contrast, mice that received two doses of 1x106 cfu of 
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M. abscessus presented with mixed lympho-histiocytic infiltrates surrounding the blood vessels 
and bronchi, which also extended into the lung parenchyma (Fig 22C). In order to determine M. 
abscessus antigen-specific T cell responses, we standardized an antigen-driven ELISpot assay, 
using heat-killed M. abscessus to stimulate lung cell suspensions from infected animals. 
Interestingly, at the peak of the response (14 dpi), mice harbored no detectable M. abscessus-
specific IFN-γ-producing cells, but rather developed a Th17 response (Fig 22D). Given the 
undetectable lung pathology and fast clearance of infection in mice challenged with the 103 cfu 
dose, we excluded that inoculum size from subsequent experiments.  
 
Figure 22. M. abscessus infection is rapidly controlled by C57BL/6 mice and induces potent Th17 responses.  
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(A) BMDMs were left untreated (-) or infected with varying MOI of M.abscessus for 120 hours and IL-1β levels in 
the culture supernatants determined by ELISA. (B) C57BL/6 mice were oropharyngeally infected with M.abscessus 
and lung bacterial burden was determined between days 0 and 28 post-infection by plating on 7H10 agar. (C) 
Pulmonary inflammation was assessed on day 14 post-infection on FFPE lung sections stained with H&E. 100X 
magnification. (D) The number of IL-17-producing, M.abscessus-specific T cells was determined in the lungs of 
infected mice 14 days post-infection by antigen-driven ELISpot. 
 
We initially assessed the broader requirement for NK cells and adaptive immunity in the 
control of M.abscessus challenge. For that purpose, Rag2-/-Il2rg-/- mice, which lack NK, B and T 
cells were challenged with 2x104 cfu of M.abscessus and bacterial burden assessed 2 weeks post-
infection. Lung bacterial burden at this time was slightly elevated in Rag2-/-Il2rg-/- mice (Fig 
23A), indicating that adaptive immunity and NK cells play a role in limiting bacterial control. 
However, the only slight increase in bacterial burden may indicate a more prominent role of 
innate immunity in the control of low infectious doses this pathogen. In contrast, Rag1-/- mice 
infected with 2 weekly doses of 1x106 cfu M.abscessus presented a 1 log increase in bacterial 
burden in comparison to wild type mice (Fig 23D). Given that Th1 and Th17 responses have 
been involved in primary defense against mycobacteria, we next determined the effect of IL-
17RA and IFN-γ deficiency on M. abscessus infection. For that purpose, Il17ra-/- or Ifng-/- mice 
were infected with 2x104 or two weekly challenges of 1x106 cfu of M.abscessus. Bacterial 
burden assessment 2 weeks after challenge showed comparable levels of M.abscessus in the 
lungs of C57BL/6, Il17ra-/- and Ifng-/- mice infected with 2x104 cfu M.abscessus (Fig 23B,C). 
Similarly, C57BL/6 and Il17rc-/- mice were able to control M.abscessus infection at the 1x106 
cfu dose to a similar extent (Fig 23E). Surprisingly, and like C57BL/6 infected controls, 
Ifngmice infected with 2x104 cfu M.abscessus were able to clear infecton by day 30 post-
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infection. However, when exposed to two challenges with 1x106 cfu M.abscessus, Ifng-/- mice 
exhibited a significant increase in bacterial burden (Fig 23F). These Ifng-/- mice harbored 
increased Th17 cells in the lung (Fig 23H) and a significant reduction in macrophage MHC class 
II expression, suggesting that Th17 cells alone were not sufficient to mediate protective 
responses (Fig 23I). These data indicate that IL-17RA signaling is dispensable for M.abscessus 
control in an oropharyngeal model of infection, while IFN-γ was required for protection against 
repeated exposure but not single low dose exposure to M.abscessus. Taken together, these data 
indicate that control of higher infectious doses of the pathogen is more dependent on a functional 
adaptive immune system. 
 
Figure 23. Adaptive immunity, and IFN-γ, but not IL-17R signaling, are required for M.abscessus control. 
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(A,D) C57BL/6 (B6) and Ifng-/-, (B) Il17ra-/-, (C) Rag2-/-Il2rg-/- (E) Il17rc-/- and (F) Rag1-/- mice were 
oropharyngeally infected with 2x104 cfu (A-C) or 2 doses of 1x106 cfu (D-F) of M.abscessus and lung bacterial 
burden was determined on D14 post-infection. Lung (G) Th1 (CD3+CD4+CD44+IFN-γ+), (H) Th17 
(CD3+CD4+CD44+IL-17+) and (I) MHC II mean fluorescence intensity (MFI) in macrophages were determined by 
flow cytometry in C57BL/6 or Ifng-/- mice infected with 2 doses of 1x106 cfu M.abscessus. *p≤0.05, **p≤0.01, 
****p≤0.0001, ns- not significant. 
 
We subsequently addressed the effect of A.fumigatus co-infection on M.abscessus control 
and associated lung pathology. For that purpose, we infected C57BL/6 mice with 2.5x107 
A.fumigatus conidia and challenged the mice with M.abscessus 3 days later, coinciding with the 
peak of A.fumigatus-induced IL-17 responses. Interestingly, we observed a differential effect of 
A.fumigatus co-infection on M.abscessus control and pathology, depending on the infectious 
dose of M.abscessus.  
Surprisingly, at a low dose of M.abscessus infection (2x104 cfu), co-infected mice had 
slightly improved M.abscessus control (Fig 24A). Similarly to A.fumigatus-only infected mice, 
A.fumigatus, M.abscessus co-infected mice cleared A.fumigatus infection, as evidenced by 
failure to amplify A.fumigatus 18S rRNA and absence of GMS staining (data not shown). Co-
infected mice, however, harbored more lung inflammation, as evidenced by more numerous 
inflammatory foci in comparison to M.abscessus-infected mice (Fig 24B). This was associated 
with increased mucus accumulation evidenced by PAS staining (Fig 24C). Since A.fumigatus 
infection can cause mucus accumulation, we studied whether deficient M.abscessus attachment 
to lung cells upon infection could underlie the decreased bacterial burden in co-infected mice. 
We thus challenged previously A.fumigatus-infected mice for 1 hour and assessed lung bacterial 
burden. M.abscessus burden did not significantly differ between control and A.fumigatus-
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infected mice, suggesting that the effects of A.fumigatus on M.abscessus control occur at a later 
point during infection (Fig 24D). We further tested the importance of mucus on A.fumigatus-
induced M.abscessus control by infecting Stat6-/- mice, which are unable to produce mucus. Co-
infected Stat6-/- mice were able to control M.abscessus to an extent similar to C57BL/6 mice (Fig 
24E), indicating that mucus production directly does not play a role in M.abscessus control.  
 
Figure 24. A. fumigatus infection enhances M.abscessus control via a mucus-independent mechanism.  
C57BL/6 (B6) A.fumigatus-infected (Mabs+Af) or control (Mabs) mice were challenged with 2x104 cfu of 
M.abscessus 3 days later. A group of mice only received A.fumigatus-infection (Af).  (A) Lung bacterial burden was 
determined 14 dpi. (B) Pulmonary inflammation was assessed on D14 FFPE lung sections stained with H&E. 100X 
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magnification. (C) FFPE lung sections were analyzed for mucus and glycogen production by the PAS stain. 200X 
magnification. (D) Lung bacterial burden was determined 1 hour following M.abscessus challenge. (E) B6 or Stat6-/- 
A.fumigatus-infected or control mice were challenged with 2x104 cfu of M.abscessus 3 days later. Lung bacterial 
burden was determined 14 dpi. *p≤0.05, ***p≤0.001, ****p≤0.0001, ns- not significant. 
 
We subsequently sought to determine which immune mechanisms are responsible for 
improved M.abscessus control in co-infected mice. We found that co-infected mice harbored 
higher numbers of M.abscessus-specific Th17 cells in their lungs 2 weeks after challenge, as 
evaluated by antigen-driven ELISpot (Fig 25A). We therefore infected Il17ra-/- mice with 
M.abscessus alone or A.fumigatus and M.abscessus, and found that Il17ra-/- co-infected mice 
harbored slightly higher numbers of bacteria in their lungs when compared to co-infected 
C57BL/6 mice (Fig 25B). This indicates that IL-17RA signaling is partially involved in 
A.fumigatus-induced M.abscessus control. Because interferon signaling has been associated with 
improved anti-mycobacterial responses, we next determined the effect of STAT-1 deficiency on 
A.fumigatus-induced M.abscessus control. Interestingly, we found that Stat1-/- co-infected mice 
retained protection (Fig 25C), indicating that interferon signaling may not be required for the 
protection observed in co-infected mice. Because multiple mechanisms may simultaneously 
contribute to M.abscessus control in co-infected mice, we next co-infected Tbx21-/-, Rorc-/- or 
Tbx21-/-Rorc-/- mice, which lack Th1, Th17 or both Th1 and Th17 responses, respectively. 
Interestingly, we found that, individually, each transcription factor was dispensable for 
A.fumigatus-induced M.abscessus protection (Fig 25D). However, co-infected mice lacking both 
transcription factors failed to improve protection against M.abscessus challenge (Fig 25D). 
Together, these results pointed toward a role for Th1 and Th17 responses in control of 
M.abscessus in A.fumigatus co-infected mice.  
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Figure 25. A. fumigatus-induced M. abscessus control is STAT-1 independent but IL-17RA, Tbx21 and Rorc-
dependent.  
C57BL/6 (B6) A.fumigatus-infected (Mabs+Af) or control (Mabs) mice were challenged with 2x104 cfu of 
M.abscessus 3 days later. A group of mice only received A.fumigatus-infection (Af).  (A) The number of IL-17-
producing, M.abscessus-specific T cells was determined in the lungs of infected mice 14 dpi. B6 and (B) Il17ra-/- 
(C) Stat1-/- (D) Tbx21-/-, Rorc-/- and Tbx21-/-Rorc-/- A.fumigatus-infected or control mice were challenged with 2x104 
cfu of M.abscessus 3 days later. Lung bacterial burden was determined 14 dpi. IFN-γ, zymosan and curdlan-treated 
or control BMDMs were infected with M.abscessus (MOI 1) for 48 hours. (E) The number of viable bacteria within 
macrophages and (F) nitrite levels in the supernatants were determined. *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001, ND- not detectable. 
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 A potential mechanism leading to improved control of M.abscessus in A.fumigatus 
infected mice could be activation of macrophages to induce M.abscessus killing. We therefore 
set up an in vitro system to address this hypothesis. Bone marrow-derived macrophages 
(BMDMs) were generated in vitro in the presence of GM-CSF and upon differentiation into DCs 
were treated for 24h with fungal products, including zymosan and curdlan. Interestingly, both 
fungal products were able to induce better bacterial killing (Fig 25E). This was associated with 
improved iNOS activation, as measured by nitrite quantification using the Griess method (Fig 
25F).  
Together, our results show that at a low infectious dose of M.abscessus, A.fumigatus 
infection confers improved protection that is mediated by Tbx21 and Rorc-expressing cells. In 
addition, A. fumigatus antigens could potentiate macrophage activation, which could, in turn, 
improve M. abscessus control in co-infected mice.    
In contrast, in mice receiving high doses of M.abscessus (1x106 cfu given twice), 
previous A. fumigatus infection is associated with a significant reduction in lung inflammation 
(Fig 26A). Interestingly, this reduction was not accompanied by a change in M.abscessus 
control, as lung bacterial burden did not differ between single-infected and co-infected mice (Fig 
26B). Histological findings were confirmed by flow cytometric analysis of lung populations, 
which revealed decreased macrophage (Fig 26C) and activated CD4+ T cell numbers (Fig 26D). 
Within the remaining infiltrating CD4+ T cells, co-infection led to an increased percentage of 
Th17 cells (Fig 26E), with no changes in the percentage of Th1 cells (Fig 26F). 
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Figure 26. A.fumigatus infection reduces M.abscessus-driven lung inflammation.  
C57BL/6 A.fumigatus-infected (Mabs+Af) or control mice (Mabs) were challenged with 1x106 cfu of M.abscessus 3 
days later. Mice were rechallenged with an equivalent dose of M.abscessus 1 week later. (A) Pulmonary 
inflammation was assessed on D14 FFPE lung sections stained with H&E. Top panel-50X magnification, middle 
panel-100X magnification, bottom panel-200X magnification. (B) Lung bacterial burden was determined on D14 
post-infection. The number of lung (C) macrophages, (D) activated CD4+ T cells (CD3+CD4+CD44+), as well as the 
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percentage of (E) Th17 (CD3+CD4+CD44+IL-17+) and (F) Th1 (CD3+CD4+CD44+IFN-γ+) cells was determined on 
D14 by flow cytometry. **p≤0.01, ***p≤0.001, ns- not significant. 
 
In order to evaluate the mechanisms leading to improved lung pathology in co-infected 
mice, we assessed cytokine and chemokine levels in lung homogenates. In line with decreased 
lung inflammation and infiltrating immune cells, there was a concomitant reduction in 
chemokines mediating T cell chemotaxis, including IP-10/CXCL-10 (Fig 27A), RANTES/CCL-
5 (Fig 27B) and MIG/CXCL-9 (Fig 27C). In order to define the mechanism driving decreased 
inflammation during A.fumigatus infection, we analyzed induction of cytokines and chemokines 
by lung cell suspensions following treatment with A.fumigatus swollen, heat-inactivated conidia 
and M.abscessus infection in vitro. We found decreased IP-10 levels in supernatants of lung cell 
suspensions pre-treated with A.fumigatus conidia, which reproduced our in vivo findings (Fig 
27D). Interestingly, this reduction in chemokine production was accompanied by increased 
levels of the anti-inflammatory cytokine IL-10 (Fig 27E). In vivo, co-infected mice harbored 
increased levels of IL-10-producing CD4+ T cells 14 days post-infection (Fig 27F). However, 
when lung cell suspensions were incubated with A.fumigatus conidia in the presence of an IL-10-
blocking antibody, chemokine expression was unaltered (data not shown), demonstrating that 
chemokine inhibition by A.fumigatus is IL-10 pathway independent. In addition, co-infected 
mice harbored a higher percentage (Fig 27G) and total number of Tregs (Fig 27H) in their lungs, 
underscoring a potential role for Treg induction in control of M.abscessus-driven lung pathology 
during co-infection with A.fumigatus. Together, these data demonstrate that A.fumigatus-driven 
suppression of chemokine production is associated with increases in immune regulatory 
mechanisms, and is independent of IL-10 in vitro.  
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Figure 27. A.fumigatus reduced M.abscessus-driven lung inflammation is associated with increased IL-10 and 
Treg accumulation in infected lungs.   
C57BL/6 A.fumigatus-infected (Mabs+Af) or control mice (Mabs) were challenged with 1x106 cfu of M.abscessus 3 
days later. Mice were rechallenged with an equivalent dose of M.abscessus 1 week later. (A) IP-10, (B) RANTES 
and (C) MIG protein levels in lung homogenates were determined on D14 post-infection. Lung cell suspensions 
from C57BL/6 mice were treated with swollen, heat-killed A.fumigatus conidia for 24h. Cells were subsequently 
infected with varying MOIs of M.abscessus for 4 days and (D) IP-10 and (E) IL-10 protein levels were determined 
in culture supernatants. C57BL/6 uninfected, A.fumigatus-infected (Mabs+Af) or control mice (Mabs) were 
challenged with 1x106 cfu of M.abscessus 3 days later. Mice were rechallenged with an equivalent dose of 
M.abscessus 1 week later. (F) the percentage of lung Th cells producing IL-10 (CD3+CD4+IL-10+) and the (G) 
percentage and (H) number of Tregs (CD3+CD4+CD25+Foxp3+) were determined on D14 post-infection by flow 
cytometry. #p=0.0886, *p≤0.05, **p≤0.01, ***p≤0.001. 
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 Given the potential clinical relevance of our findings in CF patients, we then compared 
cytokine and chemokine lung levels in the sputum of CF patients infected with NTM-alone, 
A.fumigatus-alone or co-infected with NTM and A.fumigatus. Interestingly, the co-infected 
patient expressed higher sputum protein levels for IL-17A (Fig 28A), IL-6 (Fig 28B), IP-10 (Fig 
28C) and RANTES (Fig 28D), and did not exhibit higher levels of IL-10 (data not shown) 
indicating that co-infected patients may exhibit an increased inflammatory response,. However, 
our limited sample size of samples from CF patients precludes any major conclusions to be 
drawn from these data. 
 
Figure 28. CF patients co-infected with NTM and A.fumigatus exhibit increased sputum IL-17A, IL-6, IP-10 
and RANTES levels. 
Sputum was collected from CF patients infected with NTM (NTM), A.fumigatus (Af) or NTM and A.fumigatus 
(NTM+Af) and protein levels of (A) IL-17A, (B) IL-6, (C) IP-10 and (D) RANTES were determined. The pg of each 
individual cytokine or chemokine relative to the total mg of protein used in the assay are reported. 
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7.4 DISCUSSION 
Despite the demonstration that NTM can cause disease over 60 years ago, host immunity to 
NTM has been understudied in comparison to other related mycobacteria, including Mtb and 
Mycobacterium leprae. In particular, adaptive immunity and IFN-γ-secreting Th1 cells have been 
implicated in M. abscessus control [206-209], but no studies have focused on Th17 cells in 
M.abscessus infection. Our results are in line with previously published reports demonstrating 
the higher susceptibility of B and T cell deficient mice to M. abscessus infection [207, 209]. In 
contrast with previous publications that used low dose aerosol delivery [208], oropharyngeal 
infection of Ifng-/- mice with M. abscessus L948 at an intermediate dose (2x104 cfu) did not 
significantly increase bacterial burden or lung pathology. However, using a larger inoculum size 
(1x106 cfu given twice), we were able to demonstrate the higher susceptibility of Ifng-/- mice to 
M. abscessus infection. Interestingly, the difference between our data and published reports may 
be due to the infection route used in this study. In a study that compared in vivo mucociliary 
clearance of an insoluble particulate radiotracer following aerosol delivery, oropharyngeal 
aspiration or intratracheal delivery, aerosol delivery led to a higher retention of the particles 
[219]. The immune response elicited by the particles also differed between delivery routes, with 
higher KC expression after aerosol instillation and higher TNF-α levels and immune cell 
recruitment after oropharyngeal delivery [219]. In addition, differential distribution of 
mycobacteria and their antigens along the respiratory tract as a product of the delivery route may 
activate different innate immune cells, or alter the magnitude of immune activation. For instance, 
dendritic cells, which detect foreign antigens along the respiratory mucosa, are unevenly 
distributed along the respiratory tract, with dendritic cell density diminishing when we descend 
 127 
from the upper respiratory tract down the bronchial tree [220]. Thus, in our model, 
oropharyngeal delivery, together with a differential distribution of mycobacteria along the 
respiratory tract, may stimulate immune control mechanisms, allowing improved containment of 
infection at intermediate infection doses.  
In previous chapters, we have shown that Th cell responses during mycobacterial 
infections are plastic, and can acquire different cytokine secretion profiles in response to 
microenvironmental queues. In order to understand the effect of co-infections on M.abscessus-
specific Th responses, we first need to characterize the Th responses arising naturally during 
infection. The contribution of the IL-17 pathway and Th17 cells to control of M.abscessus 
infection has not been explored. Consistent with a previous study using human PBMCs [221], we 
showed that in vitro infection of macrophages with M. abscessus induces IL-1β, a cytokine 
involved in Th17 differentiation. In addition, using a model of oropharyngeal M. abscessus 
infection, we demonstrated the dose-dependent induction of M. abscessus-specific Th17 cells. 
Despite the induction of Th17 responses, however, IL-17 receptor signaling was dispensable for 
M. abscessus control. Taken together, our data indicate that IL-17 receptor signaling is not 
critical for M. abscessus control. These results, together with the comparable control of an 
intermediate dose of M. abscessus in Ifng-/- and C57BL/6 mice bring forth the interesting notion 
that M.abscessus infection can be easily controlled, even by immune compromised mice. This is 
particularly relevant given that M.abscessus is ubiquitous in the environment and is an 
opportunistic pathogen that normally only affects individuals with structural lung abnormalities. 
The exact mechanisms responsible for mycobacterial persistence in these susceptible individuals, 
which may involve mucus thickening, promotion of biofilm formation [222], failure of 
mucociliary clearance [223] and abnormal immune responses, remain to be defined. Recently, 
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our lab and others have found that IL-17 plays a role in driving pathology, without altering 
mycobacterial control, in Mtb H37Rv [195] and M.avium [224] infections. In addition, IL-17 
expression during infection with the Mtb clinical isolate from the Beijing lineage, HN878, was 
required for control of infection [210], highlighting a dual role for IL-17 in driving both 
containment of primary mycobacterial infection and pathology. Ifng-/- mice infected with a high 
dose of M.abscessus exhibited increased lung Th17 cell accumulation. Future studies will enable 
us to further elucidate the involvement of the IL-17 pathway in M.abscessus-driven pathology. 
One of the hallmarks of CF is the presence of recurring infective pulmonary 
exacerbations, which are associated with a decline in lung function [225, 226]. Importantly, CF 
patients tend to harbor a variety of pathogens in their lungs, and how such infections interact 
with each other to affect lung function is still unknown. Using CF patient samples, several recent 
studies showed that A.fumigatus colonization is frequently associated with M.abscessus infection 
[227-229]. This association may be due to the more advanced disease and lung damage that 
predisposes patients to M.abscessus infection, and potentially to other opportunistic pathogens 
such as A.fumigatus [227]. M.abscessus-infected CF patients tend to receive lengthy treatments 
of intravenous antimicrobials, and antibiotic-resistant Aspergillus prevalence is higher in these 
patients [227]. Thus, sustained antibiotic treatment could lead to the generation of an ecologic 
niche that enables survival of antibiotic-resistant Aspergillus in M.abscessus-infected patients. 
Alternatively, one disease may directly affect the other through host-intrinsic mechanisms, such 
as competition between immune responses. Using a mouse model of co-infection between 
A.fumigatus and M.abscessus, we sought to determine the effect of A.fumigatus on protection 
and lung pathology in M.abscessus infection. Interestingly, we found an M.abscessus dose-
dependent effect of A.fumigatus.  
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At intermediate doses of M.abscessus, previous A.fumigatus infection enhanced immune 
control of M.abscessus. Using several gene-deficient mouse strains, we showed that this effect 
was partly IL-17RA-dependent. In addition, when both T-bet and RORγt, the master 
transcription factors for the Th1 and Th17 subsets, respectively, were absent, A.fumigatus-
induced protection was lost. These data suggest that the Th1 and Th17 pathways, or innate 
immune cells expressing T-bet and RORγt, can act redundantly to limit M.abscessus infection in 
co-infected mice. This is in line with previous findings in TB, where IL-23 was shown to 
compensate for IL-12p70 deficiency and to stimulate the induction of Mtb-specific Th1 and 
Th17 cells [104]. In addition, innate immune cell activation may contribute to enhanced 
M.abscessus control in co-infected mice, as in vitro stimulation of macrophages with fungal β-
glucan products such as zymosan and curdlan promoted enhanced macrophage activation and 
M.abscessus killing. β-glucans can signal through a variety of immune receptors, including CR3, 
TLR2/6 and dectin-1, which is thought to be the main β-glucan receptor on leukocytes [230]. 
Previous studies have found that macrophages can become activated in response to β-glucans, 
increasing TNF-α and iNOS expression in a MyD88 and NF-κB-dependent manner [231-233]. 
Thus, both innate and adaptive immunity may contribute to M.abscessus containtment in co-
infected mice. The relative contribution of each will be explored in future studies through the use 
of knockout mouse strains.   
In contrast, at higher infectious doses of M.abscessus, previous A.fumigatus infection did 
not affect M.abscessus clearance. Instead, M.abscessus-driven lung pathology was reduced in co-
infected mice, and was accompanied by a reduction in lung infiltrating immune cells. In addition, 
A.fumigatus reduced expression of T cell recruiting chemokines to the lungs during 
mycobacterial infection in vivo. This was associated with a trend towards increased IL-10 
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production in vivo. Furthermore, our in vitro studies showed that downregulation of chemokine 
responses was associated with increased production of the anti-inflammatory cytokine IL-10. IL-
10 has been shown to inhibit production of proinflammatory cytokines, by acting directly on 
cells of the innate immune system. In turn, it can enhance differentiation of Tregs and their own 
secretion of IL-10, while inhibiting effector Th responses [234]. IL-10 may have different effects 
depending on the infectious organism, either promoting infection through the blockade of 
effector mechanisms responsible for pathogen clearance or alleviating pathology and tissue 
damage [235]. IL-10 expression can be induced by β-glucans in a dectin-1-dependent 
mechanism, leading to the adoption of a regulatory-like phenotype in mouse macrophages [236]. 
However, in vitro blocking experiments did not reveal a reversal of diminished cytokine and 
chemokine production. This may be due to the increased cell death observed in M.abscessus-
infected cells in vitro (data not shown). Further studies will allow us to elucidate the nature of the 
IL-10-producing cells in vivo, and the involvement of this mediator in controlling M.abscessus-
driven pathology in vivo in co-infected mice. Treg accumulation was also significantly enhanced 
in vivo in co-infected mice, which may underscore an important role for this regulatory cell 
subset in limiting lung pathology during A.fumigatus and M.abscessus co-infection. Future 
studies will allow us to determine whether these cells play a functional role in this phenomenon. 
A.fumigatus can thwart the host immune response via additional mechanisms, including 
evasion of the complement system and inhibition of phagolysosome acidification in 
macrophages and lung epithelial cells [237]. More recently, A.fumigatus has been shown to 
induce indoleamine 2,3-dioxygenase (IDO), an enzyme that catabolizes tryptophan into 
kynurenines [238]. IDO plays a dual role in limiting infection through tryptophan depletion and 
regulating inflammation via inhibition of effector T cells and promotion of Treg differentiation 
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[238, 239]. In addition, IDO activity can limit the growth of M.avium, and its activation via TLR 
adjuvants enhanced the effectiveness of anti-mycobacterial drugs in vitro and in vivo [240]. We 
will explore the involvement of this pathway in Treg accumulation and regulation of 
M.abscessus pathology in future experiments.   
An important consideration in these results is the timing of A.fumigatus infection. 
A.fumigatus is highly ubiquitous in the environment [241], with average levels of conidia in the 
air ranging between 1 and 100 conidia/m3, but agitation activities such as turning of compost can 
bring conidia concentrations up to 104-107 conidia/m3 of air [242]. Thus, given the high 
probability of an individual to be exposed to or colonized with A.fumigatus, in all of our studies, 
A.fumigatus infection was performed prior to M.abscessus challenge. Our finding that 
A.fumigatus affects M.abscessus containment and pathology begs the question of whether 
inverting the order of delivery would alter the nature of the effects. It is possible that 
A.fumigatus-driven dampening of M.abscessus pathology is due to the fact that M.abscessus was 
given during the resolution phase of fungal infection, where A.fumigatus burden is undetectable. 
Therefore, studying whether these effects are equivalent whether M.abscessus is given before 
A.fumigatus will be important to better understand the dynamics of interactions between co-
infected pathogens in CF. 
We also studied sputum cytokine and chemokine levels in CF patients infected with 
NTM alone, A.fumigatus alone, or co-infected with NTM and A.fumigatus. Interestingly, IL-17A, 
IL-6 and the chemokines IP-10 and RANTES were upregulated in the sputum of a patient 
harboring a M.abscesuss and A.fumigatus co-infection in comparison to NTM-infected or 
A.fumigatus-infected patients. However, this patient did not exhibit increased levels of IL-10. 
These data are in discordance with our findings in the mouse model, but are not definitive given 
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the low number of patient samples analyzed. However, they suggest that overall, co-infected 
patients harbor higher levels of inflammatory mediators. There is also a disparity between the 
elevated levels of proinflammatory mediators in the sputum of CF patients and the relatively low 
level of inflammatory mediators and pathology in M.abscessus-infected mice. Indeed, 
comparably to TB, NTM infection in humans can develop into a cavitary disease [201], with a  
symptomatology comparable to that of pulmonary TB. The persistence observed in CF patients 
may be due to the characteristic inflammation seen in the CF lung, which is characterized by 
accumulation of neutrophils. Previous studies have shown that neutrophils can directly promote 
M.abscessus biofilm formation [216], a phenomenon that may be insufficient in M.abscessus-
infected immune competent mice. In addition, the presence of additional co-infecting pathogens, 
in CF, such as P.aeruginosa, deficient TLR signaling or structural lung abnormalities that 
predispose these patients to worsened pathogen clearance may all explain the enhanced 
inflammation and persistence of M.abscessus in patients when compared to mice. In this regard, 
gut-corrected CFTR-deficient mice, or elastase-treated mice, which will present increased lung 
damage, may prove better models to study the full impact of fungal co-infections on subsequent 
NTM infections. 
Taken together, our results demonstrate that CF-prevalent fungal infections can 
ameliorate M.abscessus control and pulmonary damage early during M.abscessus infection, 
using a mouse model. The long term effects of A.fumigatus co-infection on M.abscessus control 
and pathology, as well as the clinical significance of these findings, will be elucidated in future 
studies.  
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8.0  CONCLUSIONS, SIGNIFICANCE AND FUTURE DIRECTIONS 
Several mycobacterial pathogens can establish infections that pose a serious challenge to 
global health. The World Health Organization reported 8.7 million new cases of TB and 1.4 
million TB related deaths in 2011. Furthermore, about one third of the world’s population is 
latently infected with Mtb, and at risk of progressing to active disease. In fact, of the two billion 
infected individuals, 10%, that is, 200 million people, will likely progress to active disease 
throughout their lifetime. Current efforts to control this disease are aimed at the development of 
novel, effective vaccines, the generation of new drug regimes and an improvement in diagnostic 
and prognostic markers. The availability of such prognostic markers will allow the identification 
of populations at risk of TB reactivation and in need of closer medical surveillance. Therefore, a 
better understanding of the factors that influence TB reactivation in seemingly healthy, immune 
competent individuals, is paramount. Recently, several studies have shown that Th cell responses 
are plastic, and can acquire different effector characteristics in response to changes in the 
microenvironment. Our data show that Th responses in a chronic infection setting such as TB, 
are plastic, and can be modulated by changes in the cytokine milieu and co-infection. Future 
studies will allow us to determine the full impact of Th modulation and plasticity on TB 
reactivation.  
In countries with poorly developed infrastructure, Mtb is often co-endemic with helminth 
infections. It is currently estimated that 1 billion people in developing countries are infected with 
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one or more helminths. Schistosomiasis, caused by platyhelminth flukes of the genus 
Schistosoma affects about 207 million individuals. Helminth infections are usually chronic and 
induce strong Th2 and Treg responses, which are able to regulate the development and/or 
effector functions of Th1 and Th17 cells. Consistent with this, several human studies suggest that 
infections with helminths hinder the capacity to mount effective immune responses against BCG, 
and may be associated with TB reactivation in HIV-infected patients.  
Thus, while the full impact of co-infections on the severity of mycobacterial disease and 
the development of immunity to mycobacteria remains an open question, there is persuasive 
published evidence, supported by our data, to warrant investigation of co-infections as a relevant 
and important factor for the control of mycobacterial disease. An important secondary 
consideration is that it will be important to understand whether treatments for mycobacteria 
affect disease manifestations associated with co-infections. In this work, we have demonstrated 
for the first time that Th responses in the context of TB are plastic. In particular Th1 cells can 
acquire the cytokine secretion profiles of Th2 and Tfh, but not Th17 cells. In addition, Th17 
cells, which are important for mucosal vaccine recall responses in TB, are highly plastic, with the 
ability to acquire cytokine secretion profiles of Th1, Th2 and Tfh cells. Given the association of 
Th1 responses with primary containment of Mtb, we expected improved bacterial containment in 
mice that received IFN-γ-sufficient Th17 cells. However, unexpectedly, Th17 cells lacking IFN-
γ-secretion capacity led to more efficacious control of Mtb infection. IL-23 expression in host 
mice and CXCR5 expression on Th17 cells was required for bacterial containment. Together, 
these data indicate that developing vaccination strategies and adjuvants that boost IL-23 and 
CXCR5 expression, while limiting IFN-γ production, may enhance mycobacterial containment.    
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In addition, we have described a novel role for arginase-1 in driving lung inflammation 
during S.mansoni-Mtb co-infection. Importantly, this increased inflammation was associated 
with increased bacterial burden on day 30 post-Mtb infection and a reduction in protective 
immune responses. These effects could be reproduced by administration of SEA, a helminth 
antigen preparation, indicating that the mere presence of helminth antigens in the absence of a 
productive parasite life cycle can hinder Mtb control. Importantly, deworming strategies reversed 
the effect of co-infection, providing evidence for the utilization of anti-helminthics as a cost-
effective strategy to limit TB reactivation in populations where TB and helminths are co-
endemic. A recent study in free-ranging African buffalos showed that treatment with anti-
helminthics at a population level could lead to an enhancement of M.bovis transmission due to 
increased survival of the treated animals [243]. Thus, the potential outcomes of deworming at a 
population-level scale are not obvious and should carefully be studied prior to the 
implementation of therapeutic interventions. In addition, arginase-1-mediated increased 
inflammation and breakage of Mtb containment in co-infected hosts may lead to an unexpectedly 
higher susceptibility of Mtb to antibiotic treatment. Whether this occurs in vivo remains to be 
explored. Finally, the exact mechanisms mediating enhanced inflammation via arginase-1, as 
well as its potential effect on vaccine recall responses will be elucidated in future studies.   
In turn, NTM infections are currently emerging as a serious health concern in patients 
with previous lung conditions and transplant patients, including CF patients. Of particular 
relevance is M. abscessus infection, which constitutes the most drug-resistant NTM and is 
associated with poor treatment outcome. Indeed, sputum conversion occurs in 50-60% of treated 
patients, highlighting the low efficacy of treatment. Further, transition of M. abscessus from an 
environmentally-adapted form to the human-adapted morphotype has been associated with 
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development of a highly invasive and pathogenic disease. Defining the mechanisms that 
potentiate or limit bacterial persistence and tissue damage in patients at high risk of NTM 
infections will enable us to envision novel therapeutic avenues for treatment of NTM disease. In 
this work, we have verified the importance of adaptive immunity and Th1 cells for M.abscessus 
control. In addition, we have shown that other CF-prevalent infectious diseases such as 
A.fumigatus infection can impact M.abscessus containment and lung inflammation depending on 
the infectious dose of M.abscessus. Control of intermediate doses of M.abscessus in a co-
infection setting is mediated by Th1 and Th17 cells, while reduced pathology upon repeated 
exposure to high doses of M.abscessus may be caused by enhanced regulatory mechanisms, such 
as Treg activation and IL-10 production. Future studies will allow us to identify the mechanisms 
mediating this reduction in lung pathology and the full impact of common CF co-infections on 
NTM infections in humans.  
Together, our results provide novel information on the dynamic interplay between host 
genetics, competing host responses to parasitic and fungal antigens and Mtb co-infection.  
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